US Pat. No. 9,649,334
USE OF NITRITE SALTS IN CHRONIC ISCHEMIA
The UAB Research Foundati...
1. A method of treating peripheral neuropathy in a human subject, the method comprising: orally administering to the subject
a pharmaceutical composition comprising about 40 mg of sodium nitrite one or two times per day for at least ten days, thereby
treating the peripheral neuropathy.
a pharmaceutical composition comprising about 40 mg of sodium nitrite one or two times per day for at least ten days, thereby
treating the peripheral neuropathy.
US Pat. No. 9,518,878
APPARATUS AND METHOD FOR NANOCOMPOSITE SENSORS
BOARD OF SUPERVISORS OF L...
1. A method for forming a sensing material, comprising:
adding a polymer matrix into a first organic solvent solution and allowing the polymer matrix to dissolve;
dispersing a conductive nanofiller into a second organic solvent solution and stirring;
adding the first organic solvent solution to the second organic solvent solution, forming a mixture, and stirring the mixture;
evaporating the first and second organic solvent solutions from the mixture; and
adding a polymer curing agent to the mixture, forming a conductive nanocomposite, embedding the conductive nanocomposite into
a polymer base in a continuous pattern to form the sensing material.
adding a polymer matrix into a first organic solvent solution and allowing the polymer matrix to dissolve;
dispersing a conductive nanofiller into a second organic solvent solution and stirring;
adding the first organic solvent solution to the second organic solvent solution, forming a mixture, and stirring the mixture;
evaporating the first and second organic solvent solutions from the mixture; and
adding a polymer curing agent to the mixture, forming a conductive nanocomposite, embedding the conductive nanocomposite into
a polymer base in a continuous pattern to form the sensing material.
US Pat. No. 9,492,418
INHIBITORS OF PFKFB3 FOR CANCER THERAPY
Board of Supervisors of L...
1. A method of inhibiting an isozyme of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB) in a mammal; wherein
the mammal has a cancer in which a PFKFB isozyme is overexpressed; said method comprising administering to the mammal an effective
amount of a compound having the formula:
wherein:
X3 is OH, and X4 is OH;
Y is S or
R1 and R2 are independently selected from the group consisting of H, and CH3; and R1 and R2 may be the same or different;
R3 is CH3 or CH2CH3; and
the configuration at the carbon-carbon double bond that is depicted in the formula between R1 and R2 is either E or Z.
the mammal has a cancer in which a PFKFB isozyme is overexpressed; said method comprising administering to the mammal an effective
amount of a compound having the formula:
wherein:
X3 is OH, and X4 is OH;
Y is S or
R1 and R2 are independently selected from the group consisting of H, and CH3; and R1 and R2 may be the same or different;
R3 is CH3 or CH2CH3; and
the configuration at the carbon-carbon double bond that is depicted in the formula between R1 and R2 is either E or Z.
US Pat. No. 9,044,315
SOFT TISSUE FIXATION DEVICE
Board of Supervisors of L...
1. A device adapted to affix a soft tissue graft to a bone, said device comprising:
(a) a base member comprising:
(i) a top surface, a bottom surface, and a tubular sleeve extending from the bottom surface, wherein the exterior of said
tubular sleeve is adapted to permit said tubular sleeve to be inserted into a bone tunnel;
(ii) a passageway extending through said tubular sleeve, through said bottom surface, and through said top surface, wherein
said passageway comprises smooth sides through which a soft tissue graft may pass,
(iii) an opening in said top surface extending from said passageway,
(iv) at least one receiving section, and
(v) at least one element on said bottom surface adapted to secure said base member to bone; and
(b) an affixing member comprising an attaching section and an affixing section, wherein:
(i) said attaching section pivotally attaches to said receiving section of said base member, and
said affixing section is adapted to affix a soft tissue graft that traverses said passageway between said base member and
said affixing member.
(a) a base member comprising:
(i) a top surface, a bottom surface, and a tubular sleeve extending from the bottom surface, wherein the exterior of said
tubular sleeve is adapted to permit said tubular sleeve to be inserted into a bone tunnel;
(ii) a passageway extending through said tubular sleeve, through said bottom surface, and through said top surface, wherein
said passageway comprises smooth sides through which a soft tissue graft may pass,
(iii) an opening in said top surface extending from said passageway,
(iv) at least one receiving section, and
(v) at least one element on said bottom surface adapted to secure said base member to bone; and
(b) an affixing member comprising an attaching section and an affixing section, wherein:
(i) said attaching section pivotally attaches to said receiving section of said base member, and
said affixing section is adapted to affix a soft tissue graft that traverses said passageway between said base member and
said affixing member.
US Pat. No. 9,346,835
COMPOSITIONS AND METHODS FOR IMPROVING GLUCOSE UPTAKE
Board of Supervisors of L...
1. A compound comprising the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof:
wherein R1 and R2 are independently selected from the group consisting of hydroxy, alkoxy, and halo, and R3 is selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together with the boron atom form a cyclic boronate ester and R3 is null,
wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation
selected from the group consisting of potassium and sodium;
the ring atoms at X1, X2, X3, and X4 are independently selected from the group consisting of O, C, and N, with the proviso that no more than two of X1, X2, X3, and X4 are O or N; and
Z is selected from the group consisting of null, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted
and any carbon atom at X1, X2, X3, and X4 that is not bonded to the group Z is bonded to hydrogen.
wherein R1 and R2 are independently selected from the group consisting of hydroxy, alkoxy, and halo, and R3 is selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together with the boron atom form a cyclic boronate ester and R3 is null,
wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation
selected from the group consisting of potassium and sodium;
the ring atoms at X1, X2, X3, and X4 are independently selected from the group consisting of O, C, and N, with the proviso that no more than two of X1, X2, X3, and X4 are O or N; and
Z is selected from the group consisting of null, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted
and any carbon atom at X1, X2, X3, and X4 that is not bonded to the group Z is bonded to hydrogen.
US Pat. No. 9,480,219
RICE CULTIVAR DESIGNATED CL152
Board of Supervisors of L...
1. A rice plant of the variety CL152, a representative sample of seeds of said variety having been deposited under ATCC
Accession No. PTA-11753; or an F1 hybrid of the variety CL152.
Accession No. PTA-11753; or an F1 hybrid of the variety CL152.
US Pat. No. 9,476,815
FATIGUE MONITORING FOR COMPOSITE MATERIALS
Board of Supervisors of L...
1. A method for preventing mechanical failure of a composite material, wherein the composite material is solid-state and inhomogeneous;
wherein the composite material is subject to cyclic loading; and wherein said method comprises the following steps:
(a) measuring the temperature of the surface of the composite material, in the vicinity of a location of incipient mechanical
failure, using a temperature sensor;
(b) approximating the accumulated volumetric entropy production ? in the vicinity of the location of incipient mechanical
failure of the composite material, using a processor to approximate the numerical value of ?, using a relationship that is
equivalent to:
wherein t denotes the time, t? denotes the particular time for which ? is being determined, T denotes the temperature of
the surface of the composite material in the vicinity of the location of incipient mechanical failure, w denotes the rate
of volumetric work of permanent deformation for the composite material, and ed denotes the damage energy;
(c) predicting mechanical failure of the composite material when a processor determines that ? is approaching the value of
?f, or is approaching a user-specified fraction of the value of ?f, wherein ?f denotes the mean volumetric fracture fatigue entropy for the composite material; and
(d) stopping the cyclic loading of the composite material, using a controller, when ? approaches the value of ?f, or when ? approaches a user-specified fraction of the value of ?f.
wherein the composite material is subject to cyclic loading; and wherein said method comprises the following steps:
(a) measuring the temperature of the surface of the composite material, in the vicinity of a location of incipient mechanical
failure, using a temperature sensor;
(b) approximating the accumulated volumetric entropy production ? in the vicinity of the location of incipient mechanical
failure of the composite material, using a processor to approximate the numerical value of ?, using a relationship that is
equivalent to:
wherein t denotes the time, t? denotes the particular time for which ? is being determined, T denotes the temperature of
the surface of the composite material in the vicinity of the location of incipient mechanical failure, w denotes the rate
of volumetric work of permanent deformation for the composite material, and ed denotes the damage energy;
(c) predicting mechanical failure of the composite material when a processor determines that ? is approaching the value of
?f, or is approaching a user-specified fraction of the value of ?f, wherein ?f denotes the mean volumetric fracture fatigue entropy for the composite material; and
(d) stopping the cyclic loading of the composite material, using a controller, when ? approaches the value of ?f, or when ? approaches a user-specified fraction of the value of ?f.
US Pat. No. 9,099,224
APPARATUS AND METHOD FOR NANOCOMPOSITE SENSORS
BOARD OF SUPERVISORS OF L...
1. A sensing material for a sensor, comprising:
a polymer base; and
a nanocomposite embedded into the polymer base in a continuous pattern, wherein the nanocomposite includes a polymer matrix
and a plurality of at least one of conductive nanotubes, conductive nanowires, conductive particles and conductive flakes
suspended in the polymer matrix;
wherein the density of the plurality of the at least one of nanotubes, nanowires, particles and flakes is such that the nanocomposite
is conductive.
a polymer base; and
a nanocomposite embedded into the polymer base in a continuous pattern, wherein the nanocomposite includes a polymer matrix
and a plurality of at least one of conductive nanotubes, conductive nanowires, conductive particles and conductive flakes
suspended in the polymer matrix;
wherein the density of the plurality of the at least one of nanotubes, nanowires, particles and flakes is such that the nanocomposite
is conductive.
US Pat. No. 9,066,959
FICUS EXTRACTS HAVING ANGIOGENESIS INHIBITING ACTIVITY AND METHODS OF ISOLATING AND USING THE SAME
BOARD OF SUPERVISORS OF L...
1. A process for isolating a Ficus extract having angiogenesis inhibiting activity, the process comprising:
a) mixing a latex-containing portion of a Ficus variant with a polar solvent to provide a liquid extract;
b) washing the liquid extract with an organic solvent to provide an aqueous extract; and
c) fractionating the aqueous extract to provide a Ficus extract having angiogenesis inhibiting activity.
a) mixing a latex-containing portion of a Ficus variant with a polar solvent to provide a liquid extract;
b) washing the liquid extract with an organic solvent to provide an aqueous extract; and
c) fractionating the aqueous extract to provide a Ficus extract having angiogenesis inhibiting activity.
US Pat. No. 9,366,098
ENGINEERING PLASTIC / INORGANIC FIBER BLENDS AS LOST CIRCULATION MATERIALS
Board of Supervisors of L...
1. A method for reducing lost circulation of a fluid in a subterranean formation; said method comprising contacting the subterranean
formation with a mixture of the fluid and a lost circulation material; wherein the lost circulation material comprises composite
particles; wherein the composite particles comprise one or more engineering thermoplastic polymers, and one or more inorganic
fibers; wherein the one or more engineering thermoplastic polymers are between about ten percent and about seventy percent
of the lost circulation material by mass; wherein the one or more inorganic fibers are between about ten percent and about
seventy percent of the lost circulation material by mass; and wherein the engineering thermoplastic polymer is a matrix that
binds together the components of the lost circulation material into composite particles.
formation with a mixture of the fluid and a lost circulation material; wherein the lost circulation material comprises composite
particles; wherein the composite particles comprise one or more engineering thermoplastic polymers, and one or more inorganic
fibers; wherein the one or more engineering thermoplastic polymers are between about ten percent and about seventy percent
of the lost circulation material by mass; wherein the one or more inorganic fibers are between about ten percent and about
seventy percent of the lost circulation material by mass; and wherein the engineering thermoplastic polymer is a matrix that
binds together the components of the lost circulation material into composite particles.
US Pat. No. 9,279,105
ENRICHMENT OF STEM CELLS FROM ADULT TISSUES
Board of Supervisors of L...
1. A method to obtain a multipotent stem cell population that proliferates and differentiates into at least two cell types
by increasing the percentage of stem cells in an adult mammalian heterogeneous cell population, said method comprising the
following:
A. isolating an adult heterogeneous cell population from a mammal, wherein said heterogeneous cell population consists of
both multipotent stem cells and non-stem cells,
B. exposing the isolated heterogeneous cell population to a stress of high temperature between 44° C. to 44.5° C., wherein
such exposure occurs for duration of time such that the non-stem cells are selectively killed and the surviving cell population
has a higher percentage of stem cells;
C. culturing the surviving cell population to increase the number of multipotent stem cells; and
D. verifying that the cultured multipotent stem population differentiates into two or more cell types selected from the group
consisting of osteoblasts, adipocytes, neurons, and odontoblasts.
by increasing the percentage of stem cells in an adult mammalian heterogeneous cell population, said method comprising the
following:
A. isolating an adult heterogeneous cell population from a mammal, wherein said heterogeneous cell population consists of
both multipotent stem cells and non-stem cells,
B. exposing the isolated heterogeneous cell population to a stress of high temperature between 44° C. to 44.5° C., wherein
such exposure occurs for duration of time such that the non-stem cells are selectively killed and the surviving cell population
has a higher percentage of stem cells;
C. culturing the surviving cell population to increase the number of multipotent stem cells; and
D. verifying that the cultured multipotent stem population differentiates into two or more cell types selected from the group
consisting of osteoblasts, adipocytes, neurons, and odontoblasts.
US Pat. No. 9,416,173
PEPTIDE AND CONJUGATE VACCINES FOR FUNGAL INFECTIONS
Board of Supervisors of L...
1. A composition comprising a first monoclonal antibody and a second monoclonal antibody; wherein said first and second monoclonal
antibodies differ; wherein said first monoclonal antibody binds to Candida cell wall peptide SEQ ID NO: 1; and wherein said second monoclonal antibody binds to a Candida cell wall peptide selected from the group consisting of SEQ ID NOS: 2, 3, and 8-20.
antibodies differ; wherein said first monoclonal antibody binds to Candida cell wall peptide SEQ ID NO: 1; and wherein said second monoclonal antibody binds to a Candida cell wall peptide selected from the group consisting of SEQ ID NOS: 2, 3, and 8-20.
US Pat. No. 9,322,047
METHODS OF AND DEVICES FOR CAPTURING CIRCULATING TUMOR CELLS
BOARD OF SUPERVISORS OF L...
1. A device for capturing target cells, comprising:
a main microchannel having a first portion, a second portion, an inlet and an outlet, the first portion having a first portion
depth that is larger at the inlet of the main microchannel and tapers to a depth in the order of the diameter of the target
cells along the length of the first portion, the second portion having a second portion width that is smallest at a connection
with the first portion and that increases along a second portion length of the second portion, the second portion having a
second portion depth in the order of a diameter of the target cells; and
at least two side microchannels connected to the main microchannel on opposite sides of the first portion of the main microchannel,
each of the at least two side microchannels having a side microchannel width, a side microchannel depth and a side microchannel
length,
wherein the side microchannel depths are sufficiently smaller than the diameter of the target cells such that the target cells
cannot pass through the at least two side microchannels,
wherein a capture elements is immobilized on at least one interior surface of the main microchannel.
a main microchannel having a first portion, a second portion, an inlet and an outlet, the first portion having a first portion
depth that is larger at the inlet of the main microchannel and tapers to a depth in the order of the diameter of the target
cells along the length of the first portion, the second portion having a second portion width that is smallest at a connection
with the first portion and that increases along a second portion length of the second portion, the second portion having a
second portion depth in the order of a diameter of the target cells; and
at least two side microchannels connected to the main microchannel on opposite sides of the first portion of the main microchannel,
each of the at least two side microchannels having a side microchannel width, a side microchannel depth and a side microchannel
length,
wherein the side microchannel depths are sufficiently smaller than the diameter of the target cells such that the target cells
cannot pass through the at least two side microchannels,
wherein a capture elements is immobilized on at least one interior surface of the main microchannel.
US Pat. No. 9,201,075
COLORIMETRIC AND FLUOROMETRIC DETERMINATION OF HOMOCYSTEINE AND CYSTEINE
Board of Supervisors of L...
8. A process for selectively determining the combined concentration of homocysteine and cysteine in a substance, said process
comprising the steps of:
(a) mixing a sample of the substance with a solution comprising a dye at a pH between about 4 and about 12, at a temperature
between about 0° C. and about 100° C.;
(b) observing any perturbation in the near-infrared or visible absorbance spectrum or fluorescence spectrum of the dye as
compared to the spectrum of an otherwise identical and otherwise identically treated solution of the dye that lacks any added
homocysteine and that lacks any added cysteine; and
(c) inferring the total homocysteine and cysteine concentration from a previously-determined correlation between observed
perturbations in the spectrum of the dye and total homocysteine and cysteine concentration;
wherein the dye comprises
comprising the steps of:
(a) mixing a sample of the substance with a solution comprising a dye at a pH between about 4 and about 12, at a temperature
between about 0° C. and about 100° C.;
(b) observing any perturbation in the near-infrared or visible absorbance spectrum or fluorescence spectrum of the dye as
compared to the spectrum of an otherwise identical and otherwise identically treated solution of the dye that lacks any added
homocysteine and that lacks any added cysteine; and
(c) inferring the total homocysteine and cysteine concentration from a previously-determined correlation between observed
perturbations in the spectrum of the dye and total homocysteine and cysteine concentration;
wherein the dye comprises
US Pat. No. 9,126,210
EFFICIENT PREMIXING FUEL-AIR NOZZLE SYSTEM
Board of Supervisors of L...
1. Apparatus for the highly efficient mixing of gaseous fuel and air prior to combustion; said apparatus comprising a swirler
having a plurality of blades, each blade having internal conduits that direct fuel through the interior of the blade to through
holes on the surface of the blade; so that, in operation, fuel is injected into the air stream directly from the surface of
the blades in a direction that is perpendicular or approximately perpendicular to the surface of the blades, and that is opposite
or approximately opposite in direction to the oncoming air stream; as air enters the swirler, at least some of the air is
swirled by the blades; the swirled air encounters injected fuel in a cross-flow direction, inducing eddies of air and fuel
that enhance mixing and that enhance flame stability when the air-fuel mixture is burned.
having a plurality of blades, each blade having internal conduits that direct fuel through the interior of the blade to through
holes on the surface of the blade; so that, in operation, fuel is injected into the air stream directly from the surface of
the blades in a direction that is perpendicular or approximately perpendicular to the surface of the blades, and that is opposite
or approximately opposite in direction to the oncoming air stream; as air enters the swirler, at least some of the air is
swirled by the blades; the swirled air encounters injected fuel in a cross-flow direction, inducing eddies of air and fuel
that enhance mixing and that enhance flame stability when the air-fuel mixture is burned.
US Pat. No. 9,909,173
BIOMOLECULAR PROCESSING PLATFORM AND USES THEREOF
Cornell University, Itha...
1. A device comprising:
a biomolecular processor, each biomolecular processor comprising:
one or more bioreactor chambers defined by a solid substrate;
a support structure within each bioreactor chamber and attached to the solid substrate;
a cleaving enzyme immobilized to the support structure and operatively positioned within said bioreactor chamber to cleave
monomer or multimer units of a biopolymer molecule operatively engaged by said cleaving enzyme; and
one or more time-of-flight channels formed in the solid substrate and fluidically coupled to said one or more bioreactor chambers,
each of said one or more time-of-flight channels having an input end and an output end, wherein each of said one or more time-of-flight
channels comprise two or more sensors including at least (i) a first sensor contacting the one or more time-of-flight channels
proximate to the input end of the one or more time-of-flight channels and (ii) a second sensor contacting the one or more
time-of-flight channels proximate to the output end of the one or more time-of-flight channels.
a biomolecular processor, each biomolecular processor comprising:
one or more bioreactor chambers defined by a solid substrate;
a support structure within each bioreactor chamber and attached to the solid substrate;
a cleaving enzyme immobilized to the support structure and operatively positioned within said bioreactor chamber to cleave
monomer or multimer units of a biopolymer molecule operatively engaged by said cleaving enzyme; and
one or more time-of-flight channels formed in the solid substrate and fluidically coupled to said one or more bioreactor chambers,
each of said one or more time-of-flight channels having an input end and an output end, wherein each of said one or more time-of-flight
channels comprise two or more sensors including at least (i) a first sensor contacting the one or more time-of-flight channels
proximate to the input end of the one or more time-of-flight channels and (ii) a second sensor contacting the one or more
time-of-flight channels proximate to the output end of the one or more time-of-flight channels.
US Pat. No. 9,453,156
THERMOPLASTIC CELLULOSIC FIBER BLENDS AS LOST CIRCULATION MATERIALS
Board of Supervisors of L...
1. A method for reducing lost circulation of a fluid in a subterranean formation; said method comprising contacting the subterranean
formation with a mixture of a fluid and a lost circulation material; wherein:
(a) the lost circulation material comprises composite particles;
(b) the composite particles comprise at least two thermoplastic polymers and cellulosic fibers;
(c) the thermoplastic polymers are between about 10% and about 90% of the lost circulation material by mass;
(d) at least one of the thermoplastic polymers is a common polymer, having a melting point less than 200° C.; and at least
one of the thermoplastic polymers is an engineering polymer, having a melting point between 250° C. and 270° C.;
(e) the cellulosic fibers are between about 10% and about 80% of the lost circulation material by mass;
(f) the thermoplastic polymers form a matrix that binds together the other components into composite particles;
(g) the composite particles were formed by extrusion of the components or high-speed mixing of the components, followed by
grinding, cutting, or pelletizing the extruded or mixed components; and
(h) the composite particles have the property that, if the composite particles are allowed to absorb water, the composite
particles will swell in size while maintaining rigidity.
formation with a mixture of a fluid and a lost circulation material; wherein:
(a) the lost circulation material comprises composite particles;
(b) the composite particles comprise at least two thermoplastic polymers and cellulosic fibers;
(c) the thermoplastic polymers are between about 10% and about 90% of the lost circulation material by mass;
(d) at least one of the thermoplastic polymers is a common polymer, having a melting point less than 200° C.; and at least
one of the thermoplastic polymers is an engineering polymer, having a melting point between 250° C. and 270° C.;
(e) the cellulosic fibers are between about 10% and about 80% of the lost circulation material by mass;
(f) the thermoplastic polymers form a matrix that binds together the other components into composite particles;
(g) the composite particles were formed by extrusion of the components or high-speed mixing of the components, followed by
grinding, cutting, or pelletizing the extruded or mixed components; and
(h) the composite particles have the property that, if the composite particles are allowed to absorb water, the composite
particles will swell in size while maintaining rigidity.
US Pat. No. 9,328,341
METHODS OF MODULATING UBIQUITIN LIGASE ACTIVITY
Board of Supervisors of L...
1. A method of modulating the activity of a ubiquitin-protein E3 ligase comprising the step of inhibiting the formation of
an E6-Associated Protein (E6AP) polypeptide trimer by contacting the E6AP polypeptide with an agent that binds to the E6AP
polypeptide, wherein the agent is N-acetyl-L-phenylalanylamide, and thereby reducing the generation of a ubiquitin-protein
E3 lipase activity.
an E6-Associated Protein (E6AP) polypeptide trimer by contacting the E6AP polypeptide with an agent that binds to the E6AP
polypeptide, wherein the agent is N-acetyl-L-phenylalanylamide, and thereby reducing the generation of a ubiquitin-protein
E3 lipase activity.
US Pat. No. 9,221,877
CURCUMIN CONJUGATES FOR TREATING AND PREVENTING CANCERS
Board of Supervisors of L...
1. A compound having the structure:
US Pat. No. 9,850,660
SANDWICH PANEL WITH A DUCTILE HYBRID CORE COMPRISING TUBULAR REINFORCEMENTS
Board of Supervisors of L...
1. A composite material comprising a matrix and a grid; wherein:
(a) said matrix comprises polymer;
(b) said grid comprises a plurality of layers, wherein each said layer comprises a network of mechanically interlocking millitubes
or microtubes;
(c) said polymer has an elongation at break from 3% to 200%; an elastic modulus from 1.5 GPa to 350 GPa; and an ultimate tensile
strength from 25 MPa to 350 MPa;
(d) said millitubes or microtubes comprise hollow, shape memory-alloy tubes, with a diameter of 3 mm or less; an elongation
at break from 3% to 100%;
an elastic modulus from 1 GPa to 1000 GPa; and an ultimate tensile strength from 1 MPa to 1000 MPa;
(e) i) said layers that are adjacent to one another are interwoven with one another; or ii) said adjacent layers comprise
indentations that are interposed or seated within one another, or both; or both i) and ii);
(f) said matrix surrounds and provides support to said grid, and said grid confines and increases the strength of said matrix.
(a) said matrix comprises polymer;
(b) said grid comprises a plurality of layers, wherein each said layer comprises a network of mechanically interlocking millitubes
or microtubes;
(c) said polymer has an elongation at break from 3% to 200%; an elastic modulus from 1.5 GPa to 350 GPa; and an ultimate tensile
strength from 25 MPa to 350 MPa;
(d) said millitubes or microtubes comprise hollow, shape memory-alloy tubes, with a diameter of 3 mm or less; an elongation
at break from 3% to 100%;
an elastic modulus from 1 GPa to 1000 GPa; and an ultimate tensile strength from 1 MPa to 1000 MPa;
(e) i) said layers that are adjacent to one another are interwoven with one another; or ii) said adjacent layers comprise
indentations that are interposed or seated within one another, or both; or both i) and ii);
(f) said matrix surrounds and provides support to said grid, and said grid confines and increases the strength of said matrix.
US Pat. No. 9,428,647
SELF-HEALING COMPOSITE OF THERMOSET POLYMER AND PROGRAMMED SUPER CONTRACTION FIBERS
Board of Supervisors of L...
1. A composition comprising:
a matrix of thermoset polymer;
programmed fibrous shape memory polymer which comprises the ability to contract when heated to above its shape recovery temperature;
and,
means for healing at a molecular scale dispersed throughout said matrix.
a matrix of thermoset polymer;
programmed fibrous shape memory polymer which comprises the ability to contract when heated to above its shape recovery temperature;
and,
means for healing at a molecular scale dispersed throughout said matrix.
US Pat. No. 9,512,405
NON-ENZYMATIC METHOD FOR ISOLATING HUMAN ADIPOSE-DERIVED STROMAL STEM CELLS
Board of Supervisors of L...
1. A method to concentrate adipose-derived stromal stem cells from adipose tissue from a mammalian donor; said method comprising
the following steps:
(a) collecting a lipoaspirate of adipose tissue from the donor;
(b) separating the lipoaspirate in aqueous buffer into a floating adipose layer and a lower aqueous aspirate fluid;
(c) isolating the floating adipose layer; (d) mixing the isolated adipose layer from step (c) with buffer at a temperature
between about 25° C. and about 45° C.;
(e) shaking the mixture from step (d) for a time less than about 5 minutes, and then allowing the mixture to settle into an
upper supernatant and a lower infranatant;
(f) separating the supernatant from step (e) from the infranatant from step (e);
(g) repeating steps (d) through (f), using in step (d) adipose cells from the separated supernatant from step (f) to mix with
the buffer instead of the floating adipose layer from step (c);
(h) combining the infranatants from all repetitions; and
(i) centrifuging the combined infranatants into a cell pellet and a aqueous supernatant, whereby the cell pellet comprises
concentrated adipose-derived stromal stem cells;
wherein the concentrated adipose-derived stromal stem cells have not been subjected to enzymatic digestion or antibody affinity
purification.
the following steps:
(a) collecting a lipoaspirate of adipose tissue from the donor;
(b) separating the lipoaspirate in aqueous buffer into a floating adipose layer and a lower aqueous aspirate fluid;
(c) isolating the floating adipose layer; (d) mixing the isolated adipose layer from step (c) with buffer at a temperature
between about 25° C. and about 45° C.;
(e) shaking the mixture from step (d) for a time less than about 5 minutes, and then allowing the mixture to settle into an
upper supernatant and a lower infranatant;
(f) separating the supernatant from step (e) from the infranatant from step (e);
(g) repeating steps (d) through (f), using in step (d) adipose cells from the separated supernatant from step (f) to mix with
the buffer instead of the floating adipose layer from step (c);
(h) combining the infranatants from all repetitions; and
(i) centrifuging the combined infranatants into a cell pellet and a aqueous supernatant, whereby the cell pellet comprises
concentrated adipose-derived stromal stem cells;
wherein the concentrated adipose-derived stromal stem cells have not been subjected to enzymatic digestion or antibody affinity
purification.
US Pat. No. 9,469,659
COMPOSITIONS AND METHODS FOR IMPROVING GLUCOSE UPTAKE
BOARD OF SUPERVISORS OF L...
1. A method of treating a disease selected from the group consisting of hyperglycemia, insulin resistance, metabolic syndrome,
polycystic ovary syndrome (PCOS), prediabetes, diabetes type 1, diabetes type 2, hepatic steatosis, non-alcoholic fatty liver
disease (NAFLD), and non-alcoholic steato-hepatitis (NASH) comprising administering to a subject a therapeutically effective
amount of a compound comprising the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates
thereof:
wherein R1 and R2 are independently selected from the group consisting of hydroxy, alkoxy, and halo, and R3 is selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together with the boron atom form a cyclic boronate ester and R3 is null,
wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation
selected from the group consisting of potassium and sodium;
the ring atoms at X1, X2, X3, and X4 are independently selected from the group consisting of O, C, and N, with the proviso that no more than two of X1, X2, X3, and X4 are O or N; and
Z is selected from the group consisting of null, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted
and any carbon atom at X1, X2, X3, and X4 that is not bonded to the group Z is bonded to hydrogen.
polycystic ovary syndrome (PCOS), prediabetes, diabetes type 1, diabetes type 2, hepatic steatosis, non-alcoholic fatty liver
disease (NAFLD), and non-alcoholic steato-hepatitis (NASH) comprising administering to a subject a therapeutically effective
amount of a compound comprising the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates
thereof:
wherein R1 and R2 are independently selected from the group consisting of hydroxy, alkoxy, and halo, and R3 is selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together with the boron atom form a cyclic boronate ester and R3 is null,
wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation
selected from the group consisting of potassium and sodium;
the ring atoms at X1, X2, X3, and X4 are independently selected from the group consisting of O, C, and N, with the proviso that no more than two of X1, X2, X3, and X4 are O or N; and
Z is selected from the group consisting of null, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted
and any carbon atom at X1, X2, X3, and X4 that is not bonded to the group Z is bonded to hydrogen.
US Pat. No. 9,670,540
METHODS AND DEVICES FOR DNA SEQUENCING AND MOLECULAR DIAGNOSTICS
Cornell University, Itha...
21. A method for identifying one or more of a plurality of target nucleotide sequences, said method comprising:
providing a sample potentially containing one or more target nucleotide sequences, and/or complements thereof, each target
nucleotide sequence comprising a first, second, and third target portion, wherein the second target portion is between the
first and third target portions;
providing one or more oligonucleotide primer sets, each set characterized by (a) a first oligonucleotide primer comprising
a first primer portion that is the same as the first target portion and a second primer portion that is complementary to the
second target portion, wherein the second primer portion is 5? to the first primer portion, and (b) a second oligonucleotide
primer comprising a third primer portion that complementary to the third target portion and a fourth primer-specific portion,
wherein the fourth primer-specific portion is 5? to the third primer portion;
providing a first polymerase;
blending the sample, the oligonucleotide primer sets, and the first polymerase to form a polymerase extension reaction mixture;
subjecting the polymerase extension reaction mixture to a hybridization treatment, wherein the first and third primer portions
of the first and second oligonucleotide primers, respectively, hybridize to their respective complementary portions of the
target nucleotide sequence, or complement thereof, and an extension treatment, wherein the hybridized oligonucleotide primers
extend to form primary primer extension products;
denaturing the primary primer extension products from the target nucleotide sequences and/or complements thereof;
providing a second polymerase;
blending the polymerase extension reaction mixture after said subjecting it to the hybridization treatment and the extension
treatment and the second polymerase to form a polymerase amplification reaction mixture;
subjecting the polymerase amplification reaction mixture to one or more polymerase amplification reaction cycles comprising
a denaturation treatment, wherein hybridized nucleic acid sequences are separated, a hybridization treatment, wherein the
first and third primer portions of the first and second oligonucleotide primers, respectively, hybridize to their respective
complementary portions of the primary primer extension products and an extension treatment, wherein the hybridized oligonucleotide
primers extend to form first oligonucleotide primer extension products and second oligonucleotide primer extension products;
and
subjecting the first and/or second oligonucleotide primer extension products to a sequencing reaction to identify the presence
of one or more target nucleotide sequences in the sample.
providing a sample potentially containing one or more target nucleotide sequences, and/or complements thereof, each target
nucleotide sequence comprising a first, second, and third target portion, wherein the second target portion is between the
first and third target portions;
providing one or more oligonucleotide primer sets, each set characterized by (a) a first oligonucleotide primer comprising
a first primer portion that is the same as the first target portion and a second primer portion that is complementary to the
second target portion, wherein the second primer portion is 5? to the first primer portion, and (b) a second oligonucleotide
primer comprising a third primer portion that complementary to the third target portion and a fourth primer-specific portion,
wherein the fourth primer-specific portion is 5? to the third primer portion;
providing a first polymerase;
blending the sample, the oligonucleotide primer sets, and the first polymerase to form a polymerase extension reaction mixture;
subjecting the polymerase extension reaction mixture to a hybridization treatment, wherein the first and third primer portions
of the first and second oligonucleotide primers, respectively, hybridize to their respective complementary portions of the
target nucleotide sequence, or complement thereof, and an extension treatment, wherein the hybridized oligonucleotide primers
extend to form primary primer extension products;
denaturing the primary primer extension products from the target nucleotide sequences and/or complements thereof;
providing a second polymerase;
blending the polymerase extension reaction mixture after said subjecting it to the hybridization treatment and the extension
treatment and the second polymerase to form a polymerase amplification reaction mixture;
subjecting the polymerase amplification reaction mixture to one or more polymerase amplification reaction cycles comprising
a denaturation treatment, wherein hybridized nucleic acid sequences are separated, a hybridization treatment, wherein the
first and third primer portions of the first and second oligonucleotide primers, respectively, hybridize to their respective
complementary portions of the primary primer extension products and an extension treatment, wherein the hybridized oligonucleotide
primers extend to form first oligonucleotide primer extension products and second oligonucleotide primer extension products;
and
subjecting the first and/or second oligonucleotide primer extension products to a sequencing reaction to identify the presence
of one or more target nucleotide sequences in the sample.
US Pat. No. 9,415,107
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS
1. A pharmaceutical composition for the treatment of addiction consisting essentially of a first agent that targets the hypothalamo-pituitary-adrenal
(HPA) axis and down-regulates the effect of cortisol in a subject to whom the composition is administered, wherein the first
agent is metyrapone or a pharmaceutically acceptable salt thereof, and a second agent wherein the second agent is oxazepam
or a pharmaceutically acceptable salt thereof, wherein said pharmaceutical composition is a single combination dosage form,
and
wherein both the first agent and the second agent are present within the composition in an amount that is ineffective to treat
addiction when either the first agent or the second agent is administered alone.
(HPA) axis and down-regulates the effect of cortisol in a subject to whom the composition is administered, wherein the first
agent is metyrapone or a pharmaceutically acceptable salt thereof, and a second agent wherein the second agent is oxazepam
or a pharmaceutically acceptable salt thereof, wherein said pharmaceutical composition is a single combination dosage form,
and
wherein both the first agent and the second agent are present within the composition in an amount that is ineffective to treat
addiction when either the first agent or the second agent is administered alone.
US Pat. No. 9,977,206
ASYNCHRONOUS DISTRIBUTED OPTICAL MUTUAL EXCLUSION INTERCONNECT AND METHOD
Board of Supervisors of L...
1. A system, comprising:a first waveguide;
a second waveguide;
optical receiver elements coupled between the first waveguide and the second waveguide, each optical receiver element comprising:
a microring configured to admit light from and transfer light to at least one of the first and second waveguides;
a photodetector, coupled to the microring, configured to detect light admitted to the microring; and
a enable circuit, coupled to the microring, configured to be switched between a light admitting state to enable light to be admitted to the microring and a light rejection state to prevent light from being admitted to the microring;
wherein each optical receiver element has a relative priority with respect to one another and are configured to asynchronously arbitrate among the optical receiver elements for a token to place one of the enable circuits in the light admitting state to enable one of the optical receiver elements to receive and transmit data along the first and second waveguides based on the relative priority among the optical receiver elements.
a second waveguide;
optical receiver elements coupled between the first waveguide and the second waveguide, each optical receiver element comprising:
a microring configured to admit light from and transfer light to at least one of the first and second waveguides;
a photodetector, coupled to the microring, configured to detect light admitted to the microring; and
a enable circuit, coupled to the microring, configured to be switched between a light admitting state to enable light to be admitted to the microring and a light rejection state to prevent light from being admitted to the microring;
wherein each optical receiver element has a relative priority with respect to one another and are configured to asynchronously arbitrate among the optical receiver elements for a token to place one of the enable circuits in the light admitting state to enable one of the optical receiver elements to receive and transmit data along the first and second waveguides based on the relative priority among the optical receiver elements.
US Pat. No. 9,220,787
VITAMIN E CONJUGATES, AND THEIR USES AS ANTIOXIDANTS AND PRODRUG DELIVERY VEHICLES
Board of Supervisors of L...
1. The compound VECAR, wherein VECAR has the structure:
wherein n is an integer from 8 to 18.
wherein n is an integer from 8 to 18.
US Pat. No. 9,090,904
RESISTANCE TO ACETOHYDROXYACID SYNTHASE-INHIBITING HERBICIDES
Board of Supervisors of L...
1. An isolated, recombinant, mutagenized, or synthetic polynucleotide encoding an acetohydroxyacid synthase (AHAS) polypeptide,
wherein the sequence of the encoded AHAS polypeptide has about 95% or greater sequence identity with SEQ ID NO:25, wherein
the encoded AHAS polypeptide has a glutamic acid at the position equivalent to amino acid position 628 of SEQ ID NO:25, and
wherein said polynucleotide is operatively linked to a heterologous promoter.
wherein the sequence of the encoded AHAS polypeptide has about 95% or greater sequence identity with SEQ ID NO:25, wherein
the encoded AHAS polypeptide has a glutamic acid at the position equivalent to amino acid position 628 of SEQ ID NO:25, and
wherein said polynucleotide is operatively linked to a heterologous promoter.
US Pat. No. 9,078,886
COMPOSITIONS FOR THE TREATMENT OF ADDICTION, PSYCHIATRIC DISORDERS, AND NEURODEGENERATIVE DISEASE
Embera Neurotherapeutics,...
1. A pharmaceutical composition comprising a first agent, wherein the composition is formulated for oral or topical administration
to a patient,
wherein the first agent is metyrapone or metyrapol, and
wherein the first agent is conjugated to an agent that facilitates movement across the blood-brain barrier.
to a patient,
wherein the first agent is metyrapone or metyrapol, and
wherein the first agent is conjugated to an agent that facilitates movement across the blood-brain barrier.
US Pat. No. 9,433,659
ENHANCED GLYCEMIC CONTROL USING AD36E4ORF1 AND AKT1 INHIBITOR
Board of Supervisors of L...
1. A method of improving glycemic control in an individual, comprising administering to the individual in need thereof a therapeutically
effective amount of an Adenovirus-36 (Ad36) E4orf1 protein or a functional variant thereof and a selective AKT1 inhibitor,
wherein glycemic control is improved without substantial increase in adipogenesis.
effective amount of an Adenovirus-36 (Ad36) E4orf1 protein or a functional variant thereof and a selective AKT1 inhibitor,
wherein glycemic control is improved without substantial increase in adipogenesis.
US Pat. No. 9,249,393
ADIPOSE DERIVED ADULT STEM CELLS IN HEPATIC REGENERATION
BOARD OF SUPERVISORS OF L...
1. A method of deriving hepatic progenitor cells from adipose stem cells comprising:
(a) culturing primary stem cells isolated from adipose tissue on an extracellular matrix comprising collagen I in serum-free
culture medium comprising hepatocyte growth factor (HGF), Oncostatin M (OSM), and optionally dimethyl sulfoxide (DMSO), in
which the stem cells isolated from adipose tissue differentiate into hepatic stem cells.
(a) culturing primary stem cells isolated from adipose tissue on an extracellular matrix comprising collagen I in serum-free
culture medium comprising hepatocyte growth factor (HGF), Oncostatin M (OSM), and optionally dimethyl sulfoxide (DMSO), in
which the stem cells isolated from adipose tissue differentiate into hepatic stem cells.
US Pat. No. 9,220,220
RICE CULTIVAR DESIGNATED CL131
Board of Supervisors of L...
1. A rice seed of the variety CL131, wherein a representative sample of said seed has been deposited under ATCC Accession
No. PTA-6824.
No. PTA-6824.
US Pat. No. 10,022,383
DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION
Board of Supervisors of L...
1. A method of treating a condition in a human patient comprising:pharmacologically activating a translocator protein of 18 kDa (TSPO) by administering a therapeutically effective amount of a pharmaceutical composition to the patient; wherein the condition is chronic methamphetamine addiction, wherein the pharmaceutical composition includes one or more peripheral benzodiazepine receptor ligands selected from a group consisting of: Ro5-4864, oxazepam and therapeutically acceptable salt, solvate, clathrate, stereoisomer, enantiomer, or prodrug of these compounds or mixtures thereof; and wherein the pharmaceutical composition does not include metyrapone.
US Pat. No. 10,005,953
SHAPE MEMORY POLYMER PROPPANTS, METHODS OF MAKING SHAPE MEMORY POLYMER PROPPANTS FOR APPLICATION IN HYDRAULIC FRACTURING TREATMENTS
BOARD OF SUPERVISORS OF L...
1. A method, comprising:providing a shape memory polymer proppant to a fracture in a well, wherein the shape memory polymer proppant is composed entirely of a shape memory polymer material where the shape memory polymer material is a thermoplastic shape memory polymer, a thermosetting shape memory polymer, or a combination thereof, wherein the proppant has an activated state and a programmed state, wherein in the activated state of the proppant has an activated state diameter, wherein in the programmed state of the proppant has a programmed state diameter, wherein the activated state diameter is equal to or greater than the programmed state diameter, wherein the proppant in the programmed state will convert to the proppant in the activated state when an activation temperature is applied to the proppant in the programmed state, wherein the shape memory polymer proppant is in the programmed state;
exposing the shape memory polymer proppant in the programmed state to the activation condition in the fracture, wherein the activation condition is an activation temperature; and
converting the shape memory polymer proppant in the programmed state to the shape memory polymer in the activated state upon exposure to the activation condition in the fracture, wherein the diameter of the shape memory polymer proppant in the activated state has a diameter that is equal to or greater than the diameter of the shape memory polymer proppant in the programmed state,
wherein the activated state diameter is about 100 ?m to 1 mm, wherein the programmed state diameter is about 100 ?m to 1 mm, and wherein the activated state diameter is equal to or greater than the programmed state diameter.
exposing the shape memory polymer proppant in the programmed state to the activation condition in the fracture, wherein the activation condition is an activation temperature; and
converting the shape memory polymer proppant in the programmed state to the shape memory polymer in the activated state upon exposure to the activation condition in the fracture, wherein the diameter of the shape memory polymer proppant in the activated state has a diameter that is equal to or greater than the diameter of the shape memory polymer proppant in the programmed state,
wherein the activated state diameter is about 100 ?m to 1 mm, wherein the programmed state diameter is about 100 ?m to 1 mm, and wherein the activated state diameter is equal to or greater than the programmed state diameter.
US Pat. No. 10,005,801
COMPOUNDS FOR PH-CONTROLLED RELEASE OF HYDROGEN SULFIDE
Washington State Universi...
1. A compound having the formulawhereinR1 is aryl, alkyl, aralkyl, and substituted aryl or a combination thereof;
R2 is a hydrogen, or a part of a 3 to 7 membered ring system connecting R2 to R3;
R3 is a hydrogen, or part of the 3 to 7 membered ring system connecting to R2 to R3,
wherein the 3 to 7 membered ring system connecting R2 to R3, when present, is an optionally substituted, fully saturated or unsaturated, aromatic or a nonaromatic cyclic or hetrocyclic group;
R4 is an alkyl or a carboxylic acid,or a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer.
R2 is a hydrogen, or a part of a 3 to 7 membered ring system connecting R2 to R3;
R3 is a hydrogen, or part of the 3 to 7 membered ring system connecting to R2 to R3,
wherein the 3 to 7 membered ring system connecting R2 to R3, when present, is an optionally substituted, fully saturated or unsaturated, aromatic or a nonaromatic cyclic or hetrocyclic group;
R4 is an alkyl or a carboxylic acid,or a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer.
US Pat. No. 9,725,708
METHODS OF MODULATING UBIQUITIN LIGASE ACTIVITY
Board of Supervisors of L...
1. A method of reducing the activity of a ubiquitin-protein E3ligase (E6AP ubiquitin-protein ligase) comprising the step of
inhibiting the formation of an E6-Associated Protein (E6AP) polypeptide trimer by contacting the E6AP polypeptide with a compound
that binds to the E6AP polypeptide and thereby reducing the oligomerization of the ubiquitin-protein E3ligase polypeptide.
inhibiting the formation of an E6-Associated Protein (E6AP) polypeptide trimer by contacting the E6AP polypeptide with a compound
that binds to the E6AP polypeptide and thereby reducing the oligomerization of the ubiquitin-protein E3ligase polypeptide.
US Pat. No. 9,759,652
QUANTUM DOT LIGHT EMITTING DIODES FOR MULTIPLEX GAS SENSING
Board of Supervisors of L...
1. A gas detection device comprising:
a light emitting source including a first plurality of quantum dots of substantially discrete size and made of one or more
semiconductor materials;
a gas cell to contain the gas to be detected;
a light detector; and
the light emitting source including at least three layers, the first layer having a first thickness and including the first
plurality of quantum dots and not a second or a third pluralities of quantum dots, the second layer having a second thickness,
which is more than twice as thick as the first thickness, and including the second plurality of quantum dots and not the first
or the third pluralities of quantum dots, and the third layer having a third thickness, which is more than twice as thick
as the second thickness, and including the third plurality of quantum dots and not the first or section pluralities of quantum
dots.
a light emitting source including a first plurality of quantum dots of substantially discrete size and made of one or more
semiconductor materials;
a gas cell to contain the gas to be detected;
a light detector; and
the light emitting source including at least three layers, the first layer having a first thickness and including the first
plurality of quantum dots and not a second or a third pluralities of quantum dots, the second layer having a second thickness,
which is more than twice as thick as the first thickness, and including the second plurality of quantum dots and not the first
or the third pluralities of quantum dots, and the third layer having a third thickness, which is more than twice as thick
as the second thickness, and including the third plurality of quantum dots and not the first or section pluralities of quantum
dots.
US Pat. No. 9,718,676
POLYMERIC NANOPILLARS AND NANOTUBES, THEIR MANUFACTURE AND USES
Board of Supervisors of L...
1. An integrated system for analysis of proteins and mixtures of proteins, wherein said system is contained on a single, monolithic
microchip, said system comprising:
(a) an input adapted to receive a sample and to deliver it to a solid-phase protein extractor;
(b) a solid-phase protein extractor adapted to extract and concentrate proteins from the sample, and to output the extracted
proteins to a first separation channel;
(c) a first separation channel having a diameter less than about 100 ?m, whose surface is adapted to separate the proteins
by a first characteristic, wherein said first separation channel is adapted to output the separated proteins to a second separation
channel;
(d) a second separation channel having a diameter less than about 100 ?m, whose surface is adapted to separate the proteins
by a second characteristic, wherein said second separation channel is adapted to output the separated proteins to a solid-phase
enzymatic reactor; wherein the first and second separation characteristics are substantially different;
(e) a flow-through, solid-phase enzymatic reactor whose surface comprises one or more covalently-bound enzymes adapted to
at least partially digest the separated proteins, and to output the digested proteins to a peptide separator; and
(f) a peptide separator adapted to separate the peptide protein digest products by a third characteristic, wherein the third
characteristic may be the same as the first or second characteristic, or different from both; and wherein said peptide separator
is adapted to output the separated peptides to a detector;
wherein:
(g) each of said solid-phase extractor, said enzymatic reactor, said first separation channel, and said second separation
channel comprises an array of nanopillars having diameters between about 60 nm and about 500 nm, and aspect ratios 500 or higher, wherein said nanopillars comprise a synthetic polymer; wherein said nanopillars have solid interiors; and wherein
said nanopillars are not hollow;
and wherein:
(h) each said array of nanopillars is prepared by a process comprising the steps of:
(i) supplying a template of anodic aluminum oxide, wherein at least one surface of the template has a shape complementary
to the shape of at least one surface of the nanopillars to be made;
(ii) impregnating at least the complementary surface of the template with a liquid comprising a solution of a polymer, or
comprising a solution of a monomer precursor of a polymer, or comprising a polymer melt;
(iii) forming a solid polymer structure in the impregnated template by cooling the liquid or by inducing polymerization of
monomer precursors in the liquid;
(iv) removing the template from the solid polymer structure; and
(v) avoiding or reducing surface-tension-induced damage to the solid polymer structure by keeping it immersed in a liquid,
or by removing residual liquid by freeze-drying, or by removing residual liquid by supercritical drying;
wherein:
(vi) the solid polymer structure that is produced comprises one or more arrays of intact nanopillars, wherein the nanopillars
have diameters between about 60 nm and about 500 nm, and an aspect ratio that is 500 or higher.
microchip, said system comprising:
(a) an input adapted to receive a sample and to deliver it to a solid-phase protein extractor;
(b) a solid-phase protein extractor adapted to extract and concentrate proteins from the sample, and to output the extracted
proteins to a first separation channel;
(c) a first separation channel having a diameter less than about 100 ?m, whose surface is adapted to separate the proteins
by a first characteristic, wherein said first separation channel is adapted to output the separated proteins to a second separation
channel;
(d) a second separation channel having a diameter less than about 100 ?m, whose surface is adapted to separate the proteins
by a second characteristic, wherein said second separation channel is adapted to output the separated proteins to a solid-phase
enzymatic reactor; wherein the first and second separation characteristics are substantially different;
(e) a flow-through, solid-phase enzymatic reactor whose surface comprises one or more covalently-bound enzymes adapted to
at least partially digest the separated proteins, and to output the digested proteins to a peptide separator; and
(f) a peptide separator adapted to separate the peptide protein digest products by a third characteristic, wherein the third
characteristic may be the same as the first or second characteristic, or different from both; and wherein said peptide separator
is adapted to output the separated peptides to a detector;
wherein:
(g) each of said solid-phase extractor, said enzymatic reactor, said first separation channel, and said second separation
channel comprises an array of nanopillars having diameters between about 60 nm and about 500 nm, and aspect ratios 500 or higher, wherein said nanopillars comprise a synthetic polymer; wherein said nanopillars have solid interiors; and wherein
said nanopillars are not hollow;
and wherein:
(h) each said array of nanopillars is prepared by a process comprising the steps of:
(i) supplying a template of anodic aluminum oxide, wherein at least one surface of the template has a shape complementary
to the shape of at least one surface of the nanopillars to be made;
(ii) impregnating at least the complementary surface of the template with a liquid comprising a solution of a polymer, or
comprising a solution of a monomer precursor of a polymer, or comprising a polymer melt;
(iii) forming a solid polymer structure in the impregnated template by cooling the liquid or by inducing polymerization of
monomer precursors in the liquid;
(iv) removing the template from the solid polymer structure; and
(v) avoiding or reducing surface-tension-induced damage to the solid polymer structure by keeping it immersed in a liquid,
or by removing residual liquid by freeze-drying, or by removing residual liquid by supercritical drying;
wherein:
(vi) the solid polymer structure that is produced comprises one or more arrays of intact nanopillars, wherein the nanopillars
have diameters between about 60 nm and about 500 nm, and an aspect ratio that is 500 or higher.
US Pat. No. 9,090,907
MODIFIED INSM1-PROMOTER FOR NEUROENDOCRINE TUMOR THERAPY AND DIAGNOSTICS
Board of Supervisors of L...
1. A viral expression vector whose genome comprises: (a) the human INSM1 promoter; (b) a pair of tandem nicotinic acetylcholine
receptor neuronal restrictive silencer elements downstream from said promoter; (c) an insulator element upstream from said
promoter; and (d) one or more DNA sequences encoding a polypeptide toxin, or encoding a polypeptide reporter molecule, or
encoding both a polypeptide toxin and a polypeptide reporter molecule;
wherein:
(i) said viral expression vector is competent to infect at least some mammalian cells;
(ii) said insulator is adapted to block the influence of viral regulatory elements on the transcription within mammalian cells
of said one or more DNA sequences, but not to affect the influence of said promoter or the influence of said neuronal restrictive
silencer elements on the transcription of said one or more DNA sequences;
(iii) said promoter is operatively linked to said one or more DNA sequences, and is adapted to cause the selective transcription
of said one or more DNA sequences in tumor cells of neuroendocrine origin;
(iv) said tandem neuronal restrictive silencer elements are operatively linked to said promoter, and are adapted to selectively
repress the transcription of said one or more DNA sequences in non-neuronal cells;
(v) the reporter molecule, if expressed, facilitates the identification of cells in which the reporter molecule is expressed;
and the toxin, if expressed, is lethal or conditionally lethal to cells in which the toxin is expressed;
whereby:said viral expression vector is adapted to be administered to a mammal in vivo, and to cause the selective in vivo expression
of said one or more DNA sequences in tumor cells of neuroendocrine origin, without expression of said one or more DNA sequences
in non-neuronal cells; whereby the reporter molecule, if expressed, facilitates the identification of tumor cells of neuroendocrine
origin; and whereby the toxin, if expressed, is lethal or conditionally lethal to tumor cells of neuroendocrine origin.
receptor neuronal restrictive silencer elements downstream from said promoter; (c) an insulator element upstream from said
promoter; and (d) one or more DNA sequences encoding a polypeptide toxin, or encoding a polypeptide reporter molecule, or
encoding both a polypeptide toxin and a polypeptide reporter molecule;
wherein:
(i) said viral expression vector is competent to infect at least some mammalian cells;
(ii) said insulator is adapted to block the influence of viral regulatory elements on the transcription within mammalian cells
of said one or more DNA sequences, but not to affect the influence of said promoter or the influence of said neuronal restrictive
silencer elements on the transcription of said one or more DNA sequences;
(iii) said promoter is operatively linked to said one or more DNA sequences, and is adapted to cause the selective transcription
of said one or more DNA sequences in tumor cells of neuroendocrine origin;
(iv) said tandem neuronal restrictive silencer elements are operatively linked to said promoter, and are adapted to selectively
repress the transcription of said one or more DNA sequences in non-neuronal cells;
(v) the reporter molecule, if expressed, facilitates the identification of cells in which the reporter molecule is expressed;
and the toxin, if expressed, is lethal or conditionally lethal to cells in which the toxin is expressed;
whereby:said viral expression vector is adapted to be administered to a mammal in vivo, and to cause the selective in vivo expression
of said one or more DNA sequences in tumor cells of neuroendocrine origin, without expression of said one or more DNA sequences
in non-neuronal cells; whereby the reporter molecule, if expressed, facilitates the identification of tumor cells of neuroendocrine
origin; and whereby the toxin, if expressed, is lethal or conditionally lethal to tumor cells of neuroendocrine origin.
US Pat. No. 9,568,106
MECHANICAL SEAL WITH TEXTURED SIDEWALL
Board of Supervisors of L...
1. A stationary mating ring for a mechanical seal, comprising:
an annular body having a central axis and a sealing face having a face width; and
a plurality of dimples formed into an outer circumferential surface of said annular body, wherein the plurality of dimples
is spaced away from the sealing face and is configured to increase the exposed circumferential surface area of said annular
body;
wherein the stationary mating ring is configured to form part of the mechanical seal such that the sealing face interfaces
with a face of a rotating ring of the mechanical seal;
wherein the plurality of dimples comprises a plurality of dimple bottoms at a lower extent of the plurality of dimples;
wherein the plurality of dimples have a plurality of dimple centers and the plurality of dimple centers are located on a sealing
face side of the outer circumferential surface; and
wherein the annular body is a barrier to radial fluid flow.
an annular body having a central axis and a sealing face having a face width; and
a plurality of dimples formed into an outer circumferential surface of said annular body, wherein the plurality of dimples
is spaced away from the sealing face and is configured to increase the exposed circumferential surface area of said annular
body;
wherein the stationary mating ring is configured to form part of the mechanical seal such that the sealing face interfaces
with a face of a rotating ring of the mechanical seal;
wherein the plurality of dimples comprises a plurality of dimple bottoms at a lower extent of the plurality of dimples;
wherein the plurality of dimples have a plurality of dimple centers and the plurality of dimple centers are located on a sealing
face side of the outer circumferential surface; and
wherein the annular body is a barrier to radial fluid flow.
US Pat. No. 9,499,834
RICE CULTIVAR DESIGNATED CL151
Board of Supervisors of L...
1. A rice seed of the variety CL151, wherein a representative sample of said seed has been deposited under ATCC Accession
No. PTA-9597; wherein a CL151 rice plant grown from said rice seed is resistant to each of the following imidazolinone herbicides,
at levels of the imidazolinone herbicides that would normally inhibit the growth of a rice plant: imazethapyr, imazapic, imazaquin,
imazamox, and imazapyr.
No. PTA-9597; wherein a CL151 rice plant grown from said rice seed is resistant to each of the following imidazolinone herbicides,
at levels of the imidazolinone herbicides that would normally inhibit the growth of a rice plant: imazethapyr, imazapic, imazaquin,
imazamox, and imazapyr.
US Pat. No. 9,240,955
SYSTEM AND ARCHITECTURE FOR ROBUST MANAGEMENT OF RESOURCES IN A WIDE-AREA NETWORK
Board of Supervisors of L...
1. A system comprising:
a first networked node comprising: a first computer, a first data store, a first control process, a first one or more logic
processes, a first one or more evaluating processes, and a first communication system, said first control process having a
capability to deploy said first one or more logic processes, and said first one or more logic processes each having a capability
to cause said first one or more evaluating processes to begin,
said first data store, said first control process, said first one or more logic processes, said first evaluating process,
and said first communication system operating on said first computer, and
a second networked node comprising: a second computer, a second data store, a second control process, a second one or more
logic processes, a second one or more evaluating processes, and a second communication system, said second control process
having a capability to deploy said second one or more logic processes, and said second one or more logic processes each having
a capability to cause said second one or more evaluating processes to begin, said second data store, said second control process,
said second one or more logic processes, said second one or more evaluating processes, and said second communication system
operating on said second computer, and
wherein said first data store provides access to a global address space and said second data store provides access to said
global address space,
wherein data is available in said global address space,
wherein said first networked node and said second networked node are networked together, and
wherein said first one or more logic processes is capable of retrieving said data from said global address space via said
first communication system,
wherein said second one or more logic processes is capable of retrieving said data from said global address space via said
second communication system,
wherein said first control process is capable of deploying a first one of said first one or more logic processes with a first
set of instructions,
wherein said first one of said first one or more logic processes is capable of causing a first one of said first one or more
evaluating processes to begin executing said first set of instructions, and
wherein said first one of said first one or more evaluating processes is capable of evaluating said data to synthesize a first
result using said first set of instructions,
wherein said first one of said first one or more evaluating processes is capable of storing said first result as said data
in said global address space via said first communication system,
wherein said first one of said first one or more logic processes is capable of causing a second one of said first one or more
evaluating processes to begin executing said first set of instructions.
a first networked node comprising: a first computer, a first data store, a first control process, a first one or more logic
processes, a first one or more evaluating processes, and a first communication system, said first control process having a
capability to deploy said first one or more logic processes, and said first one or more logic processes each having a capability
to cause said first one or more evaluating processes to begin,
said first data store, said first control process, said first one or more logic processes, said first evaluating process,
and said first communication system operating on said first computer, and
a second networked node comprising: a second computer, a second data store, a second control process, a second one or more
logic processes, a second one or more evaluating processes, and a second communication system, said second control process
having a capability to deploy said second one or more logic processes, and said second one or more logic processes each having
a capability to cause said second one or more evaluating processes to begin, said second data store, said second control process,
said second one or more logic processes, said second one or more evaluating processes, and said second communication system
operating on said second computer, and
wherein said first data store provides access to a global address space and said second data store provides access to said
global address space,
wherein data is available in said global address space,
wherein said first networked node and said second networked node are networked together, and
wherein said first one or more logic processes is capable of retrieving said data from said global address space via said
first communication system,
wherein said second one or more logic processes is capable of retrieving said data from said global address space via said
second communication system,
wherein said first control process is capable of deploying a first one of said first one or more logic processes with a first
set of instructions,
wherein said first one of said first one or more logic processes is capable of causing a first one of said first one or more
evaluating processes to begin executing said first set of instructions, and
wherein said first one of said first one or more evaluating processes is capable of evaluating said data to synthesize a first
result using said first set of instructions,
wherein said first one of said first one or more evaluating processes is capable of storing said first result as said data
in said global address space via said first communication system,
wherein said first one of said first one or more logic processes is capable of causing a second one of said first one or more
evaluating processes to begin executing said first set of instructions.
US Pat. No. 9,644,072
CONTROLLED RADICAL POLYMERIZATION, AND CATALYSTS USEFUL THEREIN
Board of Supervisors of L...
1. A method of synthesizing a catalyst, said method comprising reacting in solution ArX with NiL2 wherein:
Ar denotes bithiophen-2-yl;
each of the two L ligands is 1,3-bis(diphenylphosphino)propane; and
X denotes bromine.
Ar denotes bithiophen-2-yl;
each of the two L ligands is 1,3-bis(diphenylphosphino)propane; and
X denotes bromine.
US Pat. No. 9,833,433
COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT
Board of Supervisors of L...
1. A method of treating a disease or condition consisting of: administering to a subject in need thereof, a therapeutically
effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt of the COX-2 inhibitor, and a therapeutically
effective amount of a cannabinoid, or a pharmaceutically acceptable salt of the cannabinoid, to treat the disease or condition.
effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt of the COX-2 inhibitor, and a therapeutically
effective amount of a cannabinoid, or a pharmaceutically acceptable salt of the cannabinoid, to treat the disease or condition.
US Pat. No. 9,493,643
THERMOSETTING SHAPE MEMORY POLYMERS WITH ABILITY TO PERFORM REPEATED MOLECULAR SCALE HEALING
Board of Supervisors of L...
19. A programmed shape memory polymer composite produced by a process comprising:
A) mixing a thermoset shape memory polymer matrix with a thermoplastic polymer and microballoons, whereby a composite is formed
having a native volume; and
B) programming the entire composite to a volume less than the native volume of said composite.
A) mixing a thermoset shape memory polymer matrix with a thermoplastic polymer and microballoons, whereby a composite is formed
having a native volume; and
B) programming the entire composite to a volume less than the native volume of said composite.
US Pat. No. 9,700,525
CONTINUOUS LOCAL SLOW-RELEASE OF THERAPEUTICS FOR HEAD AND NECK PROBLEMS AND UPPER AERODIGESTIVE DISORDERS
1. A method for treating head and neck cancers, said method comprising administering to a patient in need thereof a sustained
slow-release chewing gum composition suitable for sublingual and/or oral transmucosal delivery of curcumin by absorption through
the oral mucosa, said composition consisting of 350 mg to 800 mg of curcumin, gum base, corn syrup, citric acid and glycerin,
wherein said curcumin is systemically bioavailable so as to provide therapeutic concentrations of curcumin in said patient.
slow-release chewing gum composition suitable for sublingual and/or oral transmucosal delivery of curcumin by absorption through
the oral mucosa, said composition consisting of 350 mg to 800 mg of curcumin, gum base, corn syrup, citric acid and glycerin,
wherein said curcumin is systemically bioavailable so as to provide therapeutic concentrations of curcumin in said patient.
US Pat. No. 9,574,136
NANOPARTICLES, NANOSPONGES, METHODS OF SYNTHESIS, AND METHODS OF USE
Board of Supervisors of L...
1. A method for making metallic-core carbon-shell nanoparticles, said method comprising the steps of:
(a) impregnating biological fibers with a solution of metal ions in an aqueous or non-aqueous solvent;
(b) removing the solvent, while leaving at least some of the metal ions impregnated in the fibers; and
(c) heating the metal-ion-impregnated fibers in an inert atmosphere or in a vacuum to a temperature that carbonizes at least
some of the fibers, that does not vaporize most of the carbon, that reduces at least some of the metal ions to metal particles
in a zero oxidation state, and that causes a carbon shell to form around and to completely enclose most of the zero-oxidation-state
metal particles; wherein no reducing agent is present during the reduction step, other than said biological fibers themselves;
and wherein the reduction of the metal ions to metal particles in a zero oxidation state, and the formation of the carbon
shell around the zero-oxidation state metal particles occur simultaneously.
(a) impregnating biological fibers with a solution of metal ions in an aqueous or non-aqueous solvent;
(b) removing the solvent, while leaving at least some of the metal ions impregnated in the fibers; and
(c) heating the metal-ion-impregnated fibers in an inert atmosphere or in a vacuum to a temperature that carbonizes at least
some of the fibers, that does not vaporize most of the carbon, that reduces at least some of the metal ions to metal particles
in a zero oxidation state, and that causes a carbon shell to form around and to completely enclose most of the zero-oxidation-state
metal particles; wherein no reducing agent is present during the reduction step, other than said biological fibers themselves;
and wherein the reduction of the metal ions to metal particles in a zero oxidation state, and the formation of the carbon
shell around the zero-oxidation state metal particles occur simultaneously.
US Pat. No. 9,243,985
FRACTURE FATIGUE ENTROPY DETERMINATION
Board of Supervisors of L...
1. A method for preventing the mechanical failure of a metallic object; wherein the metallic object is subject to cyclic loading;
and wherein said method comprises the following steps:
(a) measuring the temperature of the surface of the metallic object, in the vicinity of the location of incipient mechanical
failure, using a temperature sensor;
(b) approximating the accumulated volumetric entropy production ? in the vicinity of the location of incipient mechanical
failure of the metallic object, using a relationship that is equivalent to:
?=?0t?(Wp/T)dt
wherein t denotes the time, t? denotes the particular time for which ? is being determined, T denotes the temperature of the
surface of the metallic object in the vicinity of the location of incipient mechanical failure, and Wp denotes the cyclic
plastic energy for the metallic object;
(c) predicting the time of mechanical failure of the metallic object when ? is approaching the value of ?f, or is approaching a user-specified fraction of the value of ?f, wherein ?f denotes the mean volumetric fracture fatigue entropy for the metallic object; and
(d) stopping the cyclic loading of the metallic object, using a controller, when ? approaches the value of ?f, or when ? approaches a user-specified fraction of the value of ?f.
and wherein said method comprises the following steps:
(a) measuring the temperature of the surface of the metallic object, in the vicinity of the location of incipient mechanical
failure, using a temperature sensor;
(b) approximating the accumulated volumetric entropy production ? in the vicinity of the location of incipient mechanical
failure of the metallic object, using a relationship that is equivalent to:
?=?0t?(Wp/T)dt
wherein t denotes the time, t? denotes the particular time for which ? is being determined, T denotes the temperature of the
surface of the metallic object in the vicinity of the location of incipient mechanical failure, and Wp denotes the cyclic
plastic energy for the metallic object;
(c) predicting the time of mechanical failure of the metallic object when ? is approaching the value of ?f, or is approaching a user-specified fraction of the value of ?f, wherein ?f denotes the mean volumetric fracture fatigue entropy for the metallic object; and
(d) stopping the cyclic loading of the metallic object, using a controller, when ? approaches the value of ?f, or when ? approaches a user-specified fraction of the value of ?f.
US Pat. No. 9,234,886
CXCR4 AND ROBO1 EXPRESSION AS MARKERS FOR AUTOIMMUNE DIABETES
Board of Supervisors of L...
1. A method for treating autoimmune diabetes in a vertebrate patient, said method comprising the steps of:
(a) assaying T cells from the patient for a patient level of roundabout axon guidance receptor homolog 1 (ROBO1) expression
as compared with a mean level of ROBO1 expression for non-diabetic, conspecific individuals; and determining if the patient
level of ROBO1 expression is significantly higher than the non-diabetic mean level at a significance level of p<0.05; and
(b) administering an SDF-1 agonist to the patient if the patient level of ROBO1 expression is significantly higher at a significance
level of p<0.05 than the non-diabetic mean level of ROBO1 expression; wherein the SDF-1 agonist is CTCE-0214.
(a) assaying T cells from the patient for a patient level of roundabout axon guidance receptor homolog 1 (ROBO1) expression
as compared with a mean level of ROBO1 expression for non-diabetic, conspecific individuals; and determining if the patient
level of ROBO1 expression is significantly higher than the non-diabetic mean level at a significance level of p<0.05; and
(b) administering an SDF-1 agonist to the patient if the patient level of ROBO1 expression is significantly higher at a significance
level of p<0.05 than the non-diabetic mean level of ROBO1 expression; wherein the SDF-1 agonist is CTCE-0214.
US Pat. No. 9,222,865
FATIGUE ASSESSMENT
Board of Supervisors of L...
1. A method of evaluating fatigue comprising:
a. subjecting a fatigued object to a cyclic mechanical stress;
b. measuring a rate of temperature rise in the fatigued object; and
c. assessing a degree of fatigue of the fatigued object based on the rate of temperature rise in the fatigued object;
d. wherein the assessing of the degree of fatigue comprises comparing the rate of temperature rise in the fatigued object
to information from a different temperature rise test on a different object;
e. wherein the rate of temperature rise is measured at the beginning of the subjecting of the fatigued object to the cyclic
mechanical stress;
f. wherein the measuring of the rate of temperature rise in the fatigued object occurs during an excitation test;
g. wherein the fatigued object is an object that has previously undergone substantial micro-structural fatigue changes;
h. wherein the degree of fatigue assessed is representative of an amount of fatigue experienced prior to the excitation test;
and
i. wherein the amount of fatigue experienced prior to the excitation test is unknown prior to the excitation test.
a. subjecting a fatigued object to a cyclic mechanical stress;
b. measuring a rate of temperature rise in the fatigued object; and
c. assessing a degree of fatigue of the fatigued object based on the rate of temperature rise in the fatigued object;
d. wherein the assessing of the degree of fatigue comprises comparing the rate of temperature rise in the fatigued object
to information from a different temperature rise test on a different object;
e. wherein the rate of temperature rise is measured at the beginning of the subjecting of the fatigued object to the cyclic
mechanical stress;
f. wherein the measuring of the rate of temperature rise in the fatigued object occurs during an excitation test;
g. wherein the fatigued object is an object that has previously undergone substantial micro-structural fatigue changes;
h. wherein the degree of fatigue assessed is representative of an amount of fatigue experienced prior to the excitation test;
and
i. wherein the amount of fatigue experienced prior to the excitation test is unknown prior to the excitation test.
US Pat. No. 9,414,598
PROTECTING WOOD WITH STABILIZED BORON COMPLEXES
Board of Supervisors of L...
6. A treated wood product comprising wood treated with a silicate, boric acid, and a complexing agent; wherein
c. said complexing agent comprises chromotropic acid (4,5-dihydroxy-2,7-naphthalenedisulfonic acid).
c. said complexing agent comprises chromotropic acid (4,5-dihydroxy-2,7-naphthalenedisulfonic acid).
US Pat. No. 9,465,024
MEASUREMENT OF BIOLOGICALLY LABILE HYDROGEN SULFIDE POOLS
Board of Supervisors of L...
17. A method to measure concentrations of one of acid-labile sulfide and sulfane-bound sulfur in a sample comprising:
one of
(1) placing a first and a second separate portions of the sample into a respective first and second evacuated containers;
adding an alkaline buffer, a chelating agent, and monobromobimane to the first portion, and incubating under low oxygen condition;
separating a sulfide-dibimane product from the first portion; and
measuring an amount of the sulfide-dibimane separated from the first portion;
adding an acid buffer to the second portion and incubating to release acid-labile sulfide as free H2S, the second portion including a liquid segment and a gaseous segment;
removing the liquid segment of the second portion;
combining the gaseous segment of the second portion with an alkaline buffer, a chelating agent, and monobromobimane, and incubating
under low oxygen conditions;
separating a sulfide-dibimane product from the second portion;
measuring an amount of the sulfide-dibimane product separated from the second portion; and
determining a measurement of the concentration of acid-labile sulfide in the sample as equal to a difference between the amount
of sulfide-dibimane product separated from the first portion and the amount of the sulfide-dibimane product separated from
the second portion; and
(2) placing a second and a third separate portions of the sample into a respective second and third evacuated containers;
and
adding an acid buffer to the second portion and incubating to release acid-labile sulfide as free H2S, the second portion including a liquid segment and a gaseous segment;
removing the liquid segment of the second portion;
combining the gaseous segment of the second portion with an alkaline buffer, a chelating agent, and monobromobimane, and incubating
under low oxygen conditions;
separating a sulfide-dibimane product from the second portion;
measuring an amount of the sulfide-dibimane product separated from the second portion;
adding an acid buffer and a reducing agent to the third portion, the third portion including a liquid segment and a gaseous
segment;
removing the liquid segment of the third portion;
combining the gaseous segment of the third portion with an alkaline buffer, a chelating agent, and monobromobimane,
incubating the third portion under low oxygen conditions;
separating a sulfide-dibimane product from the third portion;
measuring an amount of the sulfide-dibimane product separated from the third portion; and
determining a measurement of the concentration of sulfane sulfur in the sample as equal to a difference between the amount
of the sulfide-dibimane product separated from the second portion and the amount of the sulfide-dibimane product separated
from the third portion.
one of
(1) placing a first and a second separate portions of the sample into a respective first and second evacuated containers;
adding an alkaline buffer, a chelating agent, and monobromobimane to the first portion, and incubating under low oxygen condition;
separating a sulfide-dibimane product from the first portion; and
measuring an amount of the sulfide-dibimane separated from the first portion;
adding an acid buffer to the second portion and incubating to release acid-labile sulfide as free H2S, the second portion including a liquid segment and a gaseous segment;
removing the liquid segment of the second portion;
combining the gaseous segment of the second portion with an alkaline buffer, a chelating agent, and monobromobimane, and incubating
under low oxygen conditions;
separating a sulfide-dibimane product from the second portion;
measuring an amount of the sulfide-dibimane product separated from the second portion; and
determining a measurement of the concentration of acid-labile sulfide in the sample as equal to a difference between the amount
of sulfide-dibimane product separated from the first portion and the amount of the sulfide-dibimane product separated from
the second portion; and
(2) placing a second and a third separate portions of the sample into a respective second and third evacuated containers;
and
adding an acid buffer to the second portion and incubating to release acid-labile sulfide as free H2S, the second portion including a liquid segment and a gaseous segment;
removing the liquid segment of the second portion;
combining the gaseous segment of the second portion with an alkaline buffer, a chelating agent, and monobromobimane, and incubating
under low oxygen conditions;
separating a sulfide-dibimane product from the second portion;
measuring an amount of the sulfide-dibimane product separated from the second portion;
adding an acid buffer and a reducing agent to the third portion, the third portion including a liquid segment and a gaseous
segment;
removing the liquid segment of the third portion;
combining the gaseous segment of the third portion with an alkaline buffer, a chelating agent, and monobromobimane,
incubating the third portion under low oxygen conditions;
separating a sulfide-dibimane product from the third portion;
measuring an amount of the sulfide-dibimane product separated from the third portion; and
determining a measurement of the concentration of sulfane sulfur in the sample as equal to a difference between the amount
of the sulfide-dibimane product separated from the second portion and the amount of the sulfide-dibimane product separated
from the third portion.
US Pat. No. 9,284,705
OILWATER SEPARATOR
Board of Supervisors of L...
1. Apparatus for separating a mixture of oil and water into two fractions: an oil fraction comprising primarily oil, and a
water fraction comprising primarily water; wherein the oil fraction may optionally comprise one or more minor components in
addition to oil, and wherein the water fraction may optionally comprise one or more minor components in addition to water;
wherein said apparatus comprises:
(a) a first chamber and a second chamber, wherein said first and second chambers are fluidly connected to one another only
at or near the bottoms of said first and second chambers;
(b) an inlet adapted to transport a mixture of oil and water from an external source into said first chamber;
(c) a low-shear or non-emulsifying pump adapted to transport the mixture of oil and water from the external source, through
said inlet, and into said first chamber;
(d) an oil outlet adapted to transport the separated oil fraction from said first chamber; and
(e) a water outlet adapted to transport the separated water fraction from said second chamber;wherein:
(f) said oil outlet has a higher elevation than said water outlet;
(g) the respective elevations of said oil and water outlets above the fluid connection between said first and second chambers,
and the dimensions of said first chamber are such that said apparatus is adapted to operate as follows:
(i) said pump transports the mixture of oil and water from an external source, through said inlet, and into said first chamber;
(ii) within said first chamber, the turbulence and velocity of fluid flow are sufficiently low that the mixture separates
by density into an lighter, upper, oil fraction and a denser, lower, water fraction; (iii) the continued inflow of liquid
forces liquid in the denser, lower, water fractionbut not liquid in the lighter, upper, oil fractionto flow from said first
chamber through the fluid connection into said second chamber, thereby separating a water fraction; (iv) the continued inflow
of liquid forces liquid in the separated water fraction in said second chamber through said water outlet; (v) the continued
inflow of liquid forces liquid in the separated oil fraction in said first chamber through said oil outlet; and (vi) the difference
in elevation between said oil and water outlets, together with the difference in densities between the separated oil and water
fractions, and the presence of the fluid connection between said first and second chambers ensure that essentially none of
the water fraction reaches said oil outlet;
(h) a portion of said first chamber adjacent to said inlet is substantially wider than other portions of said first chamber;
wherein the dimensions of the wider portion of said first chamber are sufficiently large to inhibit the development of turbulence
within said first chamber; and wherein the narrower portions of said first chamber are at least sufficiently wide not to substantially
impede the flow of liquid through said first chamber;
(i) said first and second chambers are dimensioned so that, when said apparatus is placed in a body of water, the center of
gravity of said apparatus lies below the surface of the body of water, and so that the wider portion of said first chamber
lies fully or partially below the surface of the body of water;
(j) said apparatus is adapted to be mounted in a ship or a boat, or is adapted to be towed in the water behind a ship or a
boat; and
(k) said apparatus is adapted to operate, as described in limitation (g) above, in situ, to separate a mixture of oil and
water while said apparatus is moving on a body of water, without any necessity to first transport the mixture of oil and water
onshore or to a stationary location before the oil fraction and water fraction are separated from one another.
water fraction comprising primarily water; wherein the oil fraction may optionally comprise one or more minor components in
addition to oil, and wherein the water fraction may optionally comprise one or more minor components in addition to water;
wherein said apparatus comprises:
(a) a first chamber and a second chamber, wherein said first and second chambers are fluidly connected to one another only
at or near the bottoms of said first and second chambers;
(b) an inlet adapted to transport a mixture of oil and water from an external source into said first chamber;
(c) a low-shear or non-emulsifying pump adapted to transport the mixture of oil and water from the external source, through
said inlet, and into said first chamber;
(d) an oil outlet adapted to transport the separated oil fraction from said first chamber; and
(e) a water outlet adapted to transport the separated water fraction from said second chamber;wherein:
(f) said oil outlet has a higher elevation than said water outlet;
(g) the respective elevations of said oil and water outlets above the fluid connection between said first and second chambers,
and the dimensions of said first chamber are such that said apparatus is adapted to operate as follows:
(i) said pump transports the mixture of oil and water from an external source, through said inlet, and into said first chamber;
(ii) within said first chamber, the turbulence and velocity of fluid flow are sufficiently low that the mixture separates
by density into an lighter, upper, oil fraction and a denser, lower, water fraction; (iii) the continued inflow of liquid
forces liquid in the denser, lower, water fractionbut not liquid in the lighter, upper, oil fractionto flow from said first
chamber through the fluid connection into said second chamber, thereby separating a water fraction; (iv) the continued inflow
of liquid forces liquid in the separated water fraction in said second chamber through said water outlet; (v) the continued
inflow of liquid forces liquid in the separated oil fraction in said first chamber through said oil outlet; and (vi) the difference
in elevation between said oil and water outlets, together with the difference in densities between the separated oil and water
fractions, and the presence of the fluid connection between said first and second chambers ensure that essentially none of
the water fraction reaches said oil outlet;
(h) a portion of said first chamber adjacent to said inlet is substantially wider than other portions of said first chamber;
wherein the dimensions of the wider portion of said first chamber are sufficiently large to inhibit the development of turbulence
within said first chamber; and wherein the narrower portions of said first chamber are at least sufficiently wide not to substantially
impede the flow of liquid through said first chamber;
(i) said first and second chambers are dimensioned so that, when said apparatus is placed in a body of water, the center of
gravity of said apparatus lies below the surface of the body of water, and so that the wider portion of said first chamber
lies fully or partially below the surface of the body of water;
(j) said apparatus is adapted to be mounted in a ship or a boat, or is adapted to be towed in the water behind a ship or a
boat; and
(k) said apparatus is adapted to operate, as described in limitation (g) above, in situ, to separate a mixture of oil and
water while said apparatus is moving on a body of water, without any necessity to first transport the mixture of oil and water
onshore or to a stationary location before the oil fraction and water fraction are separated from one another.
US Pat. No. 9,827,286
USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY
Ipsen Pharma S.A.S., Bou...
1. A method of treating insulin resistance in a subject in need thereof, comprising peripheral administration of a pharmaceutical
composition comprising an effective amount of Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO:278) or
a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier to treat said insulin resistance in
said subject.
composition comprising an effective amount of Hydantoin(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO:278) or
a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier to treat said insulin resistance in
said subject.
US Pat. No. 9,714,259
COMPOSITIONS AND METHODS FOR IMPROVING GLUCOSE UPTAKE
Board of Supervisors of L...
1. A compound comprising the structure of general Formula I, pharmaceutically acceptable salts thereof, and/or solvates thereof:
wherein Ar1 is selected from the group consisting of 6-membered aryl and 6-membered heteroaryl, each of which is optionally substituted;
wherein Ar2 is selected from the group consisting of 5-membered aryl and 5-membered heteroaryl, each of which is optionally substituted;
R1 and R2 are independently selected from the group consisting of hydroxy, alkoxy, and halo, and R3 is selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together with the boron atom form a cyclic boronate ester and R3 is null,
wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation
selected from the group consisting of potassium, mercury, lithium, and sodium.
wherein Ar1 is selected from the group consisting of 6-membered aryl and 6-membered heteroaryl, each of which is optionally substituted;
wherein Ar2 is selected from the group consisting of 5-membered aryl and 5-membered heteroaryl, each of which is optionally substituted;
R1 and R2 are independently selected from the group consisting of hydroxy, alkoxy, and halo, and R3 is selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together with the boron atom form a cyclic boronate ester and R3 is null,
wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation
selected from the group consisting of potassium, mercury, lithium, and sodium.
US Pat. No. 9,599,626
THERAPEUTIC AND DIAGNOSTIC METHOD FOR ATAXIA-TELANGIECTASIA
Board of Supervisors of L...
1. A method to decrease neurodegeneration in a patient with Ataxia telangiectasia, said method comprising administering to
the patient an effective amount of an agent that inhibits the expression of a protein selected from the group consisting of
ISG15 and UbcH8 (E2-ISG15).
the patient an effective amount of an agent that inhibits the expression of a protein selected from the group consisting of
ISG15 and UbcH8 (E2-ISG15).
US Pat. No. 9,072,762
NATURAL COMPOSITION TO DECREASE EFFECTS OF A HIGH FAT DIET
Board of Supervisors of L...
1. A method to decrease symptoms in a mammal on a high fat diet; wherein said decrease in symptoms is selected from the group
consisting of decreased weight gain, decreased fat accumulation, decreased serum cholesterol, and decreased serum triglycerides;
said method comprising orally administering to the mammal an effective amount of a composition that comprises gallic acid,
ellagic acid, and rubusoside in a ratio of about 1:1.7:17; wherein the composition contains no steviol monoside.
consisting of decreased weight gain, decreased fat accumulation, decreased serum cholesterol, and decreased serum triglycerides;
said method comprising orally administering to the mammal an effective amount of a composition that comprises gallic acid,
ellagic acid, and rubusoside in a ratio of about 1:1.7:17; wherein the composition contains no steviol monoside.
US Pat. No. 9,987,286
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION, PSYCHIATRIC DISORDERS, AND NEURODEGENERATIVE DISEASE
EMBERA NEUROTHERAPEUTICS,...
1. A pharmaceutical composition for the treatment of a disorder associated with activity in the HPA axis, comprising metyrapol or a pharmaceutically acceptable salt thereof and a second pharmaceutically active agent, wherein said second agent is a benzodiazepine, wherein the composition is formulated for oral or topical administration to a patient, and wherein both the metyrapol and the second agent are present within the composition in an amount that is ineffective to treat said disorder when administered alone.
US Pat. No. 9,700,578
USE OF NITRITE SALTS FOR THE TREATMENT OF CARDIOVASCULAR CONDITIONS
The United States of Amer...
1. A method for treating or ameliorating a cardiovascular condition in a human subject by decreasing blood pressure and/or
increasing vasodilation in the subject, the method comprising administering a therapeutically effective amount of non-acidified
sodium nitrite to the subject to decrease the blood pressure and/or increase vasodilation in the subject, wherein the administration
is by a route whereby the non-acidified sodium nitrite contacts blood in the subject, and wherein the non-acidified sodium
nitrite is administered to the subject in an amount and for a sufficient period of time to reach a circulating concentration
in blood of the subject of no more than about 20 ?M, thereby treating or ameliorating the condition.
increasing vasodilation in the subject, the method comprising administering a therapeutically effective amount of non-acidified
sodium nitrite to the subject to decrease the blood pressure and/or increase vasodilation in the subject, wherein the administration
is by a route whereby the non-acidified sodium nitrite contacts blood in the subject, and wherein the non-acidified sodium
nitrite is administered to the subject in an amount and for a sufficient period of time to reach a circulating concentration
in blood of the subject of no more than about 20 ?M, thereby treating or ameliorating the condition.
US Pat. No. 10,561,668
DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION
BOARD OF SUPERVISORS OF L...
1. A method of treating a condition in a human patient comprising:pharmacologically activating a translocator protein of 18 kDa (TSPO) by administering a therapeutically effective amount of a pharmaceutical composition to the patient;
wherein the pharmaceutical composition includes one or more peripheral benzodiazepine receptor ligands selected from a group consisting of Ro5-4884, oxazepam, and a therapeutically acceptable salt, solvate, clathrate, stereoisomer, enantiomer or prodrug of these compounds or mixtures thereof; and
wherein the condition is a chronic methamphetamine addiction.
wherein the pharmaceutical composition includes one or more peripheral benzodiazepine receptor ligands selected from a group consisting of Ro5-4884, oxazepam, and a therapeutically acceptable salt, solvate, clathrate, stereoisomer, enantiomer or prodrug of these compounds or mixtures thereof; and
wherein the condition is a chronic methamphetamine addiction.
US Pat. No. 10,047,107
SMALL MOLECULE ANALOGS OF E4ORF1
Board Of Supervisors Of L...
1. A compound selected from the group consisting of:
and pharmaceutically acceptable salts and/or solvates thereof.
and pharmaceutically acceptable salts and/or solvates thereof.
US Pat. No. 9,580,704
KEXIN-DERIVED VACCINES TO PREVENT OR TREAT FUNGAL INFECTIONS
Board of Supervisors of L...
1. A fusion protein that comprises SEQ ID NO:6.
US Pat. No. 9,758,558
WHEY PROTEIN ISOLATE HYDROGELS AND THEIR USES
Board of Supervisors of L...
1. A fishing lure comprising a hydrogel; wherein said hydrogel comprises a mixture of a first component, a second component,
a third component, and a fourth component; wherein said first component comprises whey protein isolate; wherein said second
component comprises amylopectin, amylose, or both; wherein said third component comprises calcium chloride, sodium chloride,
or both; and wherein said fourth component comprises water, glycerol, or both; wherein said hydrogel contains no collagen;
and wherein said fishing lure is configured into any shape or design capable of attracting fish.
a third component, and a fourth component; wherein said first component comprises whey protein isolate; wherein said second
component comprises amylopectin, amylose, or both; wherein said third component comprises calcium chloride, sodium chloride,
or both; and wherein said fourth component comprises water, glycerol, or both; wherein said hydrogel contains no collagen;
and wherein said fishing lure is configured into any shape or design capable of attracting fish.
US Pat. No. 9,920,062
ANTIMICROBIAL MONOMERS AND POLYMERS, AND THEIR USE IN DENTAL DEVICES
Board of Supervisors of L...
1. A compound having either of the following structures:
wherein R and R? may be the same or different; and R and R? are independently selected from the group consisting of R1, R2,
R3, R5, and R6:
wherein m is an integer from 1 to 30;
wherein n is an integer from 0 to 20;
wherein A is selected from the group consisting of A2, A3, A4, and A5:
wherein X is selected from the group consisting of F, Cl, Br, I, CF3SO3, acetate, and gluconate;
wherein Y is hydrogen or an unsubstituted aliphatic group containing 1 to 6 carbons, and
wherein the various Y groups may be the same or different;
wherein Z is selected from the group consisting of one hydrogen atom, two hydrogen atoms, and an unsubstituted aliphatic group
containing 1 to 6 carbons;
wherein R1 is selected from the group consisting of hydrogen, an unsubstituted aliphatic group containing 1 to 18 carbons, benzyl, and
a cyclic aliphatic or aromatic group containing 5 to 18 carbons; and
wherein L is selected from the group consisting of L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, and L11:
wherein R and R? may be the same or different; and R and R? are independently selected from the group consisting of R1, R2,
R3, R5, and R6:
wherein m is an integer from 1 to 30;
wherein n is an integer from 0 to 20;
wherein A is selected from the group consisting of A2, A3, A4, and A5:
wherein X is selected from the group consisting of F, Cl, Br, I, CF3SO3, acetate, and gluconate;
wherein Y is hydrogen or an unsubstituted aliphatic group containing 1 to 6 carbons, and
wherein the various Y groups may be the same or different;
wherein Z is selected from the group consisting of one hydrogen atom, two hydrogen atoms, and an unsubstituted aliphatic group
containing 1 to 6 carbons;
wherein R1 is selected from the group consisting of hydrogen, an unsubstituted aliphatic group containing 1 to 18 carbons, benzyl, and
a cyclic aliphatic or aromatic group containing 5 to 18 carbons; and
wherein L is selected from the group consisting of L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, and L11:
US Pat. No. 9,872,760
SOFT TISSUE TENSIONING AND FIXATION DEVICE
Board of Supervisors of L...
1. A device adapted to affix a soft tissue or a suture attached to a soft tissue to a bone surface or other tissue surface;
said device comprising a base and an affixing member, wherein:
(a) said base comprises:
(i) a top surface and a bottom surface;
(ii) a passageway extending through said bottom surface and through said top surface, wherein said passageway comprises smooth
sides through which a soft tissue or a suture attached to a soft tissue may pass, and
(iii) at least one opening in said top surface extending from said passageway, wherein each said opening has one or more smooth
edges over which a soft tissue or a suture attached to a soft tissue may pass;
wherein:
(iv) the perimeter of said base has a generally circular shape;
(b) said affixing member is adapted to fit securely around or inside the generally circular perimeter of said base; wherein
said affixing member also has an opening through which the soft tissue or a suture attached to the soft tissue may pass to
or from the passageway through said base;
(c) a plurality of securing elements contained on the perimeter of said base, or contained on said affixing member, or both;
wherein said securing elements are adapted to hold said affixing member securely in any one of a plurality of positions as
selected by a surgeon, while said affixing member remains securely attached to a soft tissue or to a suture attached to a
soft tissue, and wherein said affixing member thereby applies a stable tension to the soft tissue; and wherein said securing
elements are adapted to permit the surgeon readily to alter the selected position, thereby allowing the surgeon to alter the
stable tension applied to the soft tissue during surgery, and allowing the surgeon to choose a position that stably applies
the amount of tension selected by the surgeon; and to maintain the chosen position, and thereby maintain the selected amount
of tension on the soft tissue following surgery as the soft tissue or a suture attached to the soft tissue is partially compressed
between said affixing member and said base.
said device comprising a base and an affixing member, wherein:
(a) said base comprises:
(i) a top surface and a bottom surface;
(ii) a passageway extending through said bottom surface and through said top surface, wherein said passageway comprises smooth
sides through which a soft tissue or a suture attached to a soft tissue may pass, and
(iii) at least one opening in said top surface extending from said passageway, wherein each said opening has one or more smooth
edges over which a soft tissue or a suture attached to a soft tissue may pass;
wherein:
(iv) the perimeter of said base has a generally circular shape;
(b) said affixing member is adapted to fit securely around or inside the generally circular perimeter of said base; wherein
said affixing member also has an opening through which the soft tissue or a suture attached to the soft tissue may pass to
or from the passageway through said base;
(c) a plurality of securing elements contained on the perimeter of said base, or contained on said affixing member, or both;
wherein said securing elements are adapted to hold said affixing member securely in any one of a plurality of positions as
selected by a surgeon, while said affixing member remains securely attached to a soft tissue or to a suture attached to a
soft tissue, and wherein said affixing member thereby applies a stable tension to the soft tissue; and wherein said securing
elements are adapted to permit the surgeon readily to alter the selected position, thereby allowing the surgeon to alter the
stable tension applied to the soft tissue during surgery, and allowing the surgeon to choose a position that stably applies
the amount of tension selected by the surgeon; and to maintain the chosen position, and thereby maintain the selected amount
of tension on the soft tissue following surgery as the soft tissue or a suture attached to the soft tissue is partially compressed
between said affixing member and said base.
US Pat. No. 9,745,713
DEVICE FOR COASTAL RESTORATION
Board of Supervisors of L...
1. A device for coastal restoration comprising:
a. a bag made of fabric, said bag having a first side and a second side;
b. said bag having a plurality of pockets, said pockets being created by fastening said first side to said second side at
a plurality of points, wherein said plurality of pockets includes a center pocket;
c. said bag and said plurality of pockets being adapted such that when aggregate material is placed in said bag, said pockets
form upper and lower lobes;
d. wherein all said pockets except said center pocket are filled with dry lightweight aggregate manufactured by a rotary kiln,
said center pocket being empty;
e. wherein said dry lightweight aggregate has a dry bulk density that is no greater than 0.68 grams per cubic centimeter;
and
f. wherein said dry lightweight aggregate will not harden when placed in water.
a. a bag made of fabric, said bag having a first side and a second side;
b. said bag having a plurality of pockets, said pockets being created by fastening said first side to said second side at
a plurality of points, wherein said plurality of pockets includes a center pocket;
c. said bag and said plurality of pockets being adapted such that when aggregate material is placed in said bag, said pockets
form upper and lower lobes;
d. wherein all said pockets except said center pocket are filled with dry lightweight aggregate manufactured by a rotary kiln,
said center pocket being empty;
e. wherein said dry lightweight aggregate has a dry bulk density that is no greater than 0.68 grams per cubic centimeter;
and
f. wherein said dry lightweight aggregate will not harden when placed in water.
US Pat. No. 9,599,602
PLASMA H2S LEVELS AS BIOMARKERS FOR VASCULAR DISEASE
Board of Supervisors of L...
1. A method for treating peripheral artery disease in a vertebrate patient, said method comprising the steps of:
(a) assaying plasma free H2S concentration and plasma NO concentration in a blood sample from a patient, wherein the plasma free H2S concentration is assessed using monobromobimane; and identifying the patient as having peripheral artery disease if the
ratio of the concentration of plasma free H2S in the patient to the concentration of plasma NO in the patient is at least 129% higher than a mean ratio in a control population
having no peripheral artery disease; and
(b) administering a therapeutic for peripheral artery disease to the patient if the patient is thus identified as having peripheral
artery disease.
(a) assaying plasma free H2S concentration and plasma NO concentration in a blood sample from a patient, wherein the plasma free H2S concentration is assessed using monobromobimane; and identifying the patient as having peripheral artery disease if the
ratio of the concentration of plasma free H2S in the patient to the concentration of plasma NO in the patient is at least 129% higher than a mean ratio in a control population
having no peripheral artery disease; and
(b) administering a therapeutic for peripheral artery disease to the patient if the patient is thus identified as having peripheral
artery disease.
US Pat. No. 9,891,006
METAL-BASED MICROCHANNEL HEAT EXCHANGERS MADE BY MOLDING REPLICATION AND ASSEMBLY
BOARD OF SUPERVISORS OF L...
1. A process for making a metal microchannel heat exchanger, the process comprising:
forming one or more open microchannels on a surface of a first homogeneous metal piece, wherein at least one of the one or
more open microchannels has a width between about 30 ?m and about 1000 ?m, and a depth between about 30 ?m and about 1000
?m;
providing a second homogeneous metal piece that, when bonded to the first homogeneous metal piece, will convert one or more
open microchannels on the first homogeneous metal piece into one or more closed microchannels, wherein the one or more closed
microchannels are adapted to transport liquid without substantial leakage;
providing a eutectic layer or a eutectic precursor layer at one or more of the following locations: a surface of the first
homogeneous metal piece, a surface of the second homogeneous metal piece, or between the first and second homogeneous metal
pieces;
simultaneously applying pressure to and heating the first and second homogeneous metal pieces, wherein:
the pressure pushes the first and second homogeneous metal pieces toward each other, with the eutectic layer or the eutectic
precursor layer between the first and second homogeneous metal pieces;
the first and second homogeneous metal pieces are heated to a eutectic melting temperature at which the eutectic layer or
the eutectic precursor layer melts, or at which the eutectic layer or the eutectic precursor layer interacts with the first
and second homogeneous metal pieces to form a molten eutectic composition between the first and second homogeneous metal pieces;
and
the eutectic melting temperature to which the first and second homogeneous metal pieces are heated is sufficiently below a
melting temperature of the first and second homogeneous metal pieces that no substantial deformation of the one or more open
microchannels occurs;
cooling the first and second homogeneous metal pieces to a cooling temperature substantially below the eutectic melting temperature,
while maintaining the pressure during at least a portion of the cooling; such that the first and second homogeneous metal
pieces fuse together;
such that the one or more open microchannels are converted into one or more closed microchannels, wherein the one or more
closed microchannels are adapted to transport liquid without substantial leakage; and
wherein no substantial blockage of the one or more closed microchannels occurs as a result of the heating, applying pressure,
and cooling;
and wherein:
the one or more closed microchannels are enclosed entirely by the fused first and second homogeneous metal pieces and the
eutectic layer or the eutectic precursor layer; and whereby the fused first and second homogeneous pieces and the eutectic
layer or the eutectic precursor layer, together with the enclosed one or more closed microchannels, form a microchannel heat
exchanger; and
wherein at least one of the closed microchannels has a surface roughness between about 3 ?m and about 15 ?m.
forming one or more open microchannels on a surface of a first homogeneous metal piece, wherein at least one of the one or
more open microchannels has a width between about 30 ?m and about 1000 ?m, and a depth between about 30 ?m and about 1000
?m;
providing a second homogeneous metal piece that, when bonded to the first homogeneous metal piece, will convert one or more
open microchannels on the first homogeneous metal piece into one or more closed microchannels, wherein the one or more closed
microchannels are adapted to transport liquid without substantial leakage;
providing a eutectic layer or a eutectic precursor layer at one or more of the following locations: a surface of the first
homogeneous metal piece, a surface of the second homogeneous metal piece, or between the first and second homogeneous metal
pieces;
simultaneously applying pressure to and heating the first and second homogeneous metal pieces, wherein:
the pressure pushes the first and second homogeneous metal pieces toward each other, with the eutectic layer or the eutectic
precursor layer between the first and second homogeneous metal pieces;
the first and second homogeneous metal pieces are heated to a eutectic melting temperature at which the eutectic layer or
the eutectic precursor layer melts, or at which the eutectic layer or the eutectic precursor layer interacts with the first
and second homogeneous metal pieces to form a molten eutectic composition between the first and second homogeneous metal pieces;
and
the eutectic melting temperature to which the first and second homogeneous metal pieces are heated is sufficiently below a
melting temperature of the first and second homogeneous metal pieces that no substantial deformation of the one or more open
microchannels occurs;
cooling the first and second homogeneous metal pieces to a cooling temperature substantially below the eutectic melting temperature,
while maintaining the pressure during at least a portion of the cooling; such that the first and second homogeneous metal
pieces fuse together;
such that the one or more open microchannels are converted into one or more closed microchannels, wherein the one or more
closed microchannels are adapted to transport liquid without substantial leakage; and
wherein no substantial blockage of the one or more closed microchannels occurs as a result of the heating, applying pressure,
and cooling;
and wherein:
the one or more closed microchannels are enclosed entirely by the fused first and second homogeneous metal pieces and the
eutectic layer or the eutectic precursor layer; and whereby the fused first and second homogeneous pieces and the eutectic
layer or the eutectic precursor layer, together with the enclosed one or more closed microchannels, form a microchannel heat
exchanger; and
wherein at least one of the closed microchannels has a surface roughness between about 3 ?m and about 15 ?m.
US Pat. No. 10,011,498
METHOD OF MAGNETITE AND FERRITE NANOPARTICLE SYNTHESIS
Board of Supervisors of L...
1. A method of producing one of magnetite and ferrite nanoparticles in a one-pot in situ synthesis comprising the steps of:mixing iron (III) nitrate [Fe(NO3)3] with a fatty acid to form a mixture;
mixing a solvent with the mixture;
heating the solvent mixture to and maintaining the solvent mixture at a temperature between 300° C. and 320° C.; and
precipitating out one of magnetite and ferrite nanoparticles;
wherein the nanoparticles have a relative standard deviation in diameter less than or equal to 10%.
mixing a solvent with the mixture;
heating the solvent mixture to and maintaining the solvent mixture at a temperature between 300° C. and 320° C.; and
precipitating out one of magnetite and ferrite nanoparticles;
wherein the nanoparticles have a relative standard deviation in diameter less than or equal to 10%.
US Pat. No. 9,782,744
DETECTION AND MOLECULAR WEIGHT DETERMINATION OF ORGANIC VAPORS
Board of Supervisors of L...
1. A composite material comprising an intermixture of one or more GUMBOS with one or more polymers, wherein:
(a) each of said GUMBOS is an organic salt having a melting point between 25° C. and 250° C.; wherein an organic salt is a
salt comprising at least one organic anion, or at least one organic cation, or both an organic anion and an organic cation;
(b) said composite material is viscoelastic; and the viscoelastic characteristics of said composite material are substantially
different from what the viscoelastic characteristics of the GUMBOS alone would be, if the GUMBOS were not intermixed with
the one or more polymers;
(c) each of said one or more GUMBOS is amorphous within said composite material.
(a) each of said GUMBOS is an organic salt having a melting point between 25° C. and 250° C.; wherein an organic salt is a
salt comprising at least one organic anion, or at least one organic cation, or both an organic anion and an organic cation;
(b) said composite material is viscoelastic; and the viscoelastic characteristics of said composite material are substantially
different from what the viscoelastic characteristics of the GUMBOS alone would be, if the GUMBOS were not intermixed with
the one or more polymers;
(c) each of said one or more GUMBOS is amorphous within said composite material.
US Pat. No. 10,064,355
RICE CULTIVAR DESIGNATED CL271
Board of Supervisors of L...
1. A rice seed of the variety CL271, a representative sample of seed of said variety having been deposited under ATCC Accession No. PTA-120713.
US Pat. No. 10,010,881
CATALYSTS USEFUL FOR BIOMASS PYROLYSIS AND BIO-OIL UPGRADING
Board of Supervisors of L...
1. A method of making a catalyst/support composition; said method comprising the steps of:(a) cleaning the surface of one or more metallic substrate particles, wherein each metallic substrate particle has a longest dimension between about 100 ?m and about 5 mm;
(b) oxidizing or nitriding the surfaces of the metallic substrate particles, to covalently attach oxide or nitride groups to the surfaces of the metallic substrate particles;
(c) covalently bonding one or more linker groups to the oxide, to the nitride, or to the metal surface;
(d) covalently bonding one or more seed layers to the one or more linker groups, wherein the one or more seed layers comprise ruthenium, rhodium, palladium, silver, osmium, iridium, platinum, gold, copper, rhenium, mercury, aluminum oxide, or nickel(II) oxide;
(e) covalently bonding a catalyst layer to the one or more seed layers, wherein the catalyst layer comprises a metal, a metal oxide, a doped metal, or a zeolite;wherein:the resulting catalyst/support composition is adapted to directly absorb electromagnetic energy from microwave irradiation, or electromagnetic induction, or both; and thereby to be rapidly heated to a temperature between about 250° C. and about 1000° C.
(b) oxidizing or nitriding the surfaces of the metallic substrate particles, to covalently attach oxide or nitride groups to the surfaces of the metallic substrate particles;
(c) covalently bonding one or more linker groups to the oxide, to the nitride, or to the metal surface;
(d) covalently bonding one or more seed layers to the one or more linker groups, wherein the one or more seed layers comprise ruthenium, rhodium, palladium, silver, osmium, iridium, platinum, gold, copper, rhenium, mercury, aluminum oxide, or nickel(II) oxide;
(e) covalently bonding a catalyst layer to the one or more seed layers, wherein the catalyst layer comprises a metal, a metal oxide, a doped metal, or a zeolite;wherein:the resulting catalyst/support composition is adapted to directly absorb electromagnetic energy from microwave irradiation, or electromagnetic induction, or both; and thereby to be rapidly heated to a temperature between about 250° C. and about 1000° C.
US Pat. No. 9,937,260
CURCUMIN CONJUGATES FOR TREATING AND PREVENTING CANCERS
BOARD OF SUPERVISORS OF L...
1. A method for killing or inhibiting the growth of cells in a tumor in a mammal; wherein the tumor expresses a receptor for luteinizing hormone-releasing hormone or a receptor for luteinizing hormone; said method comprising administrating to the mammal an effective amount of a compound having the structure:
US Pat. No. 9,821,061
ENHANCED PLASMONIC NANOPARTICLES FOR CANCER THERAPY AND DIAGNOSTICS
BOARD OF SUPERVISORS OF L...
1. A metallic nanoparticle made by the process of:
adding a first citrate compound to a gold solution resulting in a gold core solution from comprising at least one gold core;
adding ascorbic acid, a silver compound, and a strong base to the gold core solution resulting in a silver shell on at least
one gold core; and
adding a second citrate compound, hydroquinone, and a gold compound to at least one silver shell on at least one gold core
resulting in an outer gold shell on the silver shell.
adding a first citrate compound to a gold solution resulting in a gold core solution from comprising at least one gold core;
adding ascorbic acid, a silver compound, and a strong base to the gold core solution resulting in a silver shell on at least
one gold core; and
adding a second citrate compound, hydroquinone, and a gold compound to at least one silver shell on at least one gold core
resulting in an outer gold shell on the silver shell.
US Pat. No. 9,763,912
COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT
Board of Supervisors of L...
1. A composition, consisting of a COX-2 inhibitor and a cannabinoid.
US Pat. No. 9,752,145
COMPOSITIONS AND METHODS FOR REDUCING C/EBP HOMOLOGOUS PROTEIN ACTIVITY IN MYELOID-DERIVED SUPPRESSOR CELLS
Board of Supervisors of L...
9. A composition comprising an siRNA agent that when delivered to a myeloid-derived suppressor cell (MDSC) or population of
said cells reduces the level of expression of a Chop-encoding gene, thereby reducing the level of Chop in the cell or cells,
wherein the siRNA is an isolated double-stranded ribonucleic acid (dsRNA) molecule having either no overhang regions or at
least one overhang region, wherein each overhang region contains six or fewer nucleotides, and wherein the dsRNA inhibits
expression by a cell of a Chop protein, and wherein a first strand of the dsRNA is substantially identical to the sequence
according to SEQ ID NO: 1, and a second strand is substantially complementary to the first.
said cells reduces the level of expression of a Chop-encoding gene, thereby reducing the level of Chop in the cell or cells,
wherein the siRNA is an isolated double-stranded ribonucleic acid (dsRNA) molecule having either no overhang regions or at
least one overhang region, wherein each overhang region contains six or fewer nucleotides, and wherein the dsRNA inhibits
expression by a cell of a Chop protein, and wherein a first strand of the dsRNA is substantially identical to the sequence
according to SEQ ID NO: 1, and a second strand is substantially complementary to the first.
US Pat. No. 9,579,344
USE OF NITRITE SALTS IN TREATING TISSUE DAMAGE
Board of Supervisors of L...
1. A method of treating inflammation in a subject having an inflammatory disease, the method comprising:
a) identifying a subject who has an inflammatory disease characterized by inflammation; and
b) administering to the subject a pharmaceutical composition comprising an inorganic nitrite that is nitrite ion or an alkali
or alkaline metal salt of nitrite ion, wherein the inorganic nitrite is administered for a time and in an amount sufficient
to treat said inflammation of the subject; wherein the subject is human; and wherein the administering is not topical administration.
a) identifying a subject who has an inflammatory disease characterized by inflammation; and
b) administering to the subject a pharmaceutical composition comprising an inorganic nitrite that is nitrite ion or an alkali
or alkaline metal salt of nitrite ion, wherein the inorganic nitrite is administered for a time and in an amount sufficient
to treat said inflammation of the subject; wherein the subject is human; and wherein the administering is not topical administration.
US Pat. No. 10,109,802
CARBAZOLE-BASED GUMBOS FOR HIGHLY EFFICIENT BLUE OLEDS
BOARD OF SUPERVISORS OF L...
1. A composition, comprising:a solid phase carbazole-based GUMBOS (group of uniform materials based on organic salts) comprising a carbazole-based counterion.
US Pat. No. 9,777,309
HIGH THROUGHPUT ASSAY FOR MONITORING AMP PRODUCTION AND AMINOACYL-TRNA SYNTHETASE ACTIVITY
Board of Supervisors of L...
1. A method of conducting an enzymatic reaction assay that result in adenosine 5?-monophosphate (AMP) production, comprising
the steps of:
reacting one or more compounds that producing AMP;
deaminating the AMP using AMP deaminase to produce IMP; and
oxidizing the IMP in the presence of IMP dehydrogenase and NAD+ to produce XMP and NADH.
the steps of:
reacting one or more compounds that producing AMP;
deaminating the AMP using AMP deaminase to produce IMP; and
oxidizing the IMP in the presence of IMP dehydrogenase and NAD+ to produce XMP and NADH.
US Pat. No. 9,642,819
LOW DOSAGE SEROTONIN 5-HT2A RECEPTOR AGONIST TO SUPPRESS INFLAMMATION
BOARD OF SUPERVISORS OF L...
1. A method for the treatment of an inflammatory disorder in a mammal, said method comprising administering to a mammal in
need of such treatment a therapeutically effective amount of (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ((R)-DOI) in
a pharmaceutically acceptable carrier or salt thereof, wherein said inflammatory disorder is associated with a disease selected
from asthma, rheumatoid arthritis, irritable bowel syndrome, and Crohn's disease.
need of such treatment a therapeutically effective amount of (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ((R)-DOI) in
a pharmaceutically acceptable carrier or salt thereof, wherein said inflammatory disorder is associated with a disease selected
from asthma, rheumatoid arthritis, irritable bowel syndrome, and Crohn's disease.
US Pat. No. 9,765,115
INHIBITORS OF METASTASIS, METHODS OF GENERATING SUCH INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS
Board of Supervisors of L...
1. A method to inhibit metastasis in a cancerous solid tumor with tumor cells that have a receptor with a C-terminal PDZ binding
motif, and for which metastasis depends on disassembly of cellular tight junctions; said method comprising administering a
therapeutic amount of a peptide selected from the group consisting of a peptide whose amino acid sequence has 90% or greater
sequence identity with SEQ ID NO:2, and a peptide whose amino acid sequence has 90% or greater sequence identity with SEQ
ID NO:3; wherein each amino acid, if any, in said peptide that is not identical to the corresponding amino acid of SEQ ID
NO:2 or SEQ ID NO:3 is a conservative substitution; wherein said peptide inhibits interaction between the tumor cell receptor's
PDZ binding motif and the PDZ motif of zonula occludens-1; whereby the disassembly of cellular tight junctions of the tumor
cells is inhibited; whereby metastasis of the tumor is inhibited.
motif, and for which metastasis depends on disassembly of cellular tight junctions; said method comprising administering a
therapeutic amount of a peptide selected from the group consisting of a peptide whose amino acid sequence has 90% or greater
sequence identity with SEQ ID NO:2, and a peptide whose amino acid sequence has 90% or greater sequence identity with SEQ
ID NO:3; wherein each amino acid, if any, in said peptide that is not identical to the corresponding amino acid of SEQ ID
NO:2 or SEQ ID NO:3 is a conservative substitution; wherein said peptide inhibits interaction between the tumor cell receptor's
PDZ binding motif and the PDZ motif of zonula occludens-1; whereby the disassembly of cellular tight junctions of the tumor
cells is inhibited; whereby metastasis of the tumor is inhibited.
US Pat. No. 10,137,293
MEDICAL STOPCOCK VALVE
Board of Supervisors of L...
1. A medical stopcock valve comprising:a hollow body having a plurality of through holes around a perimeter of the hollow body;
an outer ring encapsulating the perimeter, the outer ring having a plurality of external ports;
the outer ring being rotatable around the perimeter to open and close access between the external ports and the through holes;
at least three through hole;
at least three exterior ports;
eight possible stable on/off positions of the outer ring as the outer ring rotates around the perimeter; and
eight unstable intermediate positions between the stable on/off positions.
an outer ring encapsulating the perimeter, the outer ring having a plurality of external ports;
the outer ring being rotatable around the perimeter to open and close access between the external ports and the through holes;
at least three through hole;
at least three exterior ports;
eight possible stable on/off positions of the outer ring as the outer ring rotates around the perimeter; and
eight unstable intermediate positions between the stable on/off positions.
US Pat. No. 10,117,913
ANTIGENS OF PNEUMOCYSTIS MURINA AND USES THEREOF
BOARD OF SUPERVISORS OF L...
1. An immunogenic composition comprising an isolated Surface Peptidase 1 (SPD-1) polypeptide of Pneumocystis murina and having the sequence according to SEQ ID NO: 1 or an immunogenic fragment thereof, wherein the fragment has an amino acid sequence of at least 90% similarity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 2 and 4, and wherein the composition further comprises a pharmaceutically acceptable carrier and an adjuvant, wherein the adjuvant is MF-59, and is formulated to induce an anti-Pneumocystis immune response when administered to an animal or human recipient.
US Pat. No. 10,254,262
HYDROGEN SULFIDE DETECTING APPARATUS
Board of Supervisors of L...
1. A hydrogen sulfide (H2S) detecting apparatus comprising:a. an injection chamber;
b. a plurality of reaction chambers in fluid communication with the injection chamber, wherein the plurality of reaction chambers comprise: a free sulfide reaction chamber; an acid labile sulfide reaction chamber; and a total sulfide reaction chamber;
c. a plurality of trapping chambers positioned adjacent to the plurality of reaction chambers;
d. a H2S-permeable membrane positioned between the plurality of reaction chambers and the plurality of trapping chambers;
wherein the plurality of reaction chambers define respective separate volumes from the injection chamber; and each of the reaction chambers are in fluid communication with the injection chamber.
b. a plurality of reaction chambers in fluid communication with the injection chamber, wherein the plurality of reaction chambers comprise: a free sulfide reaction chamber; an acid labile sulfide reaction chamber; and a total sulfide reaction chamber;
c. a plurality of trapping chambers positioned adjacent to the plurality of reaction chambers;
d. a H2S-permeable membrane positioned between the plurality of reaction chambers and the plurality of trapping chambers;
wherein the plurality of reaction chambers define respective separate volumes from the injection chamber; and each of the reaction chambers are in fluid communication with the injection chamber.
US Pat. No. 10,107,835
TIP ENHANCED LASER ASSISTED SAMPLE TRANSFER FOR BIOMOLECULE MASS SPECTROMETRY
BOARD OF SUPERVISORS OF L...
1. A method for transferring molecules from a film to a collection device for analysis via an atomic force microscope and a pulsed laser comprising:positioning a gold-coated silicon tip of the atomic force microscope above the film to image a sample of the molecules, the gold-coated silicon tip having a radius of curvature and being positioned at a first distance from the film;
focusing the pulsed laser onto the gold-coated silicon tip of the atomic force microscope;
ablating the sample from a plurality of ablation spots on the film onto the collection device, the collection device being suspended at a first position relative to the gold-coated silicon tip, wherein a first amount of material from the sample is ablated from each of the ablation spots and transferred onto the collection device.
focusing the pulsed laser onto the gold-coated silicon tip of the atomic force microscope;
ablating the sample from a plurality of ablation spots on the film onto the collection device, the collection device being suspended at a first position relative to the gold-coated silicon tip, wherein a first amount of material from the sample is ablated from each of the ablation spots and transferred onto the collection device.
US Pat. No. 10,160,955
METHOD FOR HARVESTING STEM AND PROGENITOR CELLS AND METHOD OF TREATMENT OF KIDNEY DISEASE AND NEUROLOGICAL DISEASE
Board of Supervisors of L...
1. A method of treating a central nervous system disease condition in a patient comprising the steps of:isolating neural stem/progenitor cells from a urine specimen of the patient;
growing the neural stem/progenitor cells in vitro;
selecting cells that have positive expression for CD133; and
implanting the neural selected stem/progenitor cells into the patient.
growing the neural stem/progenitor cells in vitro;
selecting cells that have positive expression for CD133; and
implanting the neural selected stem/progenitor cells into the patient.
US Pat. No. 10,130,703
VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS
BOARD OF SUPERVISORS OF L...
1. A vaccine for treating or preventing a herpes simplex virus (HSV) infection, the vaccine comprising a recombinant HSV, wherein the recombinant HSV comprises a recombinant HSV genome comprising:(a) a modified UL53 gene comprising a deletion corresponding to the region of the UL53 gene that encodes amino acids 31-68 of wild-type gK; and
(b) a modified UL20 gene comprising a deletion corresponding to the region of the UL20 gene that encodes amino acids 4-22 of wild-type UL20 protein;wherein the recombinant HSV is capable of replication in a host cell and incapable of entry into axonal compartments of neurons.
(b) a modified UL20 gene comprising a deletion corresponding to the region of the UL20 gene that encodes amino acids 4-22 of wild-type UL20 protein;wherein the recombinant HSV is capable of replication in a host cell and incapable of entry into axonal compartments of neurons.
US Pat. No. 10,117,629
HIGH ENERGY GRATING TECHNIQUES
Board of Supervisors of L...
1. An imaging technique comprising:a) providing a beam source;
b) providing a beam detector;
c) configuring the beam source and the beam detector such that a beam path connects the beam source and the beam detector;
d) positioning an object in the beam path;
e) positioning a phase grating in the beam path;
f) positioning an analyzer grating in a first position in the beam path;
g) projecting a first beam along the beam path thereby producing a first data set;
h) moving the analyzer grating from the first position to a second position;
i) projecting a second beam along the beam path thereby producing a second data set;
j) moving the analyzer grating from the second position to a third position;
k) projecting a third beam along the beam path thereby producing a third data set;
l) conducting a regression analysis fitting pixel data from a group of data sets comprising the first data set, the second data set and the third data set to a predetermined function to establish a set of fitting coefficients;
m) wherein the set of fitting coefficients characterize a set of interference properties associated with the object;
n) wherein the predetermined function is dependent on the analyzer grating position; and
o) wherein the predetermined function contains sinusoidal functions;
p) wherein the fitting of pixel data occurs based on the relationship expressed in the equation:
q) wherein crj? is an expected exposure based on grating position;
r) wherein B is a fitting function matrix that is a M×n matrix wherein M is a number of exposure steps and g is an exposure step number;
s) wherein a is a matrix containing the set of fitting coefficients;
t) wherein n is an integer that is at least 3 and
u) wherein y is a pixel number.
b) providing a beam detector;
c) configuring the beam source and the beam detector such that a beam path connects the beam source and the beam detector;
d) positioning an object in the beam path;
e) positioning a phase grating in the beam path;
f) positioning an analyzer grating in a first position in the beam path;
g) projecting a first beam along the beam path thereby producing a first data set;
h) moving the analyzer grating from the first position to a second position;
i) projecting a second beam along the beam path thereby producing a second data set;
j) moving the analyzer grating from the second position to a third position;
k) projecting a third beam along the beam path thereby producing a third data set;
l) conducting a regression analysis fitting pixel data from a group of data sets comprising the first data set, the second data set and the third data set to a predetermined function to establish a set of fitting coefficients;
m) wherein the set of fitting coefficients characterize a set of interference properties associated with the object;
n) wherein the predetermined function is dependent on the analyzer grating position; and
o) wherein the predetermined function contains sinusoidal functions;
p) wherein the fitting of pixel data occurs based on the relationship expressed in the equation:
q) wherein crj? is an expected exposure based on grating position;
r) wherein B is a fitting function matrix that is a M×n matrix wherein M is a number of exposure steps and g is an exposure step number;
s) wherein a is a matrix containing the set of fitting coefficients;
t) wherein n is an integer that is at least 3 and
u) wherein y is a pixel number.
US Pat. No. 10,089,232
MODE SWITCHING FOR INCREASED OFF-CHIP BANDWIDTH
Board of Supervisors of L...
1. A method of increasing off-chip bandwidth, comprising:designing a circuit having switchable pins;
replacing a portion of allocated pins of a processor with the switchable pins;
connecting the processor to a memory interface configured to dynamically switch the switchable pins between a power mode and a signal mode;
providing a metric configured to identify which of the power mode and the signal mode is most beneficial during a 1 millisecond interval;
switching the switchable pins to signal mode during intervals where the signal mode provides more benefit than the power mode; and
utilizing an off-chip bus connection to switch from a multi-bus mode to a single-bus mode and vice-versa,
the circuit including
a first circuit having a signal-to-power switch and a first set of five stage tri-stage buffers connected to the signal-to-power switch, wherein the first set of five stage tri-stage buffers are placed in signal lines to amplify I/O signals to compensate for parasitic capacitances of the signal-to-power switch, and wherein the signal-to-power switch allows for the switchable pins to alternate between the multi-bus and single-bus mode;
a second circuit having a signal switch and a second set of five stage tri-stage buffers connected to the signal switch, wherein the second set of five stage tri-stage buffers enable memory devices that can be accessed via buses, and wherein the signal switch ensures that data in the memory interface can be accessed in the multi-bus and single-bus modes; and
a third circuit having a signal buffer that amplifies the I/O signals in order to offset effects of parasitic capacitance, and
wherein the signal-to-power switch and signal switch are configured to route signals and power in the multi-bus and single-bus modes.
replacing a portion of allocated pins of a processor with the switchable pins;
connecting the processor to a memory interface configured to dynamically switch the switchable pins between a power mode and a signal mode;
providing a metric configured to identify which of the power mode and the signal mode is most beneficial during a 1 millisecond interval;
switching the switchable pins to signal mode during intervals where the signal mode provides more benefit than the power mode; and
utilizing an off-chip bus connection to switch from a multi-bus mode to a single-bus mode and vice-versa,
the circuit including
a first circuit having a signal-to-power switch and a first set of five stage tri-stage buffers connected to the signal-to-power switch, wherein the first set of five stage tri-stage buffers are placed in signal lines to amplify I/O signals to compensate for parasitic capacitances of the signal-to-power switch, and wherein the signal-to-power switch allows for the switchable pins to alternate between the multi-bus and single-bus mode;
a second circuit having a signal switch and a second set of five stage tri-stage buffers connected to the signal switch, wherein the second set of five stage tri-stage buffers enable memory devices that can be accessed via buses, and wherein the signal switch ensures that data in the memory interface can be accessed in the multi-bus and single-bus modes; and
a third circuit having a signal buffer that amplifies the I/O signals in order to offset effects of parasitic capacitance, and
wherein the signal-to-power switch and signal switch are configured to route signals and power in the multi-bus and single-bus modes.
US Pat. No. 10,085,646
CONTACT-TYPE ENDOSCOPE SERS PROBE, AND RELATED METHODS
BOARD OF SUPERVISORS OF L...
1. A system for contact-type endoscope surface enhanced Raman scattering (SERS) comprising:a Raman spectrometer;
a probe having a proximal end and a distal end, comprising:
a gradient-index (GRIN) lens; and
a rough metallic layer optically connected to said GRIN lens; and
an articulated arm comprising a plurality of mirrors for reflecting an illumination light from said Raman spectrometer to said probe, and for reflecting a scattered light from said probe to said Raman spectrometer,
wherein said rough metallic layer is configured to contact a sample such that the rough metallic layer is positioned between the GRIN lens and the sample; and
wherein said GRIN lens focuses said illumination light from said Raman spectrometer onto said rough metallic layer.
a probe having a proximal end and a distal end, comprising:
a gradient-index (GRIN) lens; and
a rough metallic layer optically connected to said GRIN lens; and
an articulated arm comprising a plurality of mirrors for reflecting an illumination light from said Raman spectrometer to said probe, and for reflecting a scattered light from said probe to said Raman spectrometer,
wherein said rough metallic layer is configured to contact a sample such that the rough metallic layer is positioned between the GRIN lens and the sample; and
wherein said GRIN lens focuses said illumination light from said Raman spectrometer onto said rough metallic layer.
US Pat. No. 10,328,147
HERPES SIMPLEX VIRUS TYPE-1(HSV-1) VACCINE STRAIN VC2 GENERATING AN ANTI-EHV-1 IMMUNE RESPONSE
BOARD OF SUPERVISORS OF L...
1. A recombinant nucleic acid comprising a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter, wherein the nucleotide sequence encoding the heterologous polypeptide operably linked to a promoter encodes the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof.
US Pat. No. 10,307,441
PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF
Board of Supervisors of L...
1. A method for treating peripheral neuropathy in a human, the method comprising orally administering two times per day for at least three days a solid, sustained release pharmaceutical composition comprising about 40 mg of sodium nitrite, or a pharmaceutically acceptable salt thereof, and a binding agent, wherein the pharmaceutical composition is coated with an enteric coating.
US Pat. No. 10,537,659
3D PRINTED POLYVINYL ALCOHOL MEDICAL DEVICES AND METHODS OF ACTIVATION
Board of Supervisors of L...
1. A method for creating a medical device comprising:3D printing the medical device out of polyvinyl alcohol; and
crosslinking the polyvinyl alcohol with an aldehyde;
wherein the medical device is a vascular stent; and
the aldehyde has three or more Carbon atoms.
crosslinking the polyvinyl alcohol with an aldehyde;
wherein the medical device is a vascular stent; and
the aldehyde has three or more Carbon atoms.
US Pat. No. 10,507,194
METHODS FOR TREATING OBESITY
BOARD OF SUPERVISORS OF L...
1. A mouthwash composition comprising orlistat in an amount effective treat overweight or obesity in a subject, wherein said orlistat mouthwash contains about 1 mg to about 200 mg orlistat.
US Pat. No. 10,334,685
CARBON DOT LIGHT EMITTING DIODES
Board of Supervisors of L...
1. A light emitting diode (LED) device comprising:a hole transport layer;
an electron transport layer,
an active emissive layer between the hole transport layer and the electron transport layer; and
carbon dots forming the active emissive layer;
wherein the light emitting diode device is an electroluminescent light emitting diode device, and the carbon dots are substantially spherical in shape.
an electron transport layer,
an active emissive layer between the hole transport layer and the electron transport layer; and
carbon dots forming the active emissive layer;
wherein the light emitting diode device is an electroluminescent light emitting diode device, and the carbon dots are substantially spherical in shape.
US Pat. No. 10,327,661
BIOMARKERS FOR DETERMINING SUSCEPTIBILITY TO SUDEP
Louisiana Tech Research C...
1. A method for determining an increased risk of death of a patient comprising the steps of:a. receiving electrocardiogram (ECG) data of the patient generated during a first time period;
b. receiving electroencephalogram (EEG) data of the patient generated during the first time period;
c. composing a feature of the ECG data and a feature of the EEG data over a common time frame, wherein the feature composed from the EEG or ECG data is at least one from the group consisting of mean, standard deviation, Kurtosis, skewness, autoregressive modeling coefficients, Vector autoregressive modeling coefficients, Barlow parameters, Teager energy, Hjorth parameters, Pearson product-moment correlation coefficient, Rank correlation, spectral band power at specific frequencies/frequency bands, normalized spectral band power, spectral edge frequency, median frequency, coherence, directed transfer function, partial coherence, directed coherence, generalized partial directed coherence, Shannon entropy, approximate entropy, sample entropy, spectral entropy, mutual information, transfer entropy, Lyapunov exponents, correlation dimension, recurrence quantification analysis, dynamical entrainment, non-linear interdependence, detrended fluctuation analysis, Hurst exponent, Lempel-Ziv complexity, phase synchronization, phase-amplitude coupling, bispectrum, and bicoherence;
d. determining a statistical measure of association between features of the ECG data and the EEG data;
e. determining whether the statistical measure of association exceeds a predetermined threshold, thereby indicating whether the increased risk of death is present;
f. in response to an indication of the increased risk of death, either (i) delivering a series of electrical signals to therapeutically counter-act brain electrical impulses related to seizures; or (ii) administering a therapeutic drug to the patient; and
g. wherein the patient suffers from at least one condition from the group consisting of epileptic seizures, status epilepticus, sudden infant death syndrome, sudden unexpected death in epilepsy, and sudden arrythmic death syndrome.
b. receiving electroencephalogram (EEG) data of the patient generated during the first time period;
c. composing a feature of the ECG data and a feature of the EEG data over a common time frame, wherein the feature composed from the EEG or ECG data is at least one from the group consisting of mean, standard deviation, Kurtosis, skewness, autoregressive modeling coefficients, Vector autoregressive modeling coefficients, Barlow parameters, Teager energy, Hjorth parameters, Pearson product-moment correlation coefficient, Rank correlation, spectral band power at specific frequencies/frequency bands, normalized spectral band power, spectral edge frequency, median frequency, coherence, directed transfer function, partial coherence, directed coherence, generalized partial directed coherence, Shannon entropy, approximate entropy, sample entropy, spectral entropy, mutual information, transfer entropy, Lyapunov exponents, correlation dimension, recurrence quantification analysis, dynamical entrainment, non-linear interdependence, detrended fluctuation analysis, Hurst exponent, Lempel-Ziv complexity, phase synchronization, phase-amplitude coupling, bispectrum, and bicoherence;
d. determining a statistical measure of association between features of the ECG data and the EEG data;
e. determining whether the statistical measure of association exceeds a predetermined threshold, thereby indicating whether the increased risk of death is present;
f. in response to an indication of the increased risk of death, either (i) delivering a series of electrical signals to therapeutically counter-act brain electrical impulses related to seizures; or (ii) administering a therapeutic drug to the patient; and
g. wherein the patient suffers from at least one condition from the group consisting of epileptic seizures, status epilepticus, sudden infant death syndrome, sudden unexpected death in epilepsy, and sudden arrythmic death syndrome.
US Pat. No. 10,489,523
APPARATUSES, SYSTEMS AND METHODS FOR PERFORMING REMOTE REAL-TIME EXPERIMENTS
BOARD OF SUPERVISORS OF L...
1. A processor-implemented method of controlling a mechanical system comprising first and second sub-systems, the method comprising:receiving, by a processor circuit, first and second dynamical output signals from the first and second sub-systems, respectively,
wherein the first and second sub-systems correspond to a desired configuration wherein the first and second sub-systems are located at a first facility and second facility, respectively, wherein the desired configuration includes at least a first configuration and a second configuration of respective first and second sub-systems;
providing the first dynamical output signal from the first sub-system to the second sub-system as a second input signal;
providing the second dynamical output signal from the second sub-system to the first sub-system as a first input signal;
wherein the dynamical output and input signals received from and sent to the first and second sub-systems cause the dynamical behavior of the first and second sub-systems to influence one another in real time,
wherein the first dynamical output signal mimics a process of running a first remote experiment in real-time at the first facility to obtain the first output signal, the first facility including the first configuration represented by the first input signal;
wherein the second dynamical output signal mimics a process of running a second remote experiment in real-time at the second facility to obtain the second output signal, the second facility including the second configuration represented by the second input signal; and
obtaining experimental results of the desired configuration using the first and second input and output signals.
wherein the first and second sub-systems correspond to a desired configuration wherein the first and second sub-systems are located at a first facility and second facility, respectively, wherein the desired configuration includes at least a first configuration and a second configuration of respective first and second sub-systems;
providing the first dynamical output signal from the first sub-system to the second sub-system as a second input signal;
providing the second dynamical output signal from the second sub-system to the first sub-system as a first input signal;
wherein the dynamical output and input signals received from and sent to the first and second sub-systems cause the dynamical behavior of the first and second sub-systems to influence one another in real time,
wherein the first dynamical output signal mimics a process of running a first remote experiment in real-time at the first facility to obtain the first output signal, the first facility including the first configuration represented by the first input signal;
wherein the second dynamical output signal mimics a process of running a second remote experiment in real-time at the second facility to obtain the second output signal, the second facility including the second configuration represented by the second input signal; and
obtaining experimental results of the desired configuration using the first and second input and output signals.
US Pat. No. 10,363,292
VACCINATION WITH ANTI-TICK ANTIGENS TO CONTROL MULTIPLE TICK SPECIES AND DISEASE TRANSMISSION IN WHITE-TAILED DEER AND OTHER HOST ANIMALS
The United States of Amer...
1. A method of reducing tick infestations in animals comprising administration of a vaccine composition to a non-bovine animal,wherein said vaccine composition comprises an immunogenic Rm86Texas protein and a pharmaceutically acceptable carrier,
wherein said Rm86Texas protein is in an amount effective to stimulate an immune response in said animal to said tick,
wherein said Rm86Texas protein consists of amino acids 17-624 of SEQ ID: 1, and
wherein said tick is selected from the group consisting of Ixodes scapularis and Amblyomma americanum.
wherein said Rm86Texas protein is in an amount effective to stimulate an immune response in said animal to said tick,
wherein said Rm86Texas protein consists of amino acids 17-624 of SEQ ID: 1, and
wherein said tick is selected from the group consisting of Ixodes scapularis and Amblyomma americanum.
US Pat. No. 10,239,788
SELF-HEALING COMPOSITE OF THERMOSET POLYMER AND PROGRAMMED SUPER CONTRACTION FIBERS
Board of Supervisors of L...
1. A composition comprising:a cement matrix; and
a programmed fibrous shape memory polymer which comprises the ability to contract when heated above its shape recovery temperature.
a programmed fibrous shape memory polymer which comprises the ability to contract when heated above its shape recovery temperature.
US Pat. No. 10,150,060
DEVICE FOR DEGASSING LIQUIDS
Board of Supervisors of L...
1. An apparatus that is adapted for degassing a liquid that initially contains both entrained gas bubbles and suspended solid particles, prior to transporting the de-gassed liquid to a sedimentation tank that is adapted to remove suspended solid particles from the liquid;wherein:said apparatus comprises a degassing chamber, one or more stand pipes, a feed trough, and a plurality of feed wells; wherein said feed trough has an annular shape;and wherein:
(a) (i) said degassing chamber comprises one or more inlets for receiving a pressurized, superheated liquid that initially contains both entrained gas bubbles and suspended solid particles; (ii) said degassing chamber comprises one or more outlets for transporting de-gassed liquid to said feed trough; (iii) the shape and dimensions of said degassing chamber adapt the degassing chamber to be positioned immediately above the sedimentation tank or within the sedimentation tank, such that, when the degassing chamber and the sedimentation tank are both in operation, the level of liquid in the degassing chamber is from about 0 cm to about 65 cm above the level of liquid in the sedimentation tank; (iv) the ratio of surface area to volume within said degassing chamber is between about 1.5 meter?1 and about 10.0 meter?1; (v) said degassing chamber is adapted to allow the pressurized, superheated liquid to boil rapidly by reducing its pressure to about 1 atmosphere, whereby the rapid boiling causes most of the entrained gas bubbles to escape from the liquid;
(b) said one or more stand pipes are affixed to the top of said degassing chamber; each of said stand pipes is open to the interior of said degassing chamber, and each of said stand pipes is also directly or indirectly open to the atmosphere; and the height and diameter of said stand pipes are adapted to allow escaping gases from said degassing chamber to be vented to the atmosphere, without allowing liquid to escape from said apparatus;
(c) said feed trough is adapted to receive de-gassed liquid from said degassing chamber via said one or more outlets, and to deliver de-gassed liquid to said feed wells; wherein the positioning of said one or more outlets, the positioning of said feed wells, and the shape and dimensions of said feed trough are all sufficiently symmetric that, in operation, the flow of de-gassed liquid to each of said feed wells is equal or nearly equal, such that any imbalance in the flow rates to said feed wells is insufficient to induce turbulence in the liquid in the sedimentation tank; and
(d) said feed wells are adapted to receive de-gassed liquid from said feed trough, and to deliver degassed liquid into the sedimentation tank at a level that is below the operational surface level of liquid in the sedimentation tank.
(a) (i) said degassing chamber comprises one or more inlets for receiving a pressurized, superheated liquid that initially contains both entrained gas bubbles and suspended solid particles; (ii) said degassing chamber comprises one or more outlets for transporting de-gassed liquid to said feed trough; (iii) the shape and dimensions of said degassing chamber adapt the degassing chamber to be positioned immediately above the sedimentation tank or within the sedimentation tank, such that, when the degassing chamber and the sedimentation tank are both in operation, the level of liquid in the degassing chamber is from about 0 cm to about 65 cm above the level of liquid in the sedimentation tank; (iv) the ratio of surface area to volume within said degassing chamber is between about 1.5 meter?1 and about 10.0 meter?1; (v) said degassing chamber is adapted to allow the pressurized, superheated liquid to boil rapidly by reducing its pressure to about 1 atmosphere, whereby the rapid boiling causes most of the entrained gas bubbles to escape from the liquid;
(b) said one or more stand pipes are affixed to the top of said degassing chamber; each of said stand pipes is open to the interior of said degassing chamber, and each of said stand pipes is also directly or indirectly open to the atmosphere; and the height and diameter of said stand pipes are adapted to allow escaping gases from said degassing chamber to be vented to the atmosphere, without allowing liquid to escape from said apparatus;
(c) said feed trough is adapted to receive de-gassed liquid from said degassing chamber via said one or more outlets, and to deliver de-gassed liquid to said feed wells; wherein the positioning of said one or more outlets, the positioning of said feed wells, and the shape and dimensions of said feed trough are all sufficiently symmetric that, in operation, the flow of de-gassed liquid to each of said feed wells is equal or nearly equal, such that any imbalance in the flow rates to said feed wells is insufficient to induce turbulence in the liquid in the sedimentation tank; and
(d) said feed wells are adapted to receive de-gassed liquid from said feed trough, and to deliver degassed liquid into the sedimentation tank at a level that is below the operational surface level of liquid in the sedimentation tank.
US Pat. No. 10,545,873
APPARATUSES FOR INCREASING OFF-CHIP BANDWIDTH
BOARD OF SUPERVISORS OF L...
1. A memory controller, comprising:a front arbiter;
N dedicated request queues configured to individually receive incoming requests from the front arbiter; and
an end arbiter that fetches requests residing in the queues,
wherein the requests are fed via corresponding DRAM interfaces into corresponding DIMMs while in a multi-bus mode,
wherein the requests are fed via a single DRAM interface into attached DIMMs as appended ranks while in a single-bus mode.
N dedicated request queues configured to individually receive incoming requests from the front arbiter; and
an end arbiter that fetches requests residing in the queues,
wherein the requests are fed via corresponding DRAM interfaces into corresponding DIMMs while in a multi-bus mode,
wherein the requests are fed via a single DRAM interface into attached DIMMs as appended ranks while in a single-bus mode.
US Pat. No. 10,307,750
PRODUCTION OF OIL BY PYROLYSIS OF COAL
Board of Supervisors of L...
1. A method of producing oil from coal by pyrolysis; said method comprising the steps of:(a) cleaning the surface of one or more metallic substrate particles, wherein each metallic substrate particle has a longest dimension between about 100 ?m and about 5 mm;
(b) oxidizing or nitriding the surfaces of the metallic substrate particles, to covalently attach oxide or nitride groups to the surfaces of the metallic substrate particles;
(c) covalently bonding one or more linker groups to the oxide, to the nitride, or to the metal surface;
(d) covalently bonding one or more seed layers to the one or more linker groups, wherein the one or more seed layers comprise ruthenium, rhodium, palladium, silver, osmium, iridium, platinum, gold, copper, rhenium, mercury, aluminum oxide, or nickel(II) oxide;
(e) covalently bonding a catalyst layer to the one or more seed layers, wherein the catalyst layer comprises a metal, a metal oxide, a doped metal, or a zeolite; wherein the resulting catalyst/support composition is adapted to directly absorb electromagnetic energy from microwave irradiation, or electromagnetic induction, or both, and thereby to be rapidly heated to a temperature between about 250° C. and about 1000° C.;
(f) heating the catalyst/support composition to a temperature between about 250° C. and about 1000° C. by microwave irradiation, or by electromagnetic induction, or both, in an inert atmosphere inside a reactor;
(g) contacting coal with the heated catalyst/support composition for a time sufficient to transform at least a portion of the coal into oil vapors; wherein the catalyst/support composition is hotter than the coal; and
(h) condensing the oil vapors, and collecting the resulting liquid oil.
(b) oxidizing or nitriding the surfaces of the metallic substrate particles, to covalently attach oxide or nitride groups to the surfaces of the metallic substrate particles;
(c) covalently bonding one or more linker groups to the oxide, to the nitride, or to the metal surface;
(d) covalently bonding one or more seed layers to the one or more linker groups, wherein the one or more seed layers comprise ruthenium, rhodium, palladium, silver, osmium, iridium, platinum, gold, copper, rhenium, mercury, aluminum oxide, or nickel(II) oxide;
(e) covalently bonding a catalyst layer to the one or more seed layers, wherein the catalyst layer comprises a metal, a metal oxide, a doped metal, or a zeolite; wherein the resulting catalyst/support composition is adapted to directly absorb electromagnetic energy from microwave irradiation, or electromagnetic induction, or both, and thereby to be rapidly heated to a temperature between about 250° C. and about 1000° C.;
(f) heating the catalyst/support composition to a temperature between about 250° C. and about 1000° C. by microwave irradiation, or by electromagnetic induction, or both, in an inert atmosphere inside a reactor;
(g) contacting coal with the heated catalyst/support composition for a time sufficient to transform at least a portion of the coal into oil vapors; wherein the catalyst/support composition is hotter than the coal; and
(h) condensing the oil vapors, and collecting the resulting liquid oil.
US Pat. No. 10,101,267
QUANTUM DOT LIGHT EMITTING DIODES FOR MULTIPLEX GAS SENSING
Board of Supervisors of L...
1. A gas detection device comprising:a light emitting source including
a first plurality of quantum dots of substantially discrete size and made of one or more semiconductor materials forming a first layer; and
a second plurality of quantum dots of substantially discrete size and made of one or more semiconductor materials forming a second layer;
a gas cell to contain the gas to be detected; and
a light detector;
wherein a quantum dot in any one layer is within 1.0 nm in diameter of size compared to a quantum dot in any adjacent layer.
a first plurality of quantum dots of substantially discrete size and made of one or more semiconductor materials forming a first layer; and
a second plurality of quantum dots of substantially discrete size and made of one or more semiconductor materials forming a second layer;
a gas cell to contain the gas to be detected; and
a light detector;
wherein a quantum dot in any one layer is within 1.0 nm in diameter of size compared to a quantum dot in any adjacent layer.
US Pat. No. 10,579,166
POINTER ACCELERATION SYSTEM MODELING
Board of Supervisors of L...
1. A method comprising:obtaining, by a computing device, a closed loop pointer acceleration system model, in which the closed loop pointer acceleration system model is based on (1) a model describing user pointing motions integrated with (2) a model of pointer acceleration motions under operational conditions;
obtaining, by the computing device, values for system parameters that include pointer acceleration profile parameters and operational condition parameters;
determining, by the computing device, a set of pointer trajectories for a given acceleration profile having the pointer acceleration profile parameters and operational condition parameters;
repeating the obtaining and determining operations for a new set of system and operational condition parameters; and
outputting a side-by-side comparison of determined sets of pointer trajectories for different pointer acceleration profiles on a display.
obtaining, by the computing device, values for system parameters that include pointer acceleration profile parameters and operational condition parameters;
determining, by the computing device, a set of pointer trajectories for a given acceleration profile having the pointer acceleration profile parameters and operational condition parameters;
repeating the obtaining and determining operations for a new set of system and operational condition parameters; and
outputting a side-by-side comparison of determined sets of pointer trajectories for different pointer acceleration profiles on a display.
US Pat. No. 10,393,726
UNIVERSAL MOLECULAR PROCESSOR FOR PRECISION MEDICINE
The University of North C...
1. A device comprising:a biomolecular processor, each biomolecular processor comprising:
a bioreactor chamber defined by a solid substrate;
a plurality of spaced support structures within said bioreactor chamber and attached to the solid substrate;
one or more capture molecules immobilized to some or all of said plurality of spaced support structures, said one or more capture molecules suitable to bind to a portion of a target nucleic acid molecule in a sample;
one or more nanotubes defined by the solid substrate and fluidically coupled to the bioreactor chamber, each of said one or more nanotubes having a passage extending between an input end proximate to said bioreactor chamber and an output end distal to said bioreactor chamber and comprising one or more nanopores within the passage with each nanopore having a reduced diameter relative to the passage; and
one or more units defined by the solid substrate and upstream of said biomolecular processor and one or more nanotubes, said one or more units being configured to carry out sample preparation.
a bioreactor chamber defined by a solid substrate;
a plurality of spaced support structures within said bioreactor chamber and attached to the solid substrate;
one or more capture molecules immobilized to some or all of said plurality of spaced support structures, said one or more capture molecules suitable to bind to a portion of a target nucleic acid molecule in a sample;
one or more nanotubes defined by the solid substrate and fluidically coupled to the bioreactor chamber, each of said one or more nanotubes having a passage extending between an input end proximate to said bioreactor chamber and an output end distal to said bioreactor chamber and comprising one or more nanopores within the passage with each nanopore having a reduced diameter relative to the passage; and
one or more units defined by the solid substrate and upstream of said biomolecular processor and one or more nanotubes, said one or more units being configured to carry out sample preparation.
US Pat. No. 10,292,943
DELIVERY OF BIOACTIVE, NANOENCAPSULATED ANTIOXIDANTS
Board of Supervisors of L...
1. A method for delivering lutein to the eye of a mammal, wherein the mammal has one or more cataracts; said method comprising topically administering to the mammal's eye a composition that comprises a mixture of nanoparticles and a hydrogel:(a) wherein the nanoparticles comprise: (i) a synthetic polymer or a protein, (ii) lutein, and (iii) a surfactant; wherein the polymer or protein entraps the lutein; wherein the surfactant associates with the polymer or protein; wherein the nanoparticles have a diameter between 50 nm and 250 nm; wherein the nanoparticles are more hydrophilic than is native lutein; wherein the lutein in the nanoparticles has greater resistance to degradation by oxygen, to degradation by ultraviolet light, or both than does free lutein;
(b) wherein the hydrogel comprises a mixture of water, a thermoreversible gel-forming polymer, and a bioadhesive polymer; wherein the composition is liquid at 25° C.; wherein the thermoreversible gel-forming polymer causes the composition to become a gel at the temperature of the conjunctival sac or of the surface of the cornea of the mammal; and wherein the bioadhesive polymer causes the gel to adhere to the conjunctival mucosa and cornea more strongly than the gel would adhere without the bioadhesive polymer;
(c) wherein the composition is applied as a liquid to the surface of the cornea or into the conjunctival sac; wherein the temperature of the conjunctival sac or of the surface of the cornea causes the composition to form a gel; wherein the gel adheres to the conjunctival mucosa, to the surface of the cornea, or both; and wherein the adhering gel releases lutein to the eye over a period of time; and
(d) wherein the mammal has one or more cataracts, and said method alleviates the symptoms of one or more cataracts.
(b) wherein the hydrogel comprises a mixture of water, a thermoreversible gel-forming polymer, and a bioadhesive polymer; wherein the composition is liquid at 25° C.; wherein the thermoreversible gel-forming polymer causes the composition to become a gel at the temperature of the conjunctival sac or of the surface of the cornea of the mammal; and wherein the bioadhesive polymer causes the gel to adhere to the conjunctival mucosa and cornea more strongly than the gel would adhere without the bioadhesive polymer;
(c) wherein the composition is applied as a liquid to the surface of the cornea or into the conjunctival sac; wherein the temperature of the conjunctival sac or of the surface of the cornea causes the composition to form a gel; wherein the gel adheres to the conjunctival mucosa, to the surface of the cornea, or both; and wherein the adhering gel releases lutein to the eye over a period of time; and
(d) wherein the mammal has one or more cataracts, and said method alleviates the symptoms of one or more cataracts.
US Pat. No. 10,190,955
SYSTEMS AND METHODS FOR DETERMINING THE EFFECTIVE TOUGHNESS OF A MATERIAL AND FOR IMPLEMENTING MATERIALS POSSESSING IMPROVED EFFECTIVE TOUGHNESS CHARACTERISTICS
California Institute of T...
10. An elastically heterogeneous material comprising:at least a first region comprising a first material characterized by a first elastic modulus;
a plurality of inclusions comprised of a second material characterized by a second elastic modulus;
wherein the inclusions comprise bodies having asymmetric geometries characterized by specific directionality; and
wherein the presence of the inclusions causes the elastically heterogeneous material to have a directionally asymmetric effective toughness such that the effective toughness of the elastically heterogeneous material is greater than it would be if the material was entirely characterized only by the toughness of either the first or second materials alone.
a plurality of inclusions comprised of a second material characterized by a second elastic modulus;
wherein the inclusions comprise bodies having asymmetric geometries characterized by specific directionality; and
wherein the presence of the inclusions causes the elastically heterogeneous material to have a directionally asymmetric effective toughness such that the effective toughness of the elastically heterogeneous material is greater than it would be if the material was entirely characterized only by the toughness of either the first or second materials alone.
US Pat. No. 10,596,188
USE OF NITRITE SALTS IN TREATING TISSUE DAMAGE
Board of Supervisors of L...
1. A method of treating peripheral neuropathy in a mammalian subject, the method comprising:a) identifying a mammalian subject who has peripheral neuropathy; and
b) administering to the mammalian subject a pharmaceutical composition comprising one of sodium nitrite, potassium nitrite, calcium nitrite, or some combination thereof,wherein the pharmaceutical composition is administered one of intraperitoneally, intravenously, subcutaneously, intramuscularly, sublingually, or orally;the amount of sodium nitrite, potassium nitrite, calcium nitrite, or some combination thereof is a dose of about 0.5 ?g/kg to about 5000 ?g/kg and;the pharmaceutical composition is administered until a cytokine profile generated from a tissue from the mammalian subject is found to be reduced to a level found in normal conditions for the tissue of the mammalian subject, the cytokine profile being at least one of TGF?, IFN?, or IL-17 and wherein the tissue is at or near the site of the peripheral neuropathy.
b) administering to the mammalian subject a pharmaceutical composition comprising one of sodium nitrite, potassium nitrite, calcium nitrite, or some combination thereof,wherein the pharmaceutical composition is administered one of intraperitoneally, intravenously, subcutaneously, intramuscularly, sublingually, or orally;the amount of sodium nitrite, potassium nitrite, calcium nitrite, or some combination thereof is a dose of about 0.5 ?g/kg to about 5000 ?g/kg and;the pharmaceutical composition is administered until a cytokine profile generated from a tissue from the mammalian subject is found to be reduced to a level found in normal conditions for the tissue of the mammalian subject, the cytokine profile being at least one of TGF?, IFN?, or IL-17 and wherein the tissue is at or near the site of the peripheral neuropathy.
US Pat. No. 10,429,378
METHODS OF DIFFERENTIATING PREADIPOCYTES AND USES THEREOF
Board Of Supervisors Of L...
1. A method of transdifferentiating mammalian preadipocytes, the method comprising:(a) culturing mammalian preadipocytes;
(b) infecting the mammalian preadipocytes with a viral vector encoding Oct4 such that the mammalian preadipocytes overexpress Oct4;
(c) culturing the infected cells until about 100% confluent;
(d) subculturing the cells of step (c), wherein subculturing comprises seeding at least a portion of the cells onto a mouse embryonic fibroblast (MEF) feeder cell layer;
(e) expanding the cells seeded onto the feeder layer of step (d) for a period of time sufficient to produce a population of cells which produce glucagon and which express a pancreatic alpha cell marker gene selected from the group consisting of CGC, CNTN1, PCSK1, PDK4, RGS4, IRX2, LPPR4, LOXL2, KCTD12, KL, and any combination thereof.
(b) infecting the mammalian preadipocytes with a viral vector encoding Oct4 such that the mammalian preadipocytes overexpress Oct4;
(c) culturing the infected cells until about 100% confluent;
(d) subculturing the cells of step (c), wherein subculturing comprises seeding at least a portion of the cells onto a mouse embryonic fibroblast (MEF) feeder cell layer;
(e) expanding the cells seeded onto the feeder layer of step (d) for a period of time sufficient to produce a population of cells which produce glucagon and which express a pancreatic alpha cell marker gene selected from the group consisting of CGC, CNTN1, PCSK1, PDK4, RGS4, IRX2, LPPR4, LOXL2, KCTD12, KL, and any combination thereof.
US Pat. No. 10,416,150
MICROFLUIDIC ISOLATION OF TUMOR CELLS OR OTHER RARE CELLS FROM WHOLE BLOOD OR OTHER LIQUIDS
BOARD OF SUPERVISORS OF L...
1. A method for capturing target cells from a liquid sample, comprising:(a) providing a microfluidic device comprising a substrate comprising a common fluid input and a common fluid output, and a plurality of parallel channels configured to capture or isolate target cells;
Wherein each of said plurality of parallel channels i) are fluidic-ally connected to said common fluid input and said common fluid output, ii) have a sinusoidal or quasi-sinusoidal shape, and iii) comprise antibodies or aptamers that selectively bind molecules on membranes of the target cells; and
wherein a cross-section of each of said plurality of parallel channels has a height and width taken in direction perpendicular to a length of the channels, and the length extends longitudinally from the common fluid input to the common fluid output; and
wherein the target cells have a mean diameter, the width of each of said plurality of parallel channels is at least about the mean diameter of the target cells and not greater than about twice the mean diameter of the target cells, and the height of each of said plurality of parallel channels is at least about three times the width of each respective channel; and
wherein the target cells are circulating tumor cells, pathogenic bacteria, host cells infected with pathogens, fetal cells in maternal blood, stem cells, maternal cells in an infant or adult, erythrocytes, leukocytes, platelets, tumor cells, or cancer cells; and
(b) hydrodynamic-ally processing a liquid sample comprising target cells through said microfluidic device, wherein the combination of channel width, channel height, and sinusoidal or quasi-sinusoidal shape i) causes target cells to migrate to interior surfaces of said plurality of parallel channels and bind to said antibodies or aptamers and ii) avoids blockage in said plurality of parallel channels.
Wherein each of said plurality of parallel channels i) are fluidic-ally connected to said common fluid input and said common fluid output, ii) have a sinusoidal or quasi-sinusoidal shape, and iii) comprise antibodies or aptamers that selectively bind molecules on membranes of the target cells; and
wherein a cross-section of each of said plurality of parallel channels has a height and width taken in direction perpendicular to a length of the channels, and the length extends longitudinally from the common fluid input to the common fluid output; and
wherein the target cells have a mean diameter, the width of each of said plurality of parallel channels is at least about the mean diameter of the target cells and not greater than about twice the mean diameter of the target cells, and the height of each of said plurality of parallel channels is at least about three times the width of each respective channel; and
wherein the target cells are circulating tumor cells, pathogenic bacteria, host cells infected with pathogens, fetal cells in maternal blood, stem cells, maternal cells in an infant or adult, erythrocytes, leukocytes, platelets, tumor cells, or cancer cells; and
(b) hydrodynamic-ally processing a liquid sample comprising target cells through said microfluidic device, wherein the combination of channel width, channel height, and sinusoidal or quasi-sinusoidal shape i) causes target cells to migrate to interior surfaces of said plurality of parallel channels and bind to said antibodies or aptamers and ii) avoids blockage in said plurality of parallel channels.
US Pat. No. 10,392,394
ANTIMICROBIAL COMPOUNDS AND METHODS
Board of Supervisors of L...
1. A compound having the structure:
wherein R and R? may be the same or different; and R and R? are independently selected from the group consisting of R1, R2, R3, R4, R5, and R6:
wherein m is an integer from 1 to 30;
wherein n is an integer from 0 to 20;
wherein A is A1:
wherein X is selected from the group consisting of F, Cl, Br, I, CF3SO3 (triflate), acetate, and gluconate;
wherein Y is hydrogen or an unsubstituted aliphatic group containing 1 to 6 carbons, and wherein the various Y groups may be the same or different;
wherein Z is selected from the group consisting of one hydrogen atom, two hydrogen atoms, and an unsubstituted aliphatic group containing 1 to 6 carbons;
wherein R1 is selected from the group consisting of hydrogen, an unsubstituted aliphatic group containing 1 to 18 carbons, benzyl, and a cyclic aliphatic or aromatic group containing 5 to 18 carbons; wherein, for clarity, it is noted that R1 and R1 are different; and
wherein L is selected from the group consisting of L3, L4, L5, L6, L7, L8, L9, L10, and L11:
wherein R and R? may be the same or different; and R and R? are independently selected from the group consisting of R1, R2, R3, R4, R5, and R6:
wherein m is an integer from 1 to 30;
wherein n is an integer from 0 to 20;
wherein A is A1:
wherein X is selected from the group consisting of F, Cl, Br, I, CF3SO3 (triflate), acetate, and gluconate;
wherein Y is hydrogen or an unsubstituted aliphatic group containing 1 to 6 carbons, and wherein the various Y groups may be the same or different;
wherein Z is selected from the group consisting of one hydrogen atom, two hydrogen atoms, and an unsubstituted aliphatic group containing 1 to 6 carbons;
wherein R1 is selected from the group consisting of hydrogen, an unsubstituted aliphatic group containing 1 to 18 carbons, benzyl, and a cyclic aliphatic or aromatic group containing 5 to 18 carbons; wherein, for clarity, it is noted that R1 and R1 are different; and
wherein L is selected from the group consisting of L3, L4, L5, L6, L7, L8, L9, L10, and L11:
US Pat. No. 10,376,618
THORACIC CATHETER DEVICE
Board of Supervisors of L...
1. A thoracic catheter system comprising:a flexible thoracic catheter for inserting into a thoracic cavity of a human;
a distal end of the thoracic catheter has a plurality of apertures; and
a proximate end of the thoracic catheter designed to extend out of the thoracic cavity; and
a three way valve that is one of fused with and removably attached to the proximate end of the thoracic catheter,
wherein the three way valve includes an outer ring extending around a circumference of a body of the three way valve, the outer ring defining multiple external ports, and the outer ring may be rotated with respect to the body to open and close one or more of the multiple external ports; and
wherein the three way valve has four stable on positions and four stable off positions.
a distal end of the thoracic catheter has a plurality of apertures; and
a proximate end of the thoracic catheter designed to extend out of the thoracic cavity; and
a three way valve that is one of fused with and removably attached to the proximate end of the thoracic catheter,
wherein the three way valve includes an outer ring extending around a circumference of a body of the three way valve, the outer ring defining multiple external ports, and the outer ring may be rotated with respect to the body to open and close one or more of the multiple external ports; and
wherein the three way valve has four stable on positions and four stable off positions.
US Pat. No. 10,308,939
USE OF AN MIRNA TO REDUCE PROLIFERATION OF A CANCER CELL
BOARD OF SUPERVISORS OF L...
1. A method for decreasing at least one of the proliferation and the migration of a glial tumor cell, comprising contacting the cancer cell with a pharmaceutically acceptable composition comprising a microRNA (miRNA) having the nucleotide sequence SEQ ID NO: 2, thereby decreasing at least one of the proliferation and migration of the cancer cell as compared to a control.
US Pat. No. 10,633,324
COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF INFLAMMATORY, DEGENERATIVE, AND NEURODEGENERATIVE DISEASES
Board of Supervisors of L...
1. A pharmaceutical composition comprising a compound selected from the group consisting of:
wherein in each compound:
n is 0, 2, 4, 6, 8, 10, or 12;
COOR is a carboxylic acid group, a pharmaceutically acceptable salt, or a pharmaceutically acceptable carboxylic ester thereof;
wherein if COOR is a carboxylic acid salt, the R group is a cation selected from a group consisting of: ammonium cation, iminium cation, or a metal cation, wherein the metal cation is selected from a group consisting of sodium, potassium, magnesium, zinc or calcium cation; and
wherein if COOR is a carboxylic ester, the R group is alkyl, wherein the alkyl is methyl or ethyl;
and a pharmaceutically acceptable carrier.
wherein in each compound:
n is 0, 2, 4, 6, 8, 10, or 12;
COOR is a carboxylic acid group, a pharmaceutically acceptable salt, or a pharmaceutically acceptable carboxylic ester thereof;
wherein if COOR is a carboxylic acid salt, the R group is a cation selected from a group consisting of: ammonium cation, iminium cation, or a metal cation, wherein the metal cation is selected from a group consisting of sodium, potassium, magnesium, zinc or calcium cation; and
wherein if COOR is a carboxylic ester, the R group is alkyl, wherein the alkyl is methyl or ethyl;
and a pharmaceutically acceptable carrier.
US Pat. No. 10,535,508
DEVICES AND METHODS FOR MAI IONIZATION
BOARD OF SUPERVISORS OF L...
1. A mass spectrometer system comprising:a sample mount configured to hold a sample substrate, wherein the sample substrate has an opposing front side and a back side, wherein a sample is on the front side of the sample substrate;
an ionization device configured to direct a force at the back side of a sample substrate to propagate a shockwave, wherein the ionization device is at a first distance adjacent the sample mount; and
a mass spectrometer having an inlet, wherein the sample mount is positioned a second distance from the inlet.
an ionization device configured to direct a force at the back side of a sample substrate to propagate a shockwave, wherein the ionization device is at a first distance adjacent the sample mount; and
a mass spectrometer having an inlet, wherein the sample mount is positioned a second distance from the inlet.
US Pat. No. 10,376,566
COMPOSITION AND METHOD FOR IMPROVING SLEEP DURATION AND QUALITY
Board of Supervisors of L...
1. A composition comprising:(a) a first component selected from one or more of the following: collagen, a gelatin peptide, or the amino acid glycine; wherein said first component has a molecular weight less than 3500 Dalton;
(b) a second component comprising L-theanine;
(c) a third component comprising lactucopicrin, deoxylactucopicrin, or another lactucopicrin derivative;
(d) a fourth component comprising hyaluronic acid;
(e) a fifth component comprising epigallocatechin gallate; and
(f) a sixth component comprising quinic acid;
wherein:
said composition is supplied in aqueous solution or aqueous suspension, or said composition is supplied as a powder that can be reconstituted into an aqueous solution or an aqueous suspension; wherein the concentrations of the components of the aqueous solution or aqueous suspension are such that 30-60 mL of the aqueous solution or aqueous suspension supplies one dose that comprises: (i) 0.5 to 12 g collagen peptide, or 0.5 to 5 g glycine as amino acid; i.e., all or part of said first component; (ii) a tea (Camellia sinensis) extract containing 100 to 500 mg theanine, and 50 to 300 mg epigallocatechin gallate; i.e., all or part of said second and fifth components; and (iii) 1 to 10 g chicory (Cichorium intybus) extract containing lactucopicrin, deoxylactucopicrin, or another lactucopicrin; i.e., all or part of said third component;
and wherein:
said composition has the property that, if one dose of said composition is consumed orally by a human, one or more of the following will be improved: onset of sleep, sleep depth, sleep quality, sleep duration, sleep apnea, or fatigue during the waking part of the day.
(b) a second component comprising L-theanine;
(c) a third component comprising lactucopicrin, deoxylactucopicrin, or another lactucopicrin derivative;
(d) a fourth component comprising hyaluronic acid;
(e) a fifth component comprising epigallocatechin gallate; and
(f) a sixth component comprising quinic acid;
wherein:
said composition is supplied in aqueous solution or aqueous suspension, or said composition is supplied as a powder that can be reconstituted into an aqueous solution or an aqueous suspension; wherein the concentrations of the components of the aqueous solution or aqueous suspension are such that 30-60 mL of the aqueous solution or aqueous suspension supplies one dose that comprises: (i) 0.5 to 12 g collagen peptide, or 0.5 to 5 g glycine as amino acid; i.e., all or part of said first component; (ii) a tea (Camellia sinensis) extract containing 100 to 500 mg theanine, and 50 to 300 mg epigallocatechin gallate; i.e., all or part of said second and fifth components; and (iii) 1 to 10 g chicory (Cichorium intybus) extract containing lactucopicrin, deoxylactucopicrin, or another lactucopicrin; i.e., all or part of said third component;
and wherein:
said composition has the property that, if one dose of said composition is consumed orally by a human, one or more of the following will be improved: onset of sleep, sleep depth, sleep quality, sleep duration, sleep apnea, or fatigue during the waking part of the day.
US Pat. No. 10,178,864
PORTABLE ORGAN PERFUSION SYSTEM
Board of Supervisors of L...
1. A perfusion system for a mammalian organ comprising:a first and a second pump to propel perfusion fluid through one of a closed fluid circuit system and a selectively closeable fluid circuit system that includes an organ artery and an organ vein;
a filter cartridge bank consisting of a plurality of filtration cartridges; and
a first and a second fluid reservoir,
wherein the first fluid reservoir is arranged along the fluid circuit between the first pump and the organ, downstream of the organ;
the second pump is arranged along the fluid circuit between the second fluid reservoir and the organ, upstream of the organ; and
the filter cartridge bank is arranged along the fluid circuit between the first pump and the second fluid reservoir.
a filter cartridge bank consisting of a plurality of filtration cartridges; and
a first and a second fluid reservoir,
wherein the first fluid reservoir is arranged along the fluid circuit between the first pump and the organ, downstream of the organ;
the second pump is arranged along the fluid circuit between the second fluid reservoir and the organ, upstream of the organ; and
the filter cartridge bank is arranged along the fluid circuit between the first pump and the second fluid reservoir.
US Pat. No. 10,633,541
LIQUID SEALANT WITH THERMALLY ADAPTIVE PROPERTIES
Board of Supervisors of L...
1. A composition for repairing defects in a material, wherein said composition is capable of responding to heating by decreasing in volume;wherein said composition comprises at least one two-way shape memory polymer (SMP) and a binder compatible with said SMP;
wherein said SMP is capable of temperature-dependent alterations in shape without undergoing a phase change; and
wherein said SMP is capable of decreasing in volume as the temperature increases above said SMP's glass transition temperature.
wherein said SMP is capable of temperature-dependent alterations in shape without undergoing a phase change; and
wherein said SMP is capable of decreasing in volume as the temperature increases above said SMP's glass transition temperature.
US Pat. No. 10,603,335
CANCER TREATMENT COMBINATION COMPOSITIONS, METHODS AND USES
Board of Supervisors of L...
1. A method for reducing or inhibiting proliferation of a cell comprising:a) contacting a cell that expresses a receptor that binds to a LHRH or a LHRH analog with a LHRH or a LHRH analog fused or conjugated to curcumin or a curcumin analog; and
b) contacting the cell with an anti-cell proliferative drug.
b) contacting the cell with an anti-cell proliferative drug.
US Pat. No. 10,596,237
IDENTIFICATION OF PNEUMOCYSTIS ANTIGENS AND USES THEREOF
University of New Orleans...
1. A method of eliciting an immune response in a subject, comprising administering to the subject a GSC-1 protein comprising an amino acid sequence at least 90% identical to residues 22-606 of SEQ ID NO: 111.
US Pat. No. 10,596,253
VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS
Board of Supervisors of L...
1. A vaccine comprising a recombinant herpes simplex virus (HSV), wherein the recombinant HSV comprises a recombinant HSV genome comprising:(a) a modified UL53 gene comprising a deletion corresponding to the region of the UL53 gene that encodes amino acids 31-68 of wild-type gK;
(b) a modified UL20 gene comprising a deletion corresponding to the region of the UL20 gene that encodes amino acids 4-22 of wild-type UL20 protein; and
(c) a gene encoding a foreign antigen;wherein the recombinant HSV is capable of replication in a host cell and incapable of entry into axonal compartments of neurons.
(b) a modified UL20 gene comprising a deletion corresponding to the region of the UL20 gene that encodes amino acids 4-22 of wild-type UL20 protein; and
(c) a gene encoding a foreign antigen;wherein the recombinant HSV is capable of replication in a host cell and incapable of entry into axonal compartments of neurons.
US Pat. No. 10,590,178
CHIMERIC VACCINE AGAINST FUNGAL INFECTIONS
Board of Supervisors of L...
1. A peptide comprising both an Fba domain whose amino acid sequence comprises SEQ ID NO: 1, and a Met6 domain whose amino acid sequence comprises SEQ ID NO: 2, wherein said Fba domain is covalently linked to said Met6 domain; and wherein the amino acid sequence of said peptide comprises any of SEQ ID NO: 3 through SEQ ID NO: 26.
US Pat. No. 10,575,520
CYCLOHEXYLAMINE-BASED COMPOUNDS AND USES THEREOF
BOARD OF SUPERVISORS OF L...
1. A composition comprising:an amount of a toxicant comprising a glycerol-3-phosphate salt of the compound of the formula HNR1R2, wherein R1 and R2 are independently hydrogen, a substituted or unsubstituted C4-C6-cycloalkyl group or a substituted or unsubstituted C6-C12-aryl group;
wherein the amount of the toxicant is sufficient to kill at least 30% of a population of termites in 14 days, and wherein the amount of the toxicant is between about 0.0001% and about 0.01%; and
a solvent.
wherein the amount of the toxicant is sufficient to kill at least 30% of a population of termites in 14 days, and wherein the amount of the toxicant is between about 0.0001% and about 0.01%; and
a solvent.
US Pat. No. 10,463,689
PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF
Board of Supervisors of L...
1. A sustained release pharmaceutical composition for the treatment of pain comprising:40 mg of NaNO2;
magnesium stearate;
a binding agent of polyvinyl pyrrolidone;
an enteric coating of selected from hydroxypropylmethylcellulose, methylcellulose, methyl hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, methacrylate acid copolymers, cellulose acetate trimellitate, polyvinyl acetate phthalate, hydroxyethylcellulose phthalate, or hydroxypropyl methylcellulose phthalate; and
a pharmaceutically acceptable excipient selected from ethylcellulose, methylhydroxyethylcellulose, hydroxypropyl cellulose, cellulose acetate butyrate, and cellulose triacetate;
wherein the pharmaceutical composition does not comprise an additional active ingredient; and
wherein the pharmaceutical composition is formed as one of a tablet, capsule, caplet, and gelcap.
magnesium stearate;
a binding agent of polyvinyl pyrrolidone;
an enteric coating of selected from hydroxypropylmethylcellulose, methylcellulose, methyl hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, methacrylate acid copolymers, cellulose acetate trimellitate, polyvinyl acetate phthalate, hydroxyethylcellulose phthalate, or hydroxypropyl methylcellulose phthalate; and
a pharmaceutically acceptable excipient selected from ethylcellulose, methylhydroxyethylcellulose, hydroxypropyl cellulose, cellulose acetate butyrate, and cellulose triacetate;
wherein the pharmaceutical composition does not comprise an additional active ingredient; and
wherein the pharmaceutical composition is formed as one of a tablet, capsule, caplet, and gelcap.
US Pat. No. 10,435,344
REACTION SEQUENCE FOR THE SYNTHESIS OF NOOTKATONE, DIHYDRONOOTKATONE, AND TETRAHYDRONOOTKATONE
Board of Supervisors of L...
1. A method of synthesizing nootkatone comprising the steps of:ozonolysis of Compound 6
to produce crude Compound 7without purification;converting crude Compound 7 to produce Compound 8
andconverting compound 8 to nootkatone.
to produce crude Compound 7without purification;converting crude Compound 7 to produce Compound 8
andconverting compound 8 to nootkatone.
US Pat. No. 10,429,376
MICROFLUIDIC ISOLATION OF TUMOR CELLS OR OTHER RARE CELLS FROM WHOLE BLOOD OR OTHER LIQUIDS
BOARD OF SUPERVISORS OF L...
1. A microfluidic device for capturing or isolating circulating tumor cells from a liquid, the microfluidic device comprising:a substrate comprising a common fluid input and a common fluid output, a plurality of parallel channels configured to capture or isolate circulating tumor cells and fluidically connected to the common fluid input and the common fluid output, wherein the circulating tumor cells have a mean diameter, and wherein:
a. a cross-section of each of said plurality of parallel channels has a height and width taken in direction perpendicular to a length of the channels, and the length extends longitudinally from the common fluid input to the common fluid output;
b. the width of each of said plurality of parallel channels is at least about the mean diameter of the circulating tumor cells, and is not greater than about twice the mean diameter of the circulating tumor cells;
c. the height of each of said plurality of parallel channels is at least about three times the width of each respective channel;
d. at least part of the surface within each of said plurality of parallel channels is covalently linked to one or more capture elements; wherein said capture elements comprise antibodies or aptamers that selectively bind molecules on the membranes of the circulating tumor cells; and
e. each of said plurality of parallel channels has a sinusoidal or quasi-sinusoidal shape.
a. a cross-section of each of said plurality of parallel channels has a height and width taken in direction perpendicular to a length of the channels, and the length extends longitudinally from the common fluid input to the common fluid output;
b. the width of each of said plurality of parallel channels is at least about the mean diameter of the circulating tumor cells, and is not greater than about twice the mean diameter of the circulating tumor cells;
c. the height of each of said plurality of parallel channels is at least about three times the width of each respective channel;
d. at least part of the surface within each of said plurality of parallel channels is covalently linked to one or more capture elements; wherein said capture elements comprise antibodies or aptamers that selectively bind molecules on the membranes of the circulating tumor cells; and
e. each of said plurality of parallel channels has a sinusoidal or quasi-sinusoidal shape.
US Pat. No. 10,363,117
OVERLOAD FAILURE REDUCING DENTAL IMPLANTS
Board of Supervisors of L...
1. A dental implant comprising:a base;
a central shaft having an external tooth attachment portion adjacent a first end thereof, for engagement with a dental prostheses, and a strut portion, located adjacent a second end of the central shaft, supporting a shock absorber;
the shock absorber coupling the second end of the central shaft to the base and allowing limited movement between and spacing the base and the central shaft;
the shock absorber including a plurality of arcuate flex struts;
wherein a first end of each of the plurality of flex struts are directly attached to the central shaft and a second end of each of the plurality of flex struts are directly attached to the base; and
each one of the arcuate flex struts initially projects toward the second end of the central shaft before bending back toward the first end of the central shaft and then directly attaching to the base.
a central shaft having an external tooth attachment portion adjacent a first end thereof, for engagement with a dental prostheses, and a strut portion, located adjacent a second end of the central shaft, supporting a shock absorber;
the shock absorber coupling the second end of the central shaft to the base and allowing limited movement between and spacing the base and the central shaft;
the shock absorber including a plurality of arcuate flex struts;
wherein a first end of each of the plurality of flex struts are directly attached to the central shaft and a second end of each of the plurality of flex struts are directly attached to the base; and
each one of the arcuate flex struts initially projects toward the second end of the central shaft before bending back toward the first end of the central shaft and then directly attaching to the base.
US Pat. No. 10,465,202
ABIOTIC STRESS RESISTANCE
Board of Supervisors of L...
5. A method for producing a plant, said method comprising transforming one or more plant cells with a vector comprising a polynucleotide encoding a polypeptide comprising SEQ ID NO:8 operably linked to a stress inducible promoter, wherein the plant cells are capable of regenerating into a plant, wherein the plant cells are cells of a plant other than Spartina spp., and wherein, as compared to wild-type conspecific plants, the plant has enhanced tolerance to high salinity, drought, or low temperature stress.
US Pat. No. 10,328,422
ACIDIC CATALYST
Board of Supervisors of L...
1. A composition of matter comprising:a. a catalyst comprising a metal oxide support structure and an acidic reaction site;
b. wherein the acidic reaction site has a composition according to a general formula,
c. wherein X is selected from Br and Cl;
d. wherein M is selected from Al and Si;
e. wherein one or more of M and O has a molecular bond with the metal oxide support structure and
f. wherein the catalyst is selected from an aluminum oxide based catalyst and a silicon oxide based catalyst.
b. wherein the acidic reaction site has a composition according to a general formula,
c. wherein X is selected from Br and Cl;
d. wherein M is selected from Al and Si;
e. wherein one or more of M and O has a molecular bond with the metal oxide support structure and
f. wherein the catalyst is selected from an aluminum oxide based catalyst and a silicon oxide based catalyst.
US Pat. No. 10,669,542
COMPOSITIONS AND USES FOR TREATMENT THEREOF
Board of Supervisors of L...
1. An isolated nuclease-resistant oligonucleotide comprising a nucleic acid sequence that hybridizes to a complementary target nucleic acid sequence of a gene or gene product to modulate the expression of a component of a mismatch repair (MMR) complex, wherein the component of the MMR complex comprises exon 7 of MLH3 of MutLgamma, further wherein the isolated nuclease resistant oligonucleotide does not impact the total cellular ratios of MLH1 and its binding partners.
US Pat. No. 10,603,220
CRANIAL CAP DRESSING
BOARD OF SUPERVISORS OF L...
1. A cranial cap dressing for dressing a human craniotomy wound comprising:a breathable elastic outer layer sized to fit snuggly on a head of a human patient;
an absorbent inner layer attached to the breathable elastic outer layer;
a plurality of breathing channels in the absorbent inner layer providing a passageway for air through the absorbent inner layer to the breathable elastic outer layer;
a contact film polymer layer coating on a proximal skin facing surface of the inner layer that reduces the adhesion of the inner layer to the wound;
a plurality of perforations in the contact film polymer layer coating to allow air and bodily fluids to pass through the contact film polymer layer coating;
a mechanical fastener along a circumference of the cranial cap dressing, which helps secure the cranial cap dressing on the head of the patient;
the mechanical fastener is one of a Velcro flap, a button, a snap, a latch, a buckle, a fabric tie, and a string tie;
the mechanical fastener is located at an inferior posterior most portion of the cranial cap dressing;
the mechanical fastener is a string tie and further comprising a string substantially further comprising a substantially non-elastic string extending in a channel around the circumference of the cranial cap dressing;
an anti-microbial agent is affixed to a proximal surface of the inner layer;
the antimicrobial agent is one of elemental or ionic silver;
the antimicrobial agent is one of silver nitrate and silver sulfadiazine;
the breathable elastic outer layer having a coefficient of static friction between two pieces of the same material being less than 0.3;
a proximate breathable layer attached to the inner layer, opposite to the outer layer;
a maximum thickness of the inner layer is greater in an area corresponding to an incision than a maximum thickness of the inner layer in an area spaced from the area corresponding to the incision;
the inner layer is formed as a checkered pattern of absorbent material lining a proximal skin facing surface of the outer layer;
the inner layer is a substantially a continuous layer of absorbent material extending substantially completely across a proximal skin facing surface of the outer layer;
a plurality of perforations through the inner layer to provide breathing channels for vapor to pass through the inner layer to the outer layer;
a medical adhesive or gel affixed to a circumference of the cranial cap dressing to help releasably secure the cranial cap dressing to a skin of the patient;
the cranial cap dressing substantially completely covers a cranium of the patient; and
one or more flap that may be folded down to cover incisions that extend below a circumference of the cranial cap dressing.
an absorbent inner layer attached to the breathable elastic outer layer;
a plurality of breathing channels in the absorbent inner layer providing a passageway for air through the absorbent inner layer to the breathable elastic outer layer;
a contact film polymer layer coating on a proximal skin facing surface of the inner layer that reduces the adhesion of the inner layer to the wound;
a plurality of perforations in the contact film polymer layer coating to allow air and bodily fluids to pass through the contact film polymer layer coating;
a mechanical fastener along a circumference of the cranial cap dressing, which helps secure the cranial cap dressing on the head of the patient;
the mechanical fastener is one of a Velcro flap, a button, a snap, a latch, a buckle, a fabric tie, and a string tie;
the mechanical fastener is located at an inferior posterior most portion of the cranial cap dressing;
the mechanical fastener is a string tie and further comprising a string substantially further comprising a substantially non-elastic string extending in a channel around the circumference of the cranial cap dressing;
an anti-microbial agent is affixed to a proximal surface of the inner layer;
the antimicrobial agent is one of elemental or ionic silver;
the antimicrobial agent is one of silver nitrate and silver sulfadiazine;
the breathable elastic outer layer having a coefficient of static friction between two pieces of the same material being less than 0.3;
a proximate breathable layer attached to the inner layer, opposite to the outer layer;
a maximum thickness of the inner layer is greater in an area corresponding to an incision than a maximum thickness of the inner layer in an area spaced from the area corresponding to the incision;
the inner layer is formed as a checkered pattern of absorbent material lining a proximal skin facing surface of the outer layer;
the inner layer is a substantially a continuous layer of absorbent material extending substantially completely across a proximal skin facing surface of the outer layer;
a plurality of perforations through the inner layer to provide breathing channels for vapor to pass through the inner layer to the outer layer;
a medical adhesive or gel affixed to a circumference of the cranial cap dressing to help releasably secure the cranial cap dressing to a skin of the patient;
the cranial cap dressing substantially completely covers a cranium of the patient; and
one or more flap that may be folded down to cover incisions that extend below a circumference of the cranial cap dressing.
US Pat. No. 10,568,939
COMPOSITION AND METHOD FOR IMPROVING SLEEP DURATION AND QUALITY
Board of Supervisors of L...
1. A method for improving one or more of the following conditions in a human: onset of sleep, sleep depth, sleep quality, sleep duration, sleep apnea, or fatigue during the day;wherein said method comprises the human's orally consuming a dose of a composition;
wherein the composition comprises:
(a) a first component comprising collagen, a gelatin peptide, or the amino acid glycine; wherein the first component has an average molecular weight less than 3500 Dalton;
(b) a second component comprising L-theanine;
(c) a third component comprising lactucopicrin, deoxylactucopicrin, or another lactucopicrin derivative;
(d) a fourth component comprising hyaluronic acid;
(e) a fifth component comprising epigallocatechin gallate; and
(f) a sixth component comprising quinic acid;
and wherein one or more of the following conditions improves for the human: onset of sleep, sleep depth, sleep quality, sleep duration, sleep apnea, or fatigue during the day.
wherein the composition comprises:
(a) a first component comprising collagen, a gelatin peptide, or the amino acid glycine; wherein the first component has an average molecular weight less than 3500 Dalton;
(b) a second component comprising L-theanine;
(c) a third component comprising lactucopicrin, deoxylactucopicrin, or another lactucopicrin derivative;
(d) a fourth component comprising hyaluronic acid;
(e) a fifth component comprising epigallocatechin gallate; and
(f) a sixth component comprising quinic acid;
and wherein one or more of the following conditions improves for the human: onset of sleep, sleep depth, sleep quality, sleep duration, sleep apnea, or fatigue during the day.
US Pat. No. 10,519,278
METHODS OF MAKING POLYPEPTIDES
BOARD OF SUPERVISORS OF L...
1. A method of forming a polypeptide comprising:contacting an amino acid-derived N-thiocarboxyanhydrosulfide monomer with a polymerization initiator in a nonpolar solvent to give a polypeptide.
US Pat. No. 10,695,338
CANCER TREATMENT VIA REPOSITIONED TRICYCLIC ANTI-DEPRESSANT-LIKE DRUGS AS ANTI-CANCER AGENTS AND NEW COMBINATIONS OF SUCH DRUGS
Board of Supervisors of L...
1. A method for treating a lysosomal movement associated cancer in an animal, in which the position of lysosomes can influence cancer progression, comprising:administering a pharmaceutical composition containing an effective amount of deptropine and pizotifen or pharmaceutically acceptable salts, thereof.
US Pat. No. 10,925,133
CARBON DOT LIGHT EMITTING DIODES
BOARD OF SUPERVISORS OF L...
1. A method of producing light comprising the step of:supplying a current of electricity to an electroluminescent light emitting diode (LED);
wherein the electroluminescent LED device comprises a hole transport layer, an electron transport layer, an active emissive layer between the hole transport layer and the electron transport layer, and carbon dots form the active emissive layer; and
wherein the light emitting diode device is an electroluminescent light emitting diode device, and the carbon dots are substantially spherical in shape.
wherein the electroluminescent LED device comprises a hole transport layer, an electron transport layer, an active emissive layer between the hole transport layer and the electron transport layer, and carbon dots form the active emissive layer; and
wherein the light emitting diode device is an electroluminescent light emitting diode device, and the carbon dots are substantially spherical in shape.
US Pat. No. 10,671,427
SNAPSHOT ISOLATION IN GRAPHICAL PROCESSING UNIT HARDWARE TRANSACTIONAL MEMORY
BOARD OF SUPERVISORS OF L...
1. A method comprising:receiving, at a cache associated with a processor, a request from a single-instruction, multiple-transaction (SIMT) core of the processor;
generating, in response to the request, at least one copy of a row of a memory associated with the processor, the at least one copy stored in the cache;
recording, during transactions executed by the processor, multiple versions of the row of the memory, each version in the multiple versions associated with a respective copy in the at least one copy of the row of the memory;
generating a version index table of the multiple versions, the version index table being written by a single writer within the cache, the version index table being stored in the cache;
performing, at the cache, dependent loop detection on the multiple versions; and
aborting write-write transactions based on the dependent loop detection.
generating, in response to the request, at least one copy of a row of a memory associated with the processor, the at least one copy stored in the cache;
recording, during transactions executed by the processor, multiple versions of the row of the memory, each version in the multiple versions associated with a respective copy in the at least one copy of the row of the memory;
generating a version index table of the multiple versions, the version index table being written by a single writer within the cache, the version index table being stored in the cache;
performing, at the cache, dependent loop detection on the multiple versions; and
aborting write-write transactions based on the dependent loop detection.
US Pat. No. 10,702,537
DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION
BOARD OF SUPERVISORS OF L...
1. A method of treating a condition in a human patient comprising:pharmacologically activating a translocator protein of 18 kDa (TSPO) by administering a therapeutically effective amount of a pharmaceutical composition to the patient;
wherein the pharmaceutical composition includes one or more peripheral benzodiazepine receptor ligands, or one or more therapeutically acceptable salts, clathrates, stereoisomers, or enantiomers, of these compounds or mixtures thereof, which activate the TSPO;
wherein the condition is one of
a chronic methamphetamine addiction;
a medical consequence of methamphetamine use; and
a behavioral consequence of methamphetamine use.
wherein the pharmaceutical composition includes one or more peripheral benzodiazepine receptor ligands, or one or more therapeutically acceptable salts, clathrates, stereoisomers, or enantiomers, of these compounds or mixtures thereof, which activate the TSPO;
wherein the condition is one of
a chronic methamphetamine addiction;
a medical consequence of methamphetamine use; and
a behavioral consequence of methamphetamine use.
US Pat. No. 10,690,669
BOVINE HERPESVIRUS DETECTION AND TREATMENT
BOARD OF SUPERVISORS OF L...
1. A method for determining whether an animal is infected with a Bovine herpesvirus type 1 (BoHV-1), vaccinated with a recombinant BoHV-1 triple mutant virus (BoHV-1 tmv), or uninfected with a Bovine herpesvirus type 1 (BoHV-1) comprising:(a) contacting a test sample from said animal with at least one polypeptide or peptide to form an assay mixture, where the at least one polypeptide or peptide consists of a sequence selected from the group consisting of SEQ ID NO:1, 4-44, and 45; and
(b) detecting or measuring whether a complex between the at least one polypeptide or peptide and antibodies is present in the assay mixture, and
where detecting or measuring comprises contacting the complex, or a polypeptide, a peptide, or an antibody in the complex with a binding entity, wherein the binding entity comprises at least one label.
(b) detecting or measuring whether a complex between the at least one polypeptide or peptide and antibodies is present in the assay mixture, and
where detecting or measuring comprises contacting the complex, or a polypeptide, a peptide, or an antibody in the complex with a binding entity, wherein the binding entity comprises at least one label.
US Pat. No. 10,668,286
NEURAL STIMULATOR
Board of Supervisors of L...
1. A method of stimulating tissue comprising:a. implanting an electrical circuit within a mammalian patient wherein the electrical circuit comprises:
i. a first electrical node directly connected to a first resistor wherein the first electrical node is grounded through the first resistor,
ii. a second electrical node connected to a second resistor wherein the second electrical node is grounded through the second resistor,
iii. a quantity of tissue having a tissue resistance,
iv. a first capacitor directly connected to both the first electrical node and the second electrical node,
v. a second capacitor separating the second electrical node from a biological grounding point,
vi. a first direct current source electrically connected to the first electrical node and
vii. a second direct current source electrically connected to the second electrical node,
viii. wherein the quantity of tissue is electrically connected to the first electrical node,
ix. wherein the quantity of tissue is electrically connected to the second electrical node and
x. wherein the second capacitor and the second resistor operate in parallel directly between the second electrical node and the biological grounding point;
b. applying a first voltage to the first electrical node from the first direct current source;
c. applying a second voltage to the second electrical node from the second direct current source;
d. ceasing the application of the first voltage to the first electrical node from the first direct current source;
e. ceasing the application of the second voltage to the second electrical node from the second direct current source and
f. creating a voltage waveform at the quantity of tissue sufficient to create a neural signal in the mammalian patient wherein the voltage waveform is the time dependent voltage difference between the first electrical node and the second electrical node.
i. a first electrical node directly connected to a first resistor wherein the first electrical node is grounded through the first resistor,
ii. a second electrical node connected to a second resistor wherein the second electrical node is grounded through the second resistor,
iii. a quantity of tissue having a tissue resistance,
iv. a first capacitor directly connected to both the first electrical node and the second electrical node,
v. a second capacitor separating the second electrical node from a biological grounding point,
vi. a first direct current source electrically connected to the first electrical node and
vii. a second direct current source electrically connected to the second electrical node,
viii. wherein the quantity of tissue is electrically connected to the first electrical node,
ix. wherein the quantity of tissue is electrically connected to the second electrical node and
x. wherein the second capacitor and the second resistor operate in parallel directly between the second electrical node and the biological grounding point;
b. applying a first voltage to the first electrical node from the first direct current source;
c. applying a second voltage to the second electrical node from the second direct current source;
d. ceasing the application of the first voltage to the first electrical node from the first direct current source;
e. ceasing the application of the second voltage to the second electrical node from the second direct current source and
f. creating a voltage waveform at the quantity of tissue sufficient to create a neural signal in the mammalian patient wherein the voltage waveform is the time dependent voltage difference between the first electrical node and the second electrical node.
US Pat. No. 10,664,286
ENHANCED PERFORMANCE FOR GRAPHICAL PROCESSING UNIT TRANSACTIONAL MEMORY
BOARD OF SUPERVISORS OF L...
1. A method performed by a compute device, the method comprising:accessing a conflicting address table (CAT) maintained on a per-core basis, the conflicting address table comprising a list of addresses of data correlated to read/write flags indicating whether the data at the listed address is currently being read or written to by a transaction, to access a first address of data affected by a first transaction to be committed at a commit unit (CU);
comparing, by the core, the first address to a second address affected by a second transaction; and
in response to determining the first address matches the second address, delaying or preventing validating the first transaction at the CU wherein delaying comprises pausing the first transaction to be executed by the core and preventing comprises aborting the first transaction to be committed by the core preventing the first transaction from reaching the CU for validation.
comparing, by the core, the first address to a second address affected by a second transaction; and
in response to determining the first address matches the second address, delaying or preventing validating the first transaction at the CU wherein delaying comprises pausing the first transaction to be executed by the core and preventing comprises aborting the first transaction to be committed by the core preventing the first transaction from reaching the CU for validation.
US Pat. No. 10,640,742
HYBRID LINEAR ACTUATOR CONTROLLED HYDRAULIC CELL STRETCHING
Board of Supervisors of L...
1. A hydraulic cell stretching device comprising:a source of variable pressured hydraulic fluid hydraulically coupled to a flexing chamber;
the flexing chamber having at least one cell well;
the at least one cell well having a membrane subjected to the variable pressured hydraulic fluid, wherein the membrane carries a cell culture to be subjected to cell stretching;
each cell well having multiple hydraulic openings to allow hydraulic fluid into or out of each of the at least one cell well;
a hydraulic circuit including a fluid delivery path leading to the at least one cell well and a separate fluid return path leading from the at least one cell well;
one of a one-way check valve and a gate valve positioned along the fluid delivery path;
one of another one-way check valve and another gate valve positioned along the fluid return path;
wherein a plurality of cell wells are positioned in a single baseplate;
wherein a first column of the plurality of wells are fluidically connected to one another and experience a first hydraulic pressure from a first independently operated drive module; and
wherein a second column of the plurality of cell wells are fluidically connected to one another but are fluidically separate from the cell wells of the first column and wherein the second column of the plurality of cell wells simultaneously experience a second hydraulic pressure from a second independently operated drive module distinct from the first independently operated drive module at the same time as the first column of the plurality of cell wells experiences the first hydraulic pressure.
the flexing chamber having at least one cell well;
the at least one cell well having a membrane subjected to the variable pressured hydraulic fluid, wherein the membrane carries a cell culture to be subjected to cell stretching;
each cell well having multiple hydraulic openings to allow hydraulic fluid into or out of each of the at least one cell well;
a hydraulic circuit including a fluid delivery path leading to the at least one cell well and a separate fluid return path leading from the at least one cell well;
one of a one-way check valve and a gate valve positioned along the fluid delivery path;
one of another one-way check valve and another gate valve positioned along the fluid return path;
wherein a plurality of cell wells are positioned in a single baseplate;
wherein a first column of the plurality of wells are fluidically connected to one another and experience a first hydraulic pressure from a first independently operated drive module; and
wherein a second column of the plurality of cell wells are fluidically connected to one another but are fluidically separate from the cell wells of the first column and wherein the second column of the plurality of cell wells simultaneously experience a second hydraulic pressure from a second independently operated drive module distinct from the first independently operated drive module at the same time as the first column of the plurality of cell wells experiences the first hydraulic pressure.
US Pat. No. 10,907,351
SANDWICH PANEL WITH A DUCTILE HYBRID CORE COMPRISING TUBULAR REINFORCEMENTS
BOARD OF SUPERVISORS OF L...
1. A hybrid core for structural sandwich panels, the hybrid core comprising:at least one ductile, hollow metallic tubular structural element forming a structural reinforcement layer, where the at least one ductile, hollow metallic tubular structural element has, when measured at room temperature, an elastic modulus within a range of 1-1000 GPa; an ultimate tensile strength within a range of 1-1000 MPa; and an elongation at break of 3-100%; and
a ductile matrix disposed about the at least one ductile, hollow metallic tubular structural element, where the ductile matrix has, when measured at room temperature, an elastic modulus within a range of 1.5-350 GPa; an ultimate tensile strength within a range of 25-350 MPa; and an elongation at break of 3-200%.
a ductile matrix disposed about the at least one ductile, hollow metallic tubular structural element, where the ductile matrix has, when measured at room temperature, an elastic modulus within a range of 1.5-350 GPa; an ultimate tensile strength within a range of 25-350 MPa; and an elongation at break of 3-200%.
US Pat. No. 10,870,881
BIOMOLECULAR PROCESSING PLATFORM AND USES THEREOF
CORNELL UNIVERSITY, Itha...
1. A device comprising:a biomolecular processor, each biomolecular processor comprising:
one or more bioreactor chambers defined by a solid substrate;
a support structure within each bioreactor chamber and attached to the solid substrate;
a cleaving enzyme immobilized to the support structure and operatively positioned within said bioreactor chamber to cleave monomer or multimer units of a biopolymer molecule operatively engaged by said cleaving enzyme; and
one or more time-of-flight channels formed in the solid substrate and fluidically coupled to said one or more bioreactor chambers, each of said one or more time-of-flight channels having an input end and an output end, wherein each of said one or more time-of-flight channels comprise two or more sensors including at least (i) a first sensor contacting each of the one or more time-of-flight channels proximate to the input end of the time-of-flight channel and forming a first nanogap within the time-of-flight channel, wherein said nanogap has a width that is less than the width of the time-of-flight channel, and (ii) a second sensor contacting each of the one or more time-of-flight channels proximate to the output end of the time-of-flight channel and forming a second nanogap within the time-of-flight channel, wherein said second nanogap has a width that is less than the width of the time-of-flight channel.
one or more bioreactor chambers defined by a solid substrate;
a support structure within each bioreactor chamber and attached to the solid substrate;
a cleaving enzyme immobilized to the support structure and operatively positioned within said bioreactor chamber to cleave monomer or multimer units of a biopolymer molecule operatively engaged by said cleaving enzyme; and
one or more time-of-flight channels formed in the solid substrate and fluidically coupled to said one or more bioreactor chambers, each of said one or more time-of-flight channels having an input end and an output end, wherein each of said one or more time-of-flight channels comprise two or more sensors including at least (i) a first sensor contacting each of the one or more time-of-flight channels proximate to the input end of the time-of-flight channel and forming a first nanogap within the time-of-flight channel, wherein said nanogap has a width that is less than the width of the time-of-flight channel, and (ii) a second sensor contacting each of the one or more time-of-flight channels proximate to the output end of the time-of-flight channel and forming a second nanogap within the time-of-flight channel, wherein said second nanogap has a width that is less than the width of the time-of-flight channel.
US Pat. No. 10,872,708
PHASE CONTRAST X-RAY INTERFEROMETRY
Board of Supervisors of L...
1. A phase contrast X-ray imaging system comprising:an illumination source adapted to illuminate a region of interest;
a diffraction grating adapted to receive illumination from the illuminated region of interest, the diffraction grating comprising a spatial structure having a first periodicity superimposed with a second periodicity that is different from the first periodicity; and
a detector adapted to detect illumination passing through the diffraction grating,
wherein the spatial structure is defined by varying height and/or pitch, and
wherein the spatial structure imparts a first phase dependence based on the first periodicity and an additional phase dependence based on the second periodicity on the illumination passing through the diffraction grating.
a diffraction grating adapted to receive illumination from the illuminated region of interest, the diffraction grating comprising a spatial structure having a first periodicity superimposed with a second periodicity that is different from the first periodicity; and
a detector adapted to detect illumination passing through the diffraction grating,
wherein the spatial structure is defined by varying height and/or pitch, and
wherein the spatial structure imparts a first phase dependence based on the first periodicity and an additional phase dependence based on the second periodicity on the illumination passing through the diffraction grating.
US Pat. No. 10,834,885
HYBRID RICE DESIGNATED LAH169
Board of Supervisors of L...
1. A rice plant designated LAH169, a representative sample of seeds of said LAH169 rice having been deposited under ATCC Accession No. PTA-125153.
US Pat. No. 10,704,370
SINGLE-WELL GAS-ASSISTED GRAVITY DRAINAGE PROCESS FOR OIL RECOVERY
Board of Supervisors of L...
1. A process for producing oil from a single well drilled into a subterranean hydrocarbon-bearing reservoir having a payzone; said process comprising:a) injecting a gas into the reservoir through perforations in the single well in an upper portion of the payzone at an injection rate sufficient for the gas to push hydrocarbons throughout the reservoir downward while the gas remains substantially above the hydrocarbons, wherein the injection rate is about 0.25 MMSCF/day to about 3 MMSCF/day; and
b) removing displaced hydrocarbons from the reservoir using one or more horizontal producer laterals positioned near the bottom of the payzone and drilled from the single well, wherein each lateral is adapted to produce oil from the payzone to the surface.
b) removing displaced hydrocarbons from the reservoir using one or more horizontal producer laterals positioned near the bottom of the payzone and drilled from the single well, wherein each lateral is adapted to produce oil from the payzone to the surface.
US Pat. No. 10,696,591
SELF-HEALING COMPOSITE OF THERMOSET POLYMER AND PROGRAMMED SUPER CONTRACTION FIBERS
Board of Supervisors of L...
1. A composite comprising:a matrix of thermoset polymer;
a programmed fibrous shape memory polymer which comprises the ability to contract when heated above its shape recovery temperature; and
thermoplastic polymer for healing at a molecular scale, wherein said thermoplastic polymer is dispersed throughout said matrix;
wherein said composite comprises a sandwich structure.
a programmed fibrous shape memory polymer which comprises the ability to contract when heated above its shape recovery temperature; and
thermoplastic polymer for healing at a molecular scale, wherein said thermoplastic polymer is dispersed throughout said matrix;
wherein said composite comprises a sandwich structure.
US Pat. No. 10,675,253
METHODS OF DIAGNOSIS AND TREATMENT INVOLVING NITRITE
BOARD OF SUPERVISORS OF L...
1. A method of diagnosing and treating critical limb ischemia (CLI) versus non-critical limb ischemic peripheral artery disease (PAD) in a patient comprising:determining a patient indicator value, where the patient indicator value is one of;
a total hydrogen sulfide metabolite plasma level of less than 0.75 ?M,
a total nitric oxide, nitrite, and nitrite (NOx) plasma, level of over 220 nM,
a ratio of free hydrogen sulfide plasma level to total NOx plasma level is less than 5.0, and
a ratio of total hydrogen sulfide metabolite plasma level and total NOx plasma level is less than 10;
diagnosing the patient with as having CLI based on the patient indicator value; and
administering to the patient a therapeutic for CLI.
a total hydrogen sulfide metabolite plasma level of less than 0.75 ?M,
a total nitric oxide, nitrite, and nitrite (NOx) plasma, level of over 220 nM,
a ratio of free hydrogen sulfide plasma level to total NOx plasma level is less than 5.0, and
a ratio of total hydrogen sulfide metabolite plasma level and total NOx plasma level is less than 10;
diagnosing the patient with as having CLI based on the patient indicator value; and
administering to the patient a therapeutic for CLI.
US Pat. No. 10,919,906
CONFORMATIONALLY-CONSTRAINED BIOISOSTERES OF CAFFEIC ACID, AND SYNTHESIS AND THERAPEUTIC USES
Board of Supervisors of L...
3. A chemical comprising:a bioisoter of caffeic acid having one of the following chemical structures where R is one of an alkyl group, an aryl group, an aryl/alkyl group, and a H:
or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof.
or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof.
US Pat. No. 10,916,383
MULTILAYERED GRAPHENE AND METHODS OF MAKING THE SAME
BOARD OF SUPERVISORS OF L...
1. A method of fabricating graphene, the method comprising:providing a patterned substrate, said patterned substrate comprising protrusions or indentations;
depositing graphene oxide on the patterned substrate; and
reducing the graphene oxide to graphene;
wherein the patterned substrate has structures between 50 nm and 500 nm in height.
depositing graphene oxide on the patterned substrate; and
reducing the graphene oxide to graphene;
wherein the patterned substrate has structures between 50 nm and 500 nm in height.
US Pat. No. 10,900,303
MAGNETIC GRADIENT DRILLING
BOARD OF SUPERVISORS OF L...
1. A system, comprising:a drill pipe; and
a magnetic assembly tool connected to or integrated with the drill pipe, the magnetic assembly tool comprising:
a downhole magnetic field generator configured to generate a magnetic field and create an upstream pressure drop in magnetorheological fluid outside the drill pipe, wherein the magnetic field creates a limited region in a wellbore for an upstream flow of the magnetorheological fluid outside the drill pipe; and
a magnetic shielding material configured to shield the magnetic field from the magnetorheological fluid inside the drill pipe.
a magnetic assembly tool connected to or integrated with the drill pipe, the magnetic assembly tool comprising:
a downhole magnetic field generator configured to generate a magnetic field and create an upstream pressure drop in magnetorheological fluid outside the drill pipe, wherein the magnetic field creates a limited region in a wellbore for an upstream flow of the magnetorheological fluid outside the drill pipe; and
a magnetic shielding material configured to shield the magnetic field from the magnetorheological fluid inside the drill pipe.
US Pat. No. 10,897,921
PALATABLE FOODS FOR A METHIONINE-RESTRICTED DIET
Board of Supervisors of L...
1. A method for lowering the level of methionine in a food, and for treating a human patient or a veterinary patient; said method comprising the steps of:(a) providing a food that comprises one or more proteins containing both methionine and cysteine; wherein the one or more proteins comprise at least one animal-derived protein or soy protein;
(b) oxidizing or partially oxidizing the methionine and the cysteine in the food with an oxidizing agent to produce a methionine-depleted food; wherein the methionine-depleted food contains between 0.85 gram and 1.8 gram methionine per 100 gram total protein; and wherein the methionine-depleted food contains no more than 1.8 gram combined (methionine plus cysteine) per 100 gram total protein; wherein the oxidizing agent comprises ozone or hydrogen peroxide; and wherein the one or more proteins in the methionine-depleted food retain the one or more proteins' naturally-occurring primary structure; and wherein the palatability of the methionine-depleted food is greater than the palatability of a product comprising a mixture of free amino acids whose concentrations match the amino acid levels of the methionine-depleted food; and
(c) feeding the methionine-depleted food to a human patient or veterinary patient for a period of time, until at least one condition of the patient is thereby improved; wherein the improved condition is selected from the group consisting of increased energy expenditure, reduced fat deposition, reduced body weight, and enhanced insulin sensitivity.
(b) oxidizing or partially oxidizing the methionine and the cysteine in the food with an oxidizing agent to produce a methionine-depleted food; wherein the methionine-depleted food contains between 0.85 gram and 1.8 gram methionine per 100 gram total protein; and wherein the methionine-depleted food contains no more than 1.8 gram combined (methionine plus cysteine) per 100 gram total protein; wherein the oxidizing agent comprises ozone or hydrogen peroxide; and wherein the one or more proteins in the methionine-depleted food retain the one or more proteins' naturally-occurring primary structure; and wherein the palatability of the methionine-depleted food is greater than the palatability of a product comprising a mixture of free amino acids whose concentrations match the amino acid levels of the methionine-depleted food; and
(c) feeding the methionine-depleted food to a human patient or veterinary patient for a period of time, until at least one condition of the patient is thereby improved; wherein the improved condition is selected from the group consisting of increased energy expenditure, reduced fat deposition, reduced body weight, and enhanced insulin sensitivity.
US Pat. No. 10,876,030
CEMENT MATERIALS INCLUDING SHAPE MEMORY POLYMER AND METHODS OF MAKING CEMENT MATERIALS
BOARD OF SUPERVISORS OF L...
1. A modified cement material, comprising:a cement slurry material including a shape memory polymer additive, wherein the shape memory polymer is in a programmed state; and
wherein the shape memory polymer is an ionomer.
wherein the shape memory polymer is an ionomer.
US Pat. No. 10,865,147
HIGH STRENGTH CONCRETE-LIKE FLUOROGYPSUM-BASED BLENDS AND PRODUCTION METHODS
Board of Supervisors of L...
1. A process of forming a fluorogypsum-based concrete material, comprising:mixing fluorogypsum (FG) with circulating fluidized bed combustion ash (CFBCA) to obtain treated FG;
mixing the treated FG with a pozzolanic material and hydraulic cement to form a dry mixture;
mixing the dry mixture with water at a water over dry material ratio of less than about ? to form a wet blend; and
allowing the wet blend to cure to form a fluorogypsum-based concrete material.
mixing the treated FG with a pozzolanic material and hydraulic cement to form a dry mixture;
mixing the dry mixture with water at a water over dry material ratio of less than about ? to form a wet blend; and
allowing the wet blend to cure to form a fluorogypsum-based concrete material.
US Pat. No. 10,864,229
USE OF NITRITE SALTS IN CHRONIC ISCHEMIA
BOARD OF SUPERVISORS OF L...
1. A method of treating peripheral neuropathy in a human subject, the method comprising: orally administering to the subject a pharmaceutical composition comprising about 5 mg to about 50 mg of sodium nitrite one to six times per day for at least ten days, thereby treating the peripheral neuropathy.
US Pat. No. 10,830,757
UNIVERSAL MOLECULAR PROCESSOR FOR PRECISION MEDICINE
The University of North C...
1. A method for detecting a presence of a target nucleic acid molecule in a sample, said method comprising:providing a device comprising:
a biomolecular processor, each biomolecular processor comprising:
a bioreactor chamber defined by a solid substrate;
a plurality of spaced support structures within said bioreactor chamber and attached to the solid substrate;
one or more capture molecules immobilized to some or all of said plurality of spaced support structures, said one or more capture molecules suitable to bind to a portion of a target nucleic acid molecule in a sample;
one or more nanotubes defined by the solid substrate and fluidically coupled to the bioreactor chamber; each of said one or more nanotubes having a passage extending between an input end proximate to said bioreactor chamber and an output end distal to said bioreactor chamber and comprising one or more nanopores within the passage with each nanopore having a reduced diameter relative to the passage;
electrodes positioned at locations upstream of said bioreactor chamber and downstream of said one or more nanotubes;
a voltage source electrically coupled to said electrodes to establish a voltage gradient between a location upstream of said bioreactor chamber and downstream of said one or more nanotubes causing molecules to pass from said bioreactor chamber through said one or more nanotubes to the output end; and
a detector positioned to measure changes in current levels across the one or more nanopores as molecules pass through said one or more nanotubes;
feeding a sample comprising a target nucleic acid molecule into said biomolecular processor under conditions effective for the target nucleic acid molecule to bind to the capture molecules and to be immobilized to the spaced support structures;
subjecting the immobilized target nucleic acid molecule or immobilized extension products thereof to a ligase detection reaction to produce ligation products hybridized to the immobilized target nucleic acid molecules or immobilized extension products thereof;
denaturing the ligation products from the immobilized target nucleic acid molecules, or immobilized extension products thereof, to release the ligation products from the spaced support structures;
passing the ligation products through the one or more nanotubes;
detecting, with said detector, identifying signatures of ligation products passing through the one or more nanotubes; and
identifying the presence of the target nucleic acid molecule in the sample, differing from other nucleic acid molecules in the sample, based on said detecting.
a biomolecular processor, each biomolecular processor comprising:
a bioreactor chamber defined by a solid substrate;
a plurality of spaced support structures within said bioreactor chamber and attached to the solid substrate;
one or more capture molecules immobilized to some or all of said plurality of spaced support structures, said one or more capture molecules suitable to bind to a portion of a target nucleic acid molecule in a sample;
one or more nanotubes defined by the solid substrate and fluidically coupled to the bioreactor chamber; each of said one or more nanotubes having a passage extending between an input end proximate to said bioreactor chamber and an output end distal to said bioreactor chamber and comprising one or more nanopores within the passage with each nanopore having a reduced diameter relative to the passage;
electrodes positioned at locations upstream of said bioreactor chamber and downstream of said one or more nanotubes;
a voltage source electrically coupled to said electrodes to establish a voltage gradient between a location upstream of said bioreactor chamber and downstream of said one or more nanotubes causing molecules to pass from said bioreactor chamber through said one or more nanotubes to the output end; and
a detector positioned to measure changes in current levels across the one or more nanopores as molecules pass through said one or more nanotubes;
feeding a sample comprising a target nucleic acid molecule into said biomolecular processor under conditions effective for the target nucleic acid molecule to bind to the capture molecules and to be immobilized to the spaced support structures;
subjecting the immobilized target nucleic acid molecule or immobilized extension products thereof to a ligase detection reaction to produce ligation products hybridized to the immobilized target nucleic acid molecules or immobilized extension products thereof;
denaturing the ligation products from the immobilized target nucleic acid molecules, or immobilized extension products thereof, to release the ligation products from the spaced support structures;
passing the ligation products through the one or more nanotubes;
detecting, with said detector, identifying signatures of ligation products passing through the one or more nanotubes; and
identifying the presence of the target nucleic acid molecule in the sample, differing from other nucleic acid molecules in the sample, based on said detecting.
US Pat. No. 10,829,804
METHOD FOR IDENTIFICATION AND ENUMERATION OF NUCLEIC ACID SEQUENCES, EXPRESSION, SPLICE VARIANT, TRANSLOCATION, COPY, OR DNA METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, TERMINAL TRANSFERASE, AND SEQUENCING REACTIONS
The University of North C...
1. A method for identifying, in a sample, one or more target nucleotide sequences differing from other nucleotide sequences in the sample by one or more nucleotides, one or more copy numbers, one or more transcript sequences, and/or one or more methylated residues, said method comprising:providing a sample containing one or more target nucleic acid molecules containing the target nucleotide sequence or complements thereof;
providing a solid support comprising one or more immobilized capture molecules, said capture molecules suitable to bind to a portion of the one or more target nucleic acid molecules;
binding the one or more target nucleic acid molecules to the one or more immobilized capture molecules on the solid support thereby immobilizing the one or more target nucleic acid molecules on said solid support;
subjecting the immobilized target nucleic acid molecules or immobilized complementary target nucleic acid molecules thereof to a ligase detection reaction to produce ligation products hybridized to said immobilized target nucleic acid molecules or immobilized complements thereof;
denaturing the ligation products from the immobilized target nucleic acid molecules or immobilized complementary target nucleic acid molecules thereof to release the ligation products from the solid support;
feeding the denatured ligation products through one or more nanopores capable of detecting said ligation products;
detecting, as a result of said feeding, an identifying signature of each ligation product that is generated when each product passes through the one or more nanopores; and
identifying, based on said detecting, the presence of one or more target nucleotide sequences differing from other nucleotide sequences in the sample by one or more nucleotides, one or more copy numbers, one or more transcript sequences, and/or one or more methylated residues.
providing a solid support comprising one or more immobilized capture molecules, said capture molecules suitable to bind to a portion of the one or more target nucleic acid molecules;
binding the one or more target nucleic acid molecules to the one or more immobilized capture molecules on the solid support thereby immobilizing the one or more target nucleic acid molecules on said solid support;
subjecting the immobilized target nucleic acid molecules or immobilized complementary target nucleic acid molecules thereof to a ligase detection reaction to produce ligation products hybridized to said immobilized target nucleic acid molecules or immobilized complements thereof;
denaturing the ligation products from the immobilized target nucleic acid molecules or immobilized complementary target nucleic acid molecules thereof to release the ligation products from the solid support;
feeding the denatured ligation products through one or more nanopores capable of detecting said ligation products;
detecting, as a result of said feeding, an identifying signature of each ligation product that is generated when each product passes through the one or more nanopores; and
identifying, based on said detecting, the presence of one or more target nucleotide sequences differing from other nucleotide sequences in the sample by one or more nucleotides, one or more copy numbers, one or more transcript sequences, and/or one or more methylated residues.
US Pat. No. 10,822,752
THERMOPLASTIC CELLULOSIC FIBER GRANULES USEFUL AS INFILL MATERIALS FOR ARTIFICIAL TURF
Board of Supervisors of L...
1. An artificial turf system, wherein said system comprises: polymeric, upright turf fibers resembling grass; and infill interspersed among said turf fibers; wherein at least some of said infill comprises synthetic composite particles wherein: said synthetic composite particles comprise a thermoplastic polymer, cellulosic fibers, calcium carbonate, maleated polyethylene, an ultraviolet absorber, and zinc borate; said thermoplastic polymer is between about 10% and about 90% of said synthetic composite particles by mass; said thermoplastic polymer comprises high-density polyethylene, low-density polyethylene or both; said cellulosic fibers are between about 10% and about 80% of said synthetic composite particles by mass; said cellulosic fibers comprise pine wood shavings, pine wood sawdust, or both; said calcium carbonate is between 5% and 30% of said synthetic composite particles by mass; said maleated polyethylene is between 0.5% and 2% of said synthetic composite particles by mass; said ultraviolet absorber is between 0.5% and 2% of said synthetic composite particles by mass; said zinc borate is between 0.5% and 2% of said synthetic composite particles by mass; said thermoplastic polymer is a matrix that binds together the other components of said synthetic particles into a composite material; and the density of said synthetic composite particles is greater than 1.0 g/cm3.
US Pat. No. 10,786,503
TREATMENT OF ADIPOCYTES
Melior Pharmaceuticals I,...
1. A composition comprising:a lyn kinase activator, or a pharmaceutically acceptable salt thereof; and
a TRPM8 agonist; wherein the lyn kinase activator is of the formula:
or a pharmaceutically acceptable salt thereof, and the TRPM8 agonist is menthol.
a TRPM8 agonist; wherein the lyn kinase activator is of the formula:
or a pharmaceutically acceptable salt thereof, and the TRPM8 agonist is menthol.
US Pat. No. 10,781,437
D-STEREOSPECIFIC AMINOACYL-TRNA SYNTHETASE AND METHOD OF PRODUCING D-STEREOSPECIFIC AMINOACYL-TRNA SYNTHETASE
BOARD OF SUPERVISORS OF L...
1. A method for increasing D-stereospecificity of an enzyme comprising:introducing a stereospecific editing domain into the enzyme;
wherein the enzyme is Geobacillus stearothermophilus tyrosyl-tRNA synthetase; and
the stereospecific editing domain is amino acids 83-275 of a Pyrococcus horikoshii phenylalanine-tRNA synthetase ?-subunit of Seq. ID. No. 1, that includes one of,
L202A,
L210A,
T221A,
T236A,
F125A/S211A,
L202A/S211A,
T221A/S211A,
F125A/S202A/S211A,
F125A/T221A/S211A,
L202A/T221A/S211A,
F145A/L202A/T221A/S211A, and
L202A/T221A/S211A/T236Amutations, the mutations being between one and four variants; andthe steriospecific editing domain being inserted between G161 and I162 on the Geobacillus stearothermophilus tyrosyl-tRNA synthetase of Seq. ID. No. 2.
wherein the enzyme is Geobacillus stearothermophilus tyrosyl-tRNA synthetase; and
the stereospecific editing domain is amino acids 83-275 of a Pyrococcus horikoshii phenylalanine-tRNA synthetase ?-subunit of Seq. ID. No. 1, that includes one of,
L202A,
L210A,
T221A,
T236A,
F125A/S211A,
L202A/S211A,
T221A/S211A,
F125A/S202A/S211A,
F125A/T221A/S211A,
L202A/T221A/S211A,
F145A/L202A/T221A/S211A, and
L202A/T221A/S211A/T236Amutations, the mutations being between one and four variants; andthe steriospecific editing domain being inserted between G161 and I162 on the Geobacillus stearothermophilus tyrosyl-tRNA synthetase of Seq. ID. No. 2.
US Pat. No. 10,648,561
PISTON RING
Board of Supervisors of L...
1. A piston ring comprising:a. a piston ring contact side configured for sealing contact with a cylinder wall;
b. a plurality of cavities situated on the piston ring contact side;
c. a first cavity on the piston ring contact side selected from the plurality of cavities wherein the first cavity is on a first edge of the piston ring contact side;
d. a second cavity on the piston ring contact side selected from the plurality of cavities wherein the second cavity is on a second edge of the piston ring contact side;
e. a ring width being the distance between the first edge and the second edge;
f. a first cavity centerline perpendicular to the first edge and passing through a center of the first cavity;
g. a second cavity centerline perpendicular to the first edge passing through a center of the second cavity and
h. a cavity centerline separation distance being the distance between the first cavity centerline and the second cavity centerline;
i. wherein the cavity centerline separation distance is between 16.5% and 47.5% of the ring width;
j. wherein the first cavity extends from the first edge of the piston ring contact side toward the second edge contact side by a cavity extent which is between 20% and 35% of the ring width;
k. wherein an average depth of the first cavity is less than 1/300th of the ring width;
l. wherein the plurality of cavities occupies between 40% and 60% of a length of the first edge of the piston ring contact side;
m. wherein the plurality of cavities occupies a cavity area percentage of the piston ring contact side and the cavity area percentage is between 20% and 30% and
n. wherein the piston ring is metal.
b. a plurality of cavities situated on the piston ring contact side;
c. a first cavity on the piston ring contact side selected from the plurality of cavities wherein the first cavity is on a first edge of the piston ring contact side;
d. a second cavity on the piston ring contact side selected from the plurality of cavities wherein the second cavity is on a second edge of the piston ring contact side;
e. a ring width being the distance between the first edge and the second edge;
f. a first cavity centerline perpendicular to the first edge and passing through a center of the first cavity;
g. a second cavity centerline perpendicular to the first edge passing through a center of the second cavity and
h. a cavity centerline separation distance being the distance between the first cavity centerline and the second cavity centerline;
i. wherein the cavity centerline separation distance is between 16.5% and 47.5% of the ring width;
j. wherein the first cavity extends from the first edge of the piston ring contact side toward the second edge contact side by a cavity extent which is between 20% and 35% of the ring width;
k. wherein an average depth of the first cavity is less than 1/300th of the ring width;
l. wherein the plurality of cavities occupies between 40% and 60% of a length of the first edge of the piston ring contact side;
m. wherein the plurality of cavities occupies a cavity area percentage of the piston ring contact side and the cavity area percentage is between 20% and 30% and
n. wherein the piston ring is metal.